CN102781421A - 华中五味子果实提取物和包含它的化妆品、皮肤病学和营养药组合物 - Google Patents
华中五味子果实提取物和包含它的化妆品、皮肤病学和营养药组合物 Download PDFInfo
- Publication number
- CN102781421A CN102781421A CN2010800339398A CN201080033939A CN102781421A CN 102781421 A CN102781421 A CN 102781421A CN 2010800339398 A CN2010800339398 A CN 2010800339398A CN 201080033939 A CN201080033939 A CN 201080033939A CN 102781421 A CN102781421 A CN 102781421A
- Authority
- CN
- China
- Prior art keywords
- extract
- oil
- peptide
- schisandra chinensis
- fruit
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- 239000000203 mixture Substances 0.000 title claims abstract description 134
- 235000013399 edible fruits Nutrition 0.000 title claims abstract description 31
- YEFOAORQXAOVJQ-UHFFFAOYSA-N wuweizischun A Natural products C1C(C)C(C)(O)CC2=CC(OC)=C(OC)C(OC)=C2C2=C1C=C(OC)C(OC)=C2OC YEFOAORQXAOVJQ-UHFFFAOYSA-N 0.000 title description 8
- 239000000284 extract Substances 0.000 claims abstract description 135
- 108090000765 processed proteins & peptides Proteins 0.000 claims abstract description 111
- 235000000346 sugar Nutrition 0.000 claims abstract description 61
- 239000012141 concentrate Substances 0.000 claims abstract description 40
- 238000000034 method Methods 0.000 claims abstract description 31
- 239000002537 cosmetic Substances 0.000 claims abstract description 23
- 241000736078 Schisandra sphenanthera Species 0.000 claims abstract description 9
- YEFOAORQXAOVJQ-RZFZLAGVSA-N schisandrol a Chemical compound C1[C@H](C)[C@@](C)(O)CC2=CC(OC)=C(OC)C(OC)=C2C2=C1C=C(OC)C(OC)=C2OC YEFOAORQXAOVJQ-RZFZLAGVSA-N 0.000 claims description 46
- 240000006079 Schisandra chinensis Species 0.000 claims description 41
- 229940074091 schisandra chinensis fruit extract Drugs 0.000 claims description 40
- 235000008422 Schisandra chinensis Nutrition 0.000 claims description 37
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 claims description 34
- 239000003814 drug Substances 0.000 claims description 31
- GVJHHUAWPYXKBD-UHFFFAOYSA-N d-alpha-tocopherol Natural products OC1=C(C)C(C)=C2OC(CCCC(C)CCCC(C)CCCC(C)C)(C)CCC2=C1C GVJHHUAWPYXKBD-UHFFFAOYSA-N 0.000 claims description 29
- 235000013305 food Nutrition 0.000 claims description 22
- 239000008280 blood Substances 0.000 claims description 20
- 210000004369 blood Anatomy 0.000 claims description 20
- 150000001875 compounds Chemical class 0.000 claims description 18
- 201000004700 rosacea Diseases 0.000 claims description 17
- 235000016709 nutrition Nutrition 0.000 claims description 16
- 241001303601 Rosacea Species 0.000 claims description 15
- 229940079593 drug Drugs 0.000 claims description 14
- 201000010099 disease Diseases 0.000 claims description 13
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 claims description 13
- 229930013686 lignan Natural products 0.000 claims description 13
- 235000009408 lignans Nutrition 0.000 claims description 13
- 238000007670 refining Methods 0.000 claims description 13
- 238000007127 saponification reaction Methods 0.000 claims description 13
- 230000002757 inflammatory effect Effects 0.000 claims description 12
- 150000005692 lignans Chemical class 0.000 claims description 12
- GVJHHUAWPYXKBD-IEOSBIPESA-N α-tocopherol Chemical compound OC1=C(C)C(C)=C2O[C@@](CCC[C@H](C)CCC[C@H](C)CCCC(C)C)(C)CCC2=C1C GVJHHUAWPYXKBD-IEOSBIPESA-N 0.000 claims description 11
- 229930182558 Sterol Natural products 0.000 claims description 10
- 230000008591 skin barrier function Effects 0.000 claims description 10
- 235000003702 sterols Nutrition 0.000 claims description 10
- 238000000199 molecular distillation Methods 0.000 claims description 9
- 230000002265 prevention Effects 0.000 claims description 9
- 150000003432 sterols Chemical class 0.000 claims description 9
- 206010002198 Anaphylactic reaction Diseases 0.000 claims description 7
- 238000004458 analytical method Methods 0.000 claims description 7
- 230000036783 anaphylactic response Effects 0.000 claims description 7
- 208000003455 anaphylaxis Diseases 0.000 claims description 7
- 230000000622 irritating effect Effects 0.000 claims description 7
- 230000035800 maturation Effects 0.000 claims description 7
- 230000036285 pathological change Effects 0.000 claims description 7
- 231100000915 pathological change Toxicity 0.000 claims description 7
- 230000004044 response Effects 0.000 claims description 7
- 102000004190 Enzymes Human genes 0.000 claims description 6
- 108090000790 Enzymes Proteins 0.000 claims description 6
- 229940088598 enzyme Drugs 0.000 claims description 6
- 210000000981 epithelium Anatomy 0.000 claims description 6
- 230000004682 mucosal barrier function Effects 0.000 claims description 6
- 238000002360 preparation method Methods 0.000 claims description 6
- 230000001225 therapeutic effect Effects 0.000 claims description 6
- 150000003505 terpenes Chemical class 0.000 claims description 5
- 235000007586 terpenes Nutrition 0.000 claims description 5
- 229930003799 tocopherol Natural products 0.000 claims description 5
- 235000010384 tocopherol Nutrition 0.000 claims description 5
- 239000011732 tocopherol Substances 0.000 claims description 5
- 229960001295 tocopherol Drugs 0.000 claims description 5
- 239000004365 Protease Substances 0.000 claims description 4
- 229940068517 fruit extracts Drugs 0.000 claims description 3
- 108010059892 Cellulase Proteins 0.000 claims description 2
- 108091005804 Peptidases Proteins 0.000 claims description 2
- 101150039403 ams gene Proteins 0.000 claims description 2
- 229940106157 cellulase Drugs 0.000 claims description 2
- 230000002255 enzymatic effect Effects 0.000 claims description 2
- 238000001728 nano-filtration Methods 0.000 claims description 2
- 238000000638 solvent extraction Methods 0.000 claims description 2
- 238000000108 ultra-filtration Methods 0.000 claims description 2
- 102100037486 Reverse transcriptase/ribonuclease H Human genes 0.000 claims 1
- 239000003921 oil Substances 0.000 abstract description 98
- 239000010779 crude oil Substances 0.000 abstract description 2
- 239000002417 nutraceutical Substances 0.000 abstract 2
- 235000021436 nutraceutical agent Nutrition 0.000 abstract 2
- 235000019198 oils Nutrition 0.000 description 94
- PEDCQBHIVMGVHV-UHFFFAOYSA-N Glycerine Chemical compound OCC(O)CO PEDCQBHIVMGVHV-UHFFFAOYSA-N 0.000 description 41
- SMWDFEZZVXVKRB-UHFFFAOYSA-N Quinoline Chemical compound N1=CC=CC2=CC=CC=C21 SMWDFEZZVXVKRB-UHFFFAOYSA-N 0.000 description 30
- 239000003795 chemical substances by application Substances 0.000 description 30
- 235000008504 concentrate Nutrition 0.000 description 30
- 230000014509 gene expression Effects 0.000 description 28
- 230000002421 anti-septic effect Effects 0.000 description 27
- 210000004027 cell Anatomy 0.000 description 27
- 108090000623 proteins and genes Proteins 0.000 description 27
- 210000000582 semen Anatomy 0.000 description 27
- 210000003491 skin Anatomy 0.000 description 25
- KRKNYBCHXYNGOX-UHFFFAOYSA-N citric acid Chemical compound OC(=O)CC(O)(C(O)=O)CC(O)=O KRKNYBCHXYNGOX-UHFFFAOYSA-N 0.000 description 24
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 23
- 210000002510 keratinocyte Anatomy 0.000 description 22
- 239000002994 raw material Substances 0.000 description 22
- -1 monoterpene hydrocarbon Chemical class 0.000 description 21
- 235000008673 Persea americana Nutrition 0.000 description 20
- 244000025272 Persea americana Species 0.000 description 20
- 102000005789 Vascular Endothelial Growth Factors Human genes 0.000 description 20
- 108010019530 Vascular Endothelial Growth Factors Proteins 0.000 description 20
- 241000196324 Embryophyta Species 0.000 description 19
- 238000012360 testing method Methods 0.000 description 19
- DHMQDGOQFOQNFH-UHFFFAOYSA-N Glycine Chemical compound NCC(O)=O DHMQDGOQFOQNFH-UHFFFAOYSA-N 0.000 description 18
- CIWBSHSKHKDKBQ-JLAZNSOCSA-N Ascorbic acid Chemical compound OC[C@H](O)[C@H]1OC(=O)C(O)=C1O CIWBSHSKHKDKBQ-JLAZNSOCSA-N 0.000 description 16
- FPIPGXGPPPQFEQ-OVSJKPMPSA-N all-trans-retinol Chemical compound OC\C=C(/C)\C=C\C=C(/C)\C=C\C1=C(C)CCCC1(C)C FPIPGXGPPPQFEQ-OVSJKPMPSA-N 0.000 description 16
- 235000013599 spices Nutrition 0.000 description 16
- 206010061218 Inflammation Diseases 0.000 description 15
- 241001597008 Nomeidae Species 0.000 description 15
- 230000000694 effects Effects 0.000 description 15
- 230000004054 inflammatory process Effects 0.000 description 15
- 239000000463 material Substances 0.000 description 15
- 235000019197 fats Nutrition 0.000 description 14
- 235000011187 glycerol Nutrition 0.000 description 14
- 239000011709 vitamin E Substances 0.000 description 14
- 150000002148 esters Chemical class 0.000 description 13
- 229930182783 neolignan Natural products 0.000 description 13
- 239000000047 product Substances 0.000 description 13
- 229940046009 vitamin E Drugs 0.000 description 13
- YLQBMQCUIZJEEH-UHFFFAOYSA-N Furan Chemical compound C=1C=COC=1 YLQBMQCUIZJEEH-UHFFFAOYSA-N 0.000 description 12
- 229930003427 Vitamin E Natural products 0.000 description 12
- WIGCFUFOHFEKBI-UHFFFAOYSA-N gamma-tocopherol Natural products CC(C)CCCC(C)CCCC(C)CCCC1CCC2C(C)C(O)C(C)C(C)C2O1 WIGCFUFOHFEKBI-UHFFFAOYSA-N 0.000 description 12
- DFPAKSUCGFBDDF-UHFFFAOYSA-N nicotinic acid amide Natural products NC(=O)C1=CC=CN=C1 DFPAKSUCGFBDDF-UHFFFAOYSA-N 0.000 description 12
- 235000019165 vitamin E Nutrition 0.000 description 12
- CDQSJQSWAWPGKG-UHFFFAOYSA-N butane-1,1-diol Chemical compound CCCC(O)O CDQSJQSWAWPGKG-UHFFFAOYSA-N 0.000 description 11
- 238000012545 processing Methods 0.000 description 11
- 102000004169 proteins and genes Human genes 0.000 description 11
- 239000011718 vitamin C Substances 0.000 description 11
- VBICKXHEKHSIBG-UHFFFAOYSA-N 1-monostearoylglycerol Chemical compound CCCCCCCCCCCCCCCCCC(=O)OCC(O)CO VBICKXHEKHSIBG-UHFFFAOYSA-N 0.000 description 10
- XLOMVQKBTHCTTD-UHFFFAOYSA-N Zinc monoxide Chemical compound [Zn]=O XLOMVQKBTHCTTD-UHFFFAOYSA-N 0.000 description 10
- 230000003203 everyday effect Effects 0.000 description 10
- 230000001939 inductive effect Effects 0.000 description 10
- 235000018102 proteins Nutrition 0.000 description 10
- LXNHXLLTXMVWPM-UHFFFAOYSA-N pyridoxine Chemical compound CC1=NC=C(CO)C(CO)=C1O LXNHXLLTXMVWPM-UHFFFAOYSA-N 0.000 description 10
- 235000002639 sodium chloride Nutrition 0.000 description 10
- FPIPGXGPPPQFEQ-UHFFFAOYSA-N 13-cis retinol Natural products OCC=C(C)C=CC=C(C)C=CC1=C(C)CCCC1(C)C FPIPGXGPPPQFEQ-UHFFFAOYSA-N 0.000 description 9
- YDNKGFDKKRUKPY-JHOUSYSJSA-N C16 ceramide Natural products CCCCCCCCCCCCCCCC(=O)N[C@@H](CO)[C@H](O)C=CCCCCCCCCCCCCC YDNKGFDKKRUKPY-JHOUSYSJSA-N 0.000 description 9
- 239000004471 Glycine Substances 0.000 description 9
- CRJGESKKUOMBCT-VQTJNVASSA-N N-acetylsphinganine Chemical compound CCCCCCCCCCCCCCC[C@@H](O)[C@H](CO)NC(C)=O CRJGESKKUOMBCT-VQTJNVASSA-N 0.000 description 9
- 210000004204 blood vessel Anatomy 0.000 description 9
- 229940106189 ceramide Drugs 0.000 description 9
- ZVEQCJWYRWKARO-UHFFFAOYSA-N ceramide Natural products CCCCCCCCCCCCCCC(O)C(=O)NC(CO)C(O)C=CCCC=C(C)CCCCCCCCC ZVEQCJWYRWKARO-UHFFFAOYSA-N 0.000 description 9
- 239000000839 emulsion Substances 0.000 description 9
- 210000002889 endothelial cell Anatomy 0.000 description 9
- 238000000605 extraction Methods 0.000 description 9
- VVGIYYKRAMHVLU-UHFFFAOYSA-N newbouldiamide Natural products CCCCCCCCCCCCCCCCCCCC(O)C(O)C(O)C(CO)NC(=O)CCCCCCCCCCCCCCCCC VVGIYYKRAMHVLU-UHFFFAOYSA-N 0.000 description 9
- 235000015112 vegetable and seed oil Nutrition 0.000 description 9
- 229920001285 xanthan gum Polymers 0.000 description 9
- 239000000230 xanthan gum Substances 0.000 description 9
- 229940082509 xanthan gum Drugs 0.000 description 9
- ZZZCUOFIHGPKAK-UHFFFAOYSA-N D-erythro-ascorbic acid Natural products OCC1OC(=O)C(O)=C1O ZZZCUOFIHGPKAK-UHFFFAOYSA-N 0.000 description 8
- 229930003268 Vitamin C Natural products 0.000 description 8
- 240000008042 Zea mays Species 0.000 description 8
- 235000005824 Zea mays ssp. parviglumis Nutrition 0.000 description 8
- 235000002017 Zea mays subsp mays Nutrition 0.000 description 8
- 239000012190 activator Substances 0.000 description 8
- 150000003851 azoles Chemical class 0.000 description 8
- GMRQFYUYWCNGIN-NKMMMXOESA-N calcitriol Chemical compound C1(/[C@@H]2CC[C@@H]([C@]2(CCC1)C)[C@@H](CCCC(C)(C)O)C)=C\C=C1\C[C@@H](O)C[C@H](O)C1=C GMRQFYUYWCNGIN-NKMMMXOESA-N 0.000 description 8
- 229960005084 calcitriol Drugs 0.000 description 8
- 235000020964 calcitriol Nutrition 0.000 description 8
- 239000011612 calcitriol Substances 0.000 description 8
- 229960004106 citric acid Drugs 0.000 description 8
- 235000005822 corn Nutrition 0.000 description 8
- JEJFTTRHGBKKEI-OKILXGFUSA-N deoxyschizandrin Chemical compound C1[C@H](C)[C@H](C)CC2=CC(OC)=C(OC)C(OC)=C2C2=C1C=C(OC)C(OC)=C2OC JEJFTTRHGBKKEI-OKILXGFUSA-N 0.000 description 8
- 229960003957 dexamethasone Drugs 0.000 description 8
- UREBDLICKHMUKA-CXSFZGCWSA-N dexamethasone Chemical compound C1CC2=CC(=O)C=C[C@]2(C)[C@]2(F)[C@@H]1[C@@H]1C[C@@H](C)[C@@](C(=O)CO)(O)[C@@]1(C)C[C@@H]2O UREBDLICKHMUKA-CXSFZGCWSA-N 0.000 description 8
- 210000003746 feather Anatomy 0.000 description 8
- BTSZTGGZJQFALU-UHFFFAOYSA-N piroctone olamine Chemical compound NCCO.CC(C)(C)CC(C)CC1=CC(C)=CC(=O)N1O BTSZTGGZJQFALU-UHFFFAOYSA-N 0.000 description 8
- 229940081510 piroctone olamine Drugs 0.000 description 8
- 229920001282 polysaccharide Polymers 0.000 description 8
- 239000005017 polysaccharide Substances 0.000 description 8
- YGSDEFSMJLZEOE-UHFFFAOYSA-N salicylic acid Chemical compound OC(=O)C1=CC=CC=C1O YGSDEFSMJLZEOE-UHFFFAOYSA-N 0.000 description 8
- 239000002904 solvent Substances 0.000 description 8
- 239000008158 vegetable oil Substances 0.000 description 8
- 235000019160 vitamin B3 Nutrition 0.000 description 8
- 239000011708 vitamin B3 Substances 0.000 description 8
- 235000019154 vitamin C Nutrition 0.000 description 8
- 239000011701 zinc Substances 0.000 description 8
- 108050009340 Endothelin Proteins 0.000 description 7
- 102000002045 Endothelin Human genes 0.000 description 7
- 102000004890 Interleukin-8 Human genes 0.000 description 7
- 108090001007 Interleukin-8 Proteins 0.000 description 7
- 244000299461 Theobroma cacao Species 0.000 description 7
- 108010046722 Thrombospondin 1 Proteins 0.000 description 7
- 102100036034 Thrombospondin-1 Human genes 0.000 description 7
- HCHKCACWOHOZIP-UHFFFAOYSA-N Zinc Chemical compound [Zn] HCHKCACWOHOZIP-UHFFFAOYSA-N 0.000 description 7
- ZUBDGKVDJUIMQQ-UBFCDGJISA-N endothelin-1 Chemical compound C([C@@H](C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CC(O)=O)C(=O)N[C@@H]([C@@H](C)CC)C(=O)N[C@@H]([C@@H](C)CC)C(=O)N[C@@H](CC=1C2=CC=CC=C2NC=1)C(O)=O)NC(=O)[C@H]1NC(=O)[C@H](CC=2C=CC=CC=2)NC(=O)[C@@H](CC=2C=CC(O)=CC=2)NC(=O)[C@H](C(C)C)NC(=O)[C@H]2CSSC[C@@H](C(N[C@H](CO)C(=O)N[C@@H](CO)C(=O)N[C@H](CC(C)C)C(=O)N[C@@H](CCSC)C(=O)N[C@H](CC(O)=O)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CCC(O)=O)C(=O)N2)=O)NC(=O)[C@@H](CO)NC(=O)[C@H](N)CSSC1)C1=CNC=N1 ZUBDGKVDJUIMQQ-UBFCDGJISA-N 0.000 description 7
- ZCOLJUOHXJRHDI-CMWLGVBASA-N genistein 7-O-beta-D-glucoside Chemical compound O[C@@H]1[C@@H](O)[C@H](O)[C@@H](CO)O[C@H]1OC1=CC(O)=C2C(=O)C(C=3C=CC(O)=CC=3)=COC2=C1 ZCOLJUOHXJRHDI-CMWLGVBASA-N 0.000 description 7
- XKTZWUACRZHVAN-VADRZIEHSA-N interleukin-8 Chemical compound C([C@H](NC(=O)[C@H](CC(O)=O)NC(=O)[C@H](CC=1C2=CC=CC=C2NC=1)NC(=O)[C@@H](NC(C)=O)CCSC)C(=O)N[C@@H](CC(O)=O)C(=O)N[C@@H](CC(O)=O)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H](CC=1C=CC=CC=1)C(=O)N[C@@H]([C@@H](C)O)C(=O)NCC(=O)N[C@@H](CCSC)C(=O)N1[C@H](CCC1)C(=O)N1[C@H](CCC1)C(=O)N[C@@H](C)C(=O)N[C@H](CC(O)=O)C(=O)N[C@H](CCC(O)=O)C(=O)N[C@H](CC(O)=O)C(=O)N[C@H](CC=1C=CC(O)=CC=1)C(=O)N[C@H](CO)C(=O)N1[C@H](CCC1)C(N)=O)C1=CC=CC=C1 XKTZWUACRZHVAN-VADRZIEHSA-N 0.000 description 7
- 229940096397 interleukin-8 Drugs 0.000 description 7
- 238000002372 labelling Methods 0.000 description 7
- 239000010410 layer Substances 0.000 description 7
- 150000002632 lipids Chemical class 0.000 description 7
- 235000020944 retinol Nutrition 0.000 description 7
- 239000011607 retinol Substances 0.000 description 7
- 229960003471 retinol Drugs 0.000 description 7
- 150000003839 salts Chemical class 0.000 description 7
- 210000002374 sebum Anatomy 0.000 description 7
- 230000028327 secretion Effects 0.000 description 7
- 241000894007 species Species 0.000 description 7
- 235000010493 xanthan gum Nutrition 0.000 description 7
- YBJHBAHKTGYVGT-ZKWXMUAHSA-N (+)-Biotin Chemical compound N1C(=O)N[C@@H]2[C@H](CCCCC(=O)O)SC[C@@H]21 YBJHBAHKTGYVGT-ZKWXMUAHSA-N 0.000 description 6
- 201000004384 Alopecia Diseases 0.000 description 6
- WQZGKKKJIJFFOK-GASJEMHNSA-N Glucose Natural products OC[C@H]1OC(O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-GASJEMHNSA-N 0.000 description 6
- 102000004889 Interleukin-6 Human genes 0.000 description 6
- 108090001005 Interleukin-6 Proteins 0.000 description 6
- 102100034868 Kallikrein-5 Human genes 0.000 description 6
- 101710176223 Kallikrein-5 Proteins 0.000 description 6
- OYHQOLUKZRVURQ-HZJYTTRNSA-N Linoleic acid Chemical compound CCCCC\C=C/C\C=C/CCCCCCCC(O)=O OYHQOLUKZRVURQ-HZJYTTRNSA-N 0.000 description 6
- PVNIIMVLHYAWGP-UHFFFAOYSA-N Niacin Chemical compound OC(=O)C1=CC=CN=C1 PVNIIMVLHYAWGP-UHFFFAOYSA-N 0.000 description 6
- CDBYLPFSWZWCQE-UHFFFAOYSA-L Sodium Carbonate Chemical compound [Na+].[Na+].[O-]C([O-])=O CDBYLPFSWZWCQE-UHFFFAOYSA-L 0.000 description 6
- FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 6
- 244000046101 Sophora japonica Species 0.000 description 6
- 235000010586 Sophora japonica Nutrition 0.000 description 6
- 229930003537 Vitamin B3 Natural products 0.000 description 6
- 239000002253 acid Substances 0.000 description 6
- 230000032683 aging Effects 0.000 description 6
- 229940024606 amino acid Drugs 0.000 description 6
- 235000001014 amino acid Nutrition 0.000 description 6
- 150000001413 amino acids Chemical class 0.000 description 6
- 230000004663 cell proliferation Effects 0.000 description 6
- 235000013339 cereals Nutrition 0.000 description 6
- HVYWMOMLDIMFJA-DPAQBDIFSA-N cholesterol Chemical compound C1C=C2C[C@@H](O)CC[C@]2(C)[C@@H]2[C@@H]1[C@@H]1CC[C@H]([C@H](C)CCCC(C)C)[C@@]1(C)CC2 HVYWMOMLDIMFJA-DPAQBDIFSA-N 0.000 description 6
- 239000002299 complementary DNA Substances 0.000 description 6
- ZQSIJRDFPHDXIC-UHFFFAOYSA-N daidzein Chemical compound C1=CC(O)=CC=C1C1=COC2=CC(O)=CC=C2C1=O ZQSIJRDFPHDXIC-UHFFFAOYSA-N 0.000 description 6
- 238000000556 factor analysis Methods 0.000 description 6
- 239000008103 glucose Substances 0.000 description 6
- 229940100601 interleukin-6 Drugs 0.000 description 6
- 235000020778 linoleic acid Nutrition 0.000 description 6
- OYHQOLUKZRVURQ-IXWMQOLASA-N linoleic acid Natural products CCCCC\C=C/C\C=C\CCCCCCCC(O)=O OYHQOLUKZRVURQ-IXWMQOLASA-N 0.000 description 6
- VLKZOEOYAKHREP-UHFFFAOYSA-N n-Hexane Chemical compound CCCCCC VLKZOEOYAKHREP-UHFFFAOYSA-N 0.000 description 6
- 229960003512 nicotinic acid Drugs 0.000 description 6
- BDJRBEYXGGNYIS-UHFFFAOYSA-N nonanedioic acid Chemical compound OC(=O)CCCCCCCC(O)=O BDJRBEYXGGNYIS-UHFFFAOYSA-N 0.000 description 6
- 235000015097 nutrients Nutrition 0.000 description 6
- 239000000546 pharmaceutical excipient Substances 0.000 description 6
- 150000008442 polyphenolic compounds Chemical class 0.000 description 6
- 235000013824 polyphenols Nutrition 0.000 description 6
- 229930193195 schizandrin Natural products 0.000 description 6
- 235000016804 zinc Nutrition 0.000 description 6
- 229910052725 zinc Inorganic materials 0.000 description 6
- OWVLYQRCCIEOPF-QHTZZOMLSA-L zinc;(2s)-5-oxopyrrolidine-2-carboxylate Chemical compound [Zn+2].[O-]C(=O)[C@@H]1CCC(=O)N1.[O-]C(=O)[C@@H]1CCC(=O)N1 OWVLYQRCCIEOPF-QHTZZOMLSA-L 0.000 description 6
- VEEGZPWAAPPXRB-BJMVGYQFSA-N (3e)-3-(1h-imidazol-5-ylmethylidene)-1h-indol-2-one Chemical compound O=C1NC2=CC=CC=C2\C1=C/C1=CN=CN1 VEEGZPWAAPPXRB-BJMVGYQFSA-N 0.000 description 5
- RFVNOJDQRGSOEL-UHFFFAOYSA-N 2-hydroxyethyl octadecanoate Chemical compound CCCCCCCCCCCCCCCCCC(=O)OCCO RFVNOJDQRGSOEL-UHFFFAOYSA-N 0.000 description 5
- 240000006162 Chenopodium quinoa Species 0.000 description 5
- 101000604197 Homo sapiens Neuronatin Proteins 0.000 description 5
- 102000003777 Interleukin-1 beta Human genes 0.000 description 5
- 108090000193 Interleukin-1 beta Proteins 0.000 description 5
- 239000005913 Maltodextrin Substances 0.000 description 5
- 229920002774 Maltodextrin Polymers 0.000 description 5
- XUMBMVFBXHLACL-UHFFFAOYSA-N Melanin Chemical class O=C1C(=O)C(C2=CNC3=C(C(C(=O)C4=C32)=O)C)=C2C4=CNC2=C1C XUMBMVFBXHLACL-UHFFFAOYSA-N 0.000 description 5
- 102100038816 Neuronatin Human genes 0.000 description 5
- 235000010627 Phaseolus vulgaris Nutrition 0.000 description 5
- 244000046052 Phaseolus vulgaris Species 0.000 description 5
- 229920002701 Polyoxyl 40 Stearate Polymers 0.000 description 5
- 108010015078 Pregnancy-Associated alpha 2-Macroglobulins Proteins 0.000 description 5
- 244000269722 Thea sinensis Species 0.000 description 5
- GWEVSGVZZGPLCZ-UHFFFAOYSA-N Titan oxide Chemical compound O=[Ti]=O GWEVSGVZZGPLCZ-UHFFFAOYSA-N 0.000 description 5
- 241000209140 Triticum Species 0.000 description 5
- 235000021307 Triticum Nutrition 0.000 description 5
- 206010000496 acne Diseases 0.000 description 5
- 239000013543 active substance Substances 0.000 description 5
- SHGAZHPCJJPHSC-YCNIQYBTSA-N all-trans-retinoic acid Chemical compound OC(=O)\C=C(/C)\C=C\C=C(/C)\C=C\C1=C(C)CCCC1(C)C SHGAZHPCJJPHSC-YCNIQYBTSA-N 0.000 description 5
- 231100000360 alopecia Toxicity 0.000 description 5
- 229940121369 angiogenesis inhibitor Drugs 0.000 description 5
- 239000004037 angiogenesis inhibitor Substances 0.000 description 5
- 239000003963 antioxidant agent Substances 0.000 description 5
- 230000003078 antioxidant effect Effects 0.000 description 5
- 235000006708 antioxidants Nutrition 0.000 description 5
- 230000003115 biocidal effect Effects 0.000 description 5
- 210000000481 breast Anatomy 0.000 description 5
- 239000007766 cera flava Substances 0.000 description 5
- 235000014113 dietary fatty acids Nutrition 0.000 description 5
- 210000002615 epidermis Anatomy 0.000 description 5
- 229930195729 fatty acid Natural products 0.000 description 5
- 239000000194 fatty acid Substances 0.000 description 5
- 150000004665 fatty acids Chemical class 0.000 description 5
- 229930003935 flavonoid Natural products 0.000 description 5
- 235000017173 flavonoids Nutrition 0.000 description 5
- 150000002215 flavonoids Chemical class 0.000 description 5
- 235000006539 genistein Nutrition 0.000 description 5
- 229940045109 genistein Drugs 0.000 description 5
- TZBJGXHYKVUXJN-UHFFFAOYSA-N genistein Natural products C1=CC(O)=CC=C1C1=COC2=CC(O)=CC(O)=C2C1=O TZBJGXHYKVUXJN-UHFFFAOYSA-N 0.000 description 5
- 150000004676 glycans Chemical class 0.000 description 5
- 229940075507 glyceryl monostearate Drugs 0.000 description 5
- 150000002333 glycines Chemical class 0.000 description 5
- 230000001965 increasing effect Effects 0.000 description 5
- 229960004999 lycopene Drugs 0.000 description 5
- 239000001751 lycopene Substances 0.000 description 5
- 239000011777 magnesium Substances 0.000 description 5
- 229910052749 magnesium Inorganic materials 0.000 description 5
- 229940035034 maltodextrin Drugs 0.000 description 5
- 239000001788 mono and diglycerides of fatty acids Substances 0.000 description 5
- 239000003910 polypeptide antibiotic agent Substances 0.000 description 5
- RADKZDMFGJYCBB-UHFFFAOYSA-N pyridoxal hydrochloride Natural products CC1=NC=C(CO)C(C=O)=C1O RADKZDMFGJYCBB-UHFFFAOYSA-N 0.000 description 5
- 229940100486 rice starch Drugs 0.000 description 5
- 229960004889 salicylic acid Drugs 0.000 description 5
- 239000003352 sequestering agent Substances 0.000 description 5
- 229940083466 soybean lecithin Drugs 0.000 description 5
- 239000007921 spray Substances 0.000 description 5
- 239000000126 substance Substances 0.000 description 5
- 229920001864 tannin Polymers 0.000 description 5
- 239000001648 tannin Substances 0.000 description 5
- 238000002560 therapeutic procedure Methods 0.000 description 5
- 235000013619 trace mineral Nutrition 0.000 description 5
- 239000011573 trace mineral Substances 0.000 description 5
- 229960001727 tretinoin Drugs 0.000 description 5
- 238000012795 verification Methods 0.000 description 5
- 235000019158 vitamin B6 Nutrition 0.000 description 5
- 239000011726 vitamin B6 Substances 0.000 description 5
- 229940011671 vitamin b6 Drugs 0.000 description 5
- 239000011787 zinc oxide Substances 0.000 description 5
- ODHCTXKNWHHXJC-UHFFFAOYSA-N 5-oxoproline Chemical compound OC(=O)C1CCC(=O)N1 ODHCTXKNWHHXJC-UHFFFAOYSA-N 0.000 description 4
- 208000002874 Acne Vulgaris Diseases 0.000 description 4
- CURLTUGMZLYLDI-UHFFFAOYSA-N Carbon dioxide Chemical compound O=C=O CURLTUGMZLYLDI-UHFFFAOYSA-N 0.000 description 4
- GHOKWGTUZJEAQD-UHFFFAOYSA-N Chick antidermatitis factor Natural products OCC(C)(C)C(O)C(=O)NCCC(O)=O GHOKWGTUZJEAQD-UHFFFAOYSA-N 0.000 description 4
- 235000013162 Cocos nucifera Nutrition 0.000 description 4
- 244000060011 Cocos nucifera Species 0.000 description 4
- 102000004127 Cytokines Human genes 0.000 description 4
- 108090000695 Cytokines Proteins 0.000 description 4
- 208000001840 Dandruff Diseases 0.000 description 4
- RTZKSTLPRTWFEV-OLZOCXBDSA-N Deoxygomisin A Chemical compound COC1=C2C=3C(OC)=C(OC)C(OC)=CC=3C[C@@H](C)[C@@H](C)CC2=CC2=C1OCO2 RTZKSTLPRTWFEV-OLZOCXBDSA-N 0.000 description 4
- KCXVZYZYPLLWCC-UHFFFAOYSA-N EDTA Chemical compound OC(=O)CN(CC(O)=O)CCN(CC(O)=O)CC(O)=O KCXVZYZYPLLWCC-UHFFFAOYSA-N 0.000 description 4
- 238000002965 ELISA Methods 0.000 description 4
- QIGBRXMKCJKVMJ-UHFFFAOYSA-N Hydroquinone Chemical compound OC1=CC=C(O)C=C1 QIGBRXMKCJKVMJ-UHFFFAOYSA-N 0.000 description 4
- RTZKSTLPRTWFEV-UHFFFAOYSA-N Isokadsuranin Natural products COC1=C2C=3C(OC)=C(OC)C(OC)=CC=3CC(C)C(C)CC2=CC2=C1OCO2 RTZKSTLPRTWFEV-UHFFFAOYSA-N 0.000 description 4
- 108010076876 Keratins Proteins 0.000 description 4
- 102000011782 Keratins Human genes 0.000 description 4
- OUYCCCASQSFEME-QMMMGPOBSA-N L-tyrosine Chemical compound OC(=O)[C@@H](N)CC1=CC=C(O)C=C1 OUYCCCASQSFEME-QMMMGPOBSA-N 0.000 description 4
- UPYKUZBSLRQECL-UKMVMLAPSA-N Lycopene Natural products CC(=C/C=C/C=C(C)/C=C/C=C(C)/C=C/C1C(=C)CCCC1(C)C)C=CC=C(/C)C=CC2C(=C)CCCC2(C)C UPYKUZBSLRQECL-UKMVMLAPSA-N 0.000 description 4
- JEVVKJMRZMXFBT-XWDZUXABSA-N Lycophyll Natural products OC/C(=C/CC/C(=C\C=C\C(=C/C=C/C(=C\C=C\C=C(/C=C/C=C(\C=C\C=C(/CC/C=C(/CO)\C)\C)/C)\C)/C)\C)/C)/C JEVVKJMRZMXFBT-XWDZUXABSA-N 0.000 description 4
- 241001465754 Metazoa Species 0.000 description 4
- 229920002292 Nylon 6 Polymers 0.000 description 4
- 102000003728 Peroxisome Proliferator-Activated Receptors Human genes 0.000 description 4
- 108090000029 Peroxisome Proliferator-Activated Receptors Proteins 0.000 description 4
- LOUPRKONTZGTKE-WZBLMQSHSA-N Quinine Chemical compound C([C@H]([C@H](C1)C=C)C2)C[N@@]1[C@@H]2[C@H](O)C1=CC=NC2=CC=C(OC)C=C21 LOUPRKONTZGTKE-WZBLMQSHSA-N 0.000 description 4
- YASAKCUCGLMORW-UHFFFAOYSA-N Rosiglitazone Chemical compound C=1C=CC=NC=1N(C)CCOC(C=C1)=CC=C1CC1SC(=O)NC1=O YASAKCUCGLMORW-UHFFFAOYSA-N 0.000 description 4
- BUGBHKTXTAQXES-UHFFFAOYSA-N Selenium Chemical compound [Se] BUGBHKTXTAQXES-UHFFFAOYSA-N 0.000 description 4
- 235000021355 Stearic acid Nutrition 0.000 description 4
- 235000009470 Theobroma cacao Nutrition 0.000 description 4
- 229930003779 Vitamin B12 Natural products 0.000 description 4
- 229930003571 Vitamin B5 Natural products 0.000 description 4
- 229930003316 Vitamin D Natural products 0.000 description 4
- QYSXJUFSXHHAJI-XFEUOLMDSA-N Vitamin D3 Natural products C1(/[C@@H]2CC[C@@H]([C@]2(CCC1)C)[C@H](C)CCCC(C)C)=C/C=C1\C[C@@H](O)CCC1=C QYSXJUFSXHHAJI-XFEUOLMDSA-N 0.000 description 4
- HVUMOYIDDBPOLL-XGKPLOKHSA-N [2-[(2r,3r,4s)-3,4-dihydroxyoxolan-2-yl]-2-hydroxyethyl] octadecanoate Chemical compound CCCCCCCCCCCCCCCCCC(=O)OCC(O)[C@H]1OC[C@H](O)[C@H]1O HVUMOYIDDBPOLL-XGKPLOKHSA-N 0.000 description 4
- 230000003213 activating effect Effects 0.000 description 4
- 239000003513 alkali Substances 0.000 description 4
- AGBQKNBQESQNJD-UHFFFAOYSA-N alpha-Lipoic acid Natural products OC(=O)CCCCC1CCSS1 AGBQKNBQESQNJD-UHFFFAOYSA-N 0.000 description 4
- 230000003110 anti-inflammatory effect Effects 0.000 description 4
- 230000003796 beauty Effects 0.000 description 4
- 235000013361 beverage Nutrition 0.000 description 4
- RYYVLZVUVIJVGH-UHFFFAOYSA-N caffeine Chemical group CN1C(=O)N(C)C(=O)C2=C1N=CN2C RYYVLZVUVIJVGH-UHFFFAOYSA-N 0.000 description 4
- FAPWYRCQGJNNSJ-UBKPKTQASA-L calcium D-pantothenic acid Chemical compound [Ca+2].OCC(C)(C)[C@@H](O)C(=O)NCCC([O-])=O.OCC(C)(C)[C@@H](O)C(=O)NCCC([O-])=O FAPWYRCQGJNNSJ-UBKPKTQASA-L 0.000 description 4
- 229960002079 calcium pantothenate Drugs 0.000 description 4
- POIUWJQBRNEFGX-XAMSXPGMSA-N cathelicidin Chemical compound C([C@@H](C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CO)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H]([C@@H](C)CC)C(=O)NCC(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CC=1C=CC=CC=1)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H]([C@@H](C)CC)C(=O)N[C@@H](C(C)C)C(=O)N[C@@H](CCC(N)=O)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H]([C@@H](C)CC)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CC(O)=O)C(=O)N[C@@H](CC=1C=CC=CC=1)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](C(C)C)C(=O)N1[C@@H](CCC1)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H]([C@@H](C)O)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CO)C(O)=O)NC(=O)[C@H](CC=1C=CC=CC=1)NC(=O)[C@H](CC(O)=O)NC(=O)CNC(=O)[C@H](CC(C)C)NC(=O)[C@@H](N)CC(C)C)C1=CC=CC=C1 POIUWJQBRNEFGX-XAMSXPGMSA-N 0.000 description 4
- 108060001132 cathelicidin Proteins 0.000 description 4
- 102000014509 cathelicidin Human genes 0.000 description 4
- AGVAZMGAQJOSFJ-WZHZPDAFSA-M cobalt(2+);[(2r,3s,4r,5s)-5-(5,6-dimethylbenzimidazol-1-yl)-4-hydroxy-2-(hydroxymethyl)oxolan-3-yl] [(2r)-1-[3-[(1r,2r,3r,4z,7s,9z,12s,13s,14z,17s,18s,19r)-2,13,18-tris(2-amino-2-oxoethyl)-7,12,17-tris(3-amino-3-oxopropyl)-3,5,8,8,13,15,18,19-octamethyl-2 Chemical compound [Co+2].N#[C-].[N-]([C@@H]1[C@H](CC(N)=O)[C@@]2(C)CCC(=O)NC[C@@H](C)OP(O)(=O)O[C@H]3[C@H]([C@H](O[C@@H]3CO)N3C4=CC(C)=C(C)C=C4N=C3)O)\C2=C(C)/C([C@H](C\2(C)C)CCC(N)=O)=N/C/2=C\C([C@H]([C@@]/2(CC(N)=O)C)CCC(N)=O)=N\C\2=C(C)/C2=N[C@]1(C)[C@@](C)(CC(N)=O)[C@@H]2CCC(N)=O AGVAZMGAQJOSFJ-WZHZPDAFSA-M 0.000 description 4
- 235000009508 confectionery Nutrition 0.000 description 4
- 239000012228 culture supernatant Substances 0.000 description 4
- JEJFTTRHGBKKEI-UHFFFAOYSA-N deoxyschizandrin Natural products C1C(C)C(C)CC2=CC(OC)=C(OC)C(OC)=C2C2=C1C=C(OC)C(OC)=C2OC JEJFTTRHGBKKEI-UHFFFAOYSA-N 0.000 description 4
- 229960005215 dichloroacetic acid Drugs 0.000 description 4
- 235000015872 dietary supplement Nutrition 0.000 description 4
- JEJFTTRHGBKKEI-KBPBESRZSA-N dimethylgomisin J Natural products C1[C@H](C)[C@@H](C)CC2=CC(OC)=C(OC)C(OC)=C2C2=C1C=C(OC)C(OC)=C2OC JEJFTTRHGBKKEI-KBPBESRZSA-N 0.000 description 4
- 238000004821 distillation Methods 0.000 description 4
- 239000000796 flavoring agent Substances 0.000 description 4
- 235000013376 functional food Nutrition 0.000 description 4
- 235000009569 green tea Nutrition 0.000 description 4
- 239000002955 immunomodulating agent Substances 0.000 description 4
- 229940121354 immunomodulator Drugs 0.000 description 4
- 230000002584 immunomodulator Effects 0.000 description 4
- CGIGDMFJXJATDK-UHFFFAOYSA-N indomethacin Chemical compound CC1=C(CC(O)=O)C2=CC(OC)=CC=C2N1C(=O)C1=CC=C(Cl)C=C1 CGIGDMFJXJATDK-UHFFFAOYSA-N 0.000 description 4
- 230000005764 inhibitory process Effects 0.000 description 4
- JVTAAEKCZFNVCJ-UHFFFAOYSA-N lactic acid Chemical compound CC(O)C(O)=O JVTAAEKCZFNVCJ-UHFFFAOYSA-N 0.000 description 4
- 239000007788 liquid Substances 0.000 description 4
- 239000006210 lotion Substances 0.000 description 4
- 235000012661 lycopene Nutrition 0.000 description 4
- OAIJSZIZWZSQBC-GYZMGTAESA-N lycopene Chemical compound CC(C)=CCC\C(C)=C\C=C\C(\C)=C\C=C\C(\C)=C\C=C\C=C(/C)\C=C\C=C(/C)\C=C\C=C(/C)CCC=C(C)C OAIJSZIZWZSQBC-GYZMGTAESA-N 0.000 description 4
- 239000002609 medium Substances 0.000 description 4
- 235000013336 milk Nutrition 0.000 description 4
- 239000008267 milk Substances 0.000 description 4
- 210000004080 milk Anatomy 0.000 description 4
- PGSADBUBUOPOJS-UHFFFAOYSA-N neutral red Chemical compound Cl.C1=C(C)C(N)=CC2=NC3=CC(N(C)C)=CC=C3N=C21 PGSADBUBUOPOJS-UHFFFAOYSA-N 0.000 description 4
- QIQXTHQIDYTFRH-UHFFFAOYSA-N octadecanoic acid Chemical compound CCCCCCCCCCCCCCCCCC(O)=O QIQXTHQIDYTFRH-UHFFFAOYSA-N 0.000 description 4
- OQCDKBAXFALNLD-UHFFFAOYSA-N octadecanoic acid Natural products CCCCCCCC(C)CCCCCCCCC(O)=O OQCDKBAXFALNLD-UHFFFAOYSA-N 0.000 description 4
- FJKROLUGYXJWQN-UHFFFAOYSA-N papa-hydroxy-benzoic acid Natural products OC(=O)C1=CC=C(O)C=C1 FJKROLUGYXJWQN-UHFFFAOYSA-N 0.000 description 4
- 230000001717 pathogenic effect Effects 0.000 description 4
- 239000000049 pigment Substances 0.000 description 4
- HYAFETHFCAUJAY-UHFFFAOYSA-N pioglitazone Chemical compound N1=CC(CC)=CC=C1CCOC(C=C1)=CC=C1CC1C(=O)NC(=O)S1 HYAFETHFCAUJAY-UHFFFAOYSA-N 0.000 description 4
- 239000000419 plant extract Substances 0.000 description 4
- 239000000843 powder Substances 0.000 description 4
- 239000006041 probiotic Substances 0.000 description 4
- 235000018291 probiotics Nutrition 0.000 description 4
- 230000001105 regulatory effect Effects 0.000 description 4
- 229930002330 retinoic acid Natural products 0.000 description 4
- 239000011669 selenium Substances 0.000 description 4
- 229910052711 selenium Inorganic materials 0.000 description 4
- 235000011649 selenium Nutrition 0.000 description 4
- LUPNKHXLFSSUGS-UHFFFAOYSA-M sodium;2,2-dichloroacetate Chemical compound [Na+].[O-]C(=O)C(Cl)Cl LUPNKHXLFSSUGS-UHFFFAOYSA-M 0.000 description 4
- 229940084106 spermaceti Drugs 0.000 description 4
- 239000012177 spermaceti Substances 0.000 description 4
- PRAKJMSDJKAYCZ-UHFFFAOYSA-N squalane Chemical compound CC(C)CCCC(C)CCCC(C)CCCCC(C)CCCC(C)CCCC(C)C PRAKJMSDJKAYCZ-UHFFFAOYSA-N 0.000 description 4
- 239000008117 stearic acid Substances 0.000 description 4
- 150000003431 steroids Chemical class 0.000 description 4
- 239000006188 syrup Substances 0.000 description 4
- 235000020357 syrup Nutrition 0.000 description 4
- 235000018553 tannin Nutrition 0.000 description 4
- ZFXYFBGIUFBOJW-UHFFFAOYSA-N theophylline Chemical compound O=C1N(C)C(=O)N(C)C2=C1NC=N2 ZFXYFBGIUFBOJW-UHFFFAOYSA-N 0.000 description 4
- ZCIHMQAPACOQHT-ZGMPDRQDSA-N trans-isorenieratene Natural products CC(=C/C=C/C=C(C)/C=C/C=C(C)/C=C/c1c(C)ccc(C)c1C)C=CC=C(/C)C=Cc2c(C)ccc(C)c2C ZCIHMQAPACOQHT-ZGMPDRQDSA-N 0.000 description 4
- 239000011720 vitamin B Substances 0.000 description 4
- 235000019163 vitamin B12 Nutrition 0.000 description 4
- 239000011715 vitamin B12 Substances 0.000 description 4
- 235000009492 vitamin B5 Nutrition 0.000 description 4
- 239000011675 vitamin B5 Substances 0.000 description 4
- 235000019166 vitamin D Nutrition 0.000 description 4
- 239000011710 vitamin D Substances 0.000 description 4
- 150000003710 vitamin D derivatives Chemical class 0.000 description 4
- 229940046008 vitamin d Drugs 0.000 description 4
- KIUKXJAPPMFGSW-DNGZLQJQSA-N (2S,3S,4S,5R,6R)-6-[(2S,3R,4R,5S,6R)-3-Acetamido-2-[(2S,3S,4R,5R,6R)-6-[(2R,3R,4R,5S,6R)-3-acetamido-2,5-dihydroxy-6-(hydroxymethyl)oxan-4-yl]oxy-2-carboxy-4,5-dihydroxyoxan-3-yl]oxy-5-hydroxy-6-(hydroxymethyl)oxan-4-yl]oxy-3,4,5-trihydroxyoxane-2-carboxylic acid Chemical compound CC(=O)N[C@H]1[C@H](O)O[C@H](CO)[C@@H](O)[C@@H]1O[C@H]1[C@H](O)[C@@H](O)[C@H](O[C@H]2[C@@H]([C@@H](O[C@H]3[C@@H]([C@@H](O)[C@H](O)[C@H](O3)C(O)=O)O)[C@H](O)[C@@H](CO)O2)NC(C)=O)[C@@H](C(O)=O)O1 KIUKXJAPPMFGSW-DNGZLQJQSA-N 0.000 description 3
- JLPULHDHAOZNQI-ZTIMHPMXSA-N 1-hexadecanoyl-2-(9Z,12Z-octadecadienoyl)-sn-glycero-3-phosphocholine Chemical compound CCCCCCCCCCCCCCCC(=O)OC[C@H](COP([O-])(=O)OCC[N+](C)(C)C)OC(=O)CCCCCCC\C=C/C\C=C/CCCCC JLPULHDHAOZNQI-ZTIMHPMXSA-N 0.000 description 3
- UIVPNOBLHXUKDX-UHFFFAOYSA-N 3,5,5-trimethylhexyl 3,5,5-trimethylhexanoate Chemical compound CC(C)(C)CC(C)CCOC(=O)CC(C)CC(C)(C)C UIVPNOBLHXUKDX-UHFFFAOYSA-N 0.000 description 3
- QTBSBXVTEAMEQO-UHFFFAOYSA-N Acetic acid Chemical compound CC(O)=O QTBSBXVTEAMEQO-UHFFFAOYSA-N 0.000 description 3
- CSCPPACGZOOCGX-UHFFFAOYSA-N Acetone Chemical compound CC(C)=O CSCPPACGZOOCGX-UHFFFAOYSA-N 0.000 description 3
- NIXOWILDQLNWCW-UHFFFAOYSA-N Acrylic acid Chemical compound OC(=O)C=C NIXOWILDQLNWCW-UHFFFAOYSA-N 0.000 description 3
- PLXMOAALOJOTIY-FPTXNFDTSA-N Aesculin Natural products OC[C@@H]1[C@@H](O)[C@H](O)[C@@H](O)[C@H](O)[C@H]1Oc2cc3C=CC(=O)Oc3cc2O PLXMOAALOJOTIY-FPTXNFDTSA-N 0.000 description 3
- 206010059245 Angiopathy Diseases 0.000 description 3
- 241000894006 Bacteria Species 0.000 description 3
- 239000004342 Benzoyl peroxide Substances 0.000 description 3
- OMPJBNCRMGITSC-UHFFFAOYSA-N Benzoylperoxide Chemical compound C=1C=CC=CC=1C(=O)OOC(=O)C1=CC=CC=C1 OMPJBNCRMGITSC-UHFFFAOYSA-N 0.000 description 3
- OYPRJOBELJOOCE-UHFFFAOYSA-N Calcium Chemical compound [Ca] OYPRJOBELJOOCE-UHFFFAOYSA-N 0.000 description 3
- 208000035484 Cellulite Diseases 0.000 description 3
- ACTIUHUUMQJHFO-UHFFFAOYSA-N Coenzym Q10 Natural products COC1=C(OC)C(=O)C(CC=C(C)CCC=C(C)CCC=C(C)CCC=C(C)CCC=C(C)CCC=C(C)CCC=C(C)CCC=C(C)CCC=C(C)CCC=C(C)C)=C(C)C1=O ACTIUHUUMQJHFO-UHFFFAOYSA-N 0.000 description 3
- RYGMFSIKBFXOCR-UHFFFAOYSA-N Copper Chemical compound [Cu] RYGMFSIKBFXOCR-UHFFFAOYSA-N 0.000 description 3
- 241000195493 Cryptophyta Species 0.000 description 3
- 235000009852 Cucurbita pepo Nutrition 0.000 description 3
- 240000001980 Cucurbita pepo Species 0.000 description 3
- SNPLKNRPJHDVJA-ZETCQYMHSA-N D-panthenol Chemical compound OCC(C)(C)[C@@H](O)C(=O)NCCCO SNPLKNRPJHDVJA-ZETCQYMHSA-N 0.000 description 3
- AERBNCYCJBRYDG-UHFFFAOYSA-N D-ribo-phytosphingosine Natural products CCCCCCCCCCCCCCC(O)C(O)C(N)CO AERBNCYCJBRYDG-UHFFFAOYSA-N 0.000 description 3
- 108020004414 DNA Proteins 0.000 description 3
- 206010015150 Erythema Diseases 0.000 description 3
- LYCAIKOWRPUZTN-UHFFFAOYSA-N Ethylene glycol Chemical compound OCCO LYCAIKOWRPUZTN-UHFFFAOYSA-N 0.000 description 3
- 244000166124 Eucalyptus globulus Species 0.000 description 3
- 241000628997 Flos Species 0.000 description 3
- 108010010803 Gelatin Proteins 0.000 description 3
- 244000194101 Ginkgo biloba Species 0.000 description 3
- 235000008100 Ginkgo biloba Nutrition 0.000 description 3
- AEMRFAOFKBGASW-UHFFFAOYSA-N Glycolic acid Natural products OCC(O)=O AEMRFAOFKBGASW-UHFFFAOYSA-N 0.000 description 3
- 229920002683 Glycosaminoglycan Polymers 0.000 description 3
- 235000000421 Lepidium meyenii Nutrition 0.000 description 3
- 240000000759 Lepidium meyenii Species 0.000 description 3
- FYYHWMGAXLPEAU-UHFFFAOYSA-N Magnesium Chemical compound [Mg] FYYHWMGAXLPEAU-UHFFFAOYSA-N 0.000 description 3
- OKKJLVBELUTLKV-UHFFFAOYSA-N Methanol Chemical compound OC OKKJLVBELUTLKV-UHFFFAOYSA-N 0.000 description 3
- 240000007594 Oryza sativa Species 0.000 description 3
- 235000007164 Oryza sativa Nutrition 0.000 description 3
- 240000004371 Panax ginseng Species 0.000 description 3
- 206010049752 Peau d'orange Diseases 0.000 description 3
- 208000012641 Pigmentation disease Diseases 0.000 description 3
- 201000004681 Psoriasis Diseases 0.000 description 3
- 241000605385 Ruscus Species 0.000 description 3
- 235000005318 Serenoa repens Nutrition 0.000 description 3
- 240000006661 Serenoa repens Species 0.000 description 3
- 229920002125 Sokalan® Polymers 0.000 description 3
- 244000062793 Sorghum vulgare Species 0.000 description 3
- QJJXYPPXXYFBGM-LFZNUXCKSA-N Tacrolimus Chemical compound C1C[C@@H](O)[C@H](OC)C[C@@H]1\C=C(/C)[C@@H]1[C@H](C)[C@@H](O)CC(=O)[C@H](CC=C)/C=C(C)/C[C@H](C)C[C@H](OC)[C@H]([C@H](C[C@H]2C)OC)O[C@@]2(O)C(=O)C(=O)N2CCCC[C@H]2C(=O)O1 QJJXYPPXXYFBGM-LFZNUXCKSA-N 0.000 description 3
- 235000017537 Vaccinium myrtillus Nutrition 0.000 description 3
- 244000078534 Vaccinium myrtillus Species 0.000 description 3
- WHMDKBIGKVEYHS-IYEMJOQQSA-L Zinc gluconate Chemical compound [Zn+2].OC[C@@H](O)[C@@H](O)[C@H](O)[C@@H](O)C([O-])=O.OC[C@@H](O)[C@@H](O)[C@H](O)[C@@H](O)C([O-])=O WHMDKBIGKVEYHS-IYEMJOQQSA-L 0.000 description 3
- OENHQHLEOONYIE-UKMVMLAPSA-N all-trans beta-carotene Natural products CC=1CCCC(C)(C)C=1/C=C/C(/C)=C/C=C/C(/C)=C/C=C/C=C(C)C=CC=C(C)C=CC1=C(C)CCCC1(C)C OENHQHLEOONYIE-UKMVMLAPSA-N 0.000 description 3
- 229930002945 all-trans-retinaldehyde Natural products 0.000 description 3
- 229940087168 alpha tocopherol Drugs 0.000 description 3
- ALYNCZNDIQEVRV-UHFFFAOYSA-N aniline-p-carboxylic acid Natural products NC1=CC=C(C(O)=O)C=C1 ALYNCZNDIQEVRV-UHFFFAOYSA-N 0.000 description 3
- 230000003064 anti-oxidating effect Effects 0.000 description 3
- 208000010668 atopic eczema Diseases 0.000 description 3
- 235000019400 benzoyl peroxide Nutrition 0.000 description 3
- 235000013734 beta-carotene Nutrition 0.000 description 3
- 239000011648 beta-carotene Substances 0.000 description 3
- TUPZEYHYWIEDIH-WAIFQNFQSA-N beta-carotene Natural products CC(=C/C=C/C=C(C)/C=C/C=C(C)/C=C/C1=C(C)CCCC1(C)C)C=CC=C(/C)C=CC2=CCCCC2(C)C TUPZEYHYWIEDIH-WAIFQNFQSA-N 0.000 description 3
- 229960002747 betacarotene Drugs 0.000 description 3
- 229960002685 biotin Drugs 0.000 description 3
- 235000020958 biotin Nutrition 0.000 description 3
- 239000011616 biotin Substances 0.000 description 3
- 235000014121 butter Nutrition 0.000 description 3
- 239000011575 calcium Substances 0.000 description 3
- 229910052791 calcium Inorganic materials 0.000 description 3
- 229960001631 carbomer Drugs 0.000 description 3
- 235000019219 chocolate Nutrition 0.000 description 3
- 235000012000 cholesterol Nutrition 0.000 description 3
- 229940107161 cholesterol Drugs 0.000 description 3
- 235000020971 citrus fruits Nutrition 0.000 description 3
- 229940080421 coco glucoside Drugs 0.000 description 3
- 235000017471 coenzyme Q10 Nutrition 0.000 description 3
- 229940110767 coenzyme Q10 Drugs 0.000 description 3
- ACTIUHUUMQJHFO-UPTCCGCDSA-N coenzyme Q10 Chemical compound COC1=C(OC)C(=O)C(C\C=C(/C)CC\C=C(/C)CC\C=C(/C)CC\C=C(/C)CC\C=C(/C)CC\C=C(/C)CC\C=C(/C)CC\C=C(/C)CC\C=C(/C)CCC=C(C)C)=C(C)C1=O ACTIUHUUMQJHFO-UPTCCGCDSA-N 0.000 description 3
- 238000007906 compression Methods 0.000 description 3
- 230000006835 compression Effects 0.000 description 3
- 239000010949 copper Substances 0.000 description 3
- 229910052802 copper Inorganic materials 0.000 description 3
- 229940108928 copper Drugs 0.000 description 3
- 229960000633 dextran sulfate Drugs 0.000 description 3
- 239000003974 emollient agent Substances 0.000 description 3
- 210000003725 endotheliocyte Anatomy 0.000 description 3
- 238000005516 engineering process Methods 0.000 description 3
- XHCADAYNFIFUHF-TVKJYDDYSA-N esculin Chemical compound O[C@@H]1[C@@H](O)[C@H](O)[C@@H](CO)O[C@H]1OC(C(=C1)O)=CC2=C1OC(=O)C=C2 XHCADAYNFIFUHF-TVKJYDDYSA-N 0.000 description 3
- 238000002474 experimental method Methods 0.000 description 3
- 235000013355 food flavoring agent Nutrition 0.000 description 3
- 238000009472 formulation Methods 0.000 description 3
- 230000006870 function Effects 0.000 description 3
- 239000008273 gelatin Substances 0.000 description 3
- 229920000159 gelatin Polymers 0.000 description 3
- 235000019322 gelatine Nutrition 0.000 description 3
- 235000011852 gelatine desserts Nutrition 0.000 description 3
- 235000008434 ginseng Nutrition 0.000 description 3
- 230000012447 hatching Effects 0.000 description 3
- 229920002674 hyaluronan Polymers 0.000 description 3
- 229960003160 hyaluronic acid Drugs 0.000 description 3
- 239000003112 inhibitor Substances 0.000 description 3
- 229910052500 inorganic mineral Inorganic materials 0.000 description 3
- GOMNOOKGLZYEJT-UHFFFAOYSA-N isoflavone Chemical compound C=1OC2=CC=CC=C2C(=O)C=1C1=CC=CC=C1 GOMNOOKGLZYEJT-UHFFFAOYSA-N 0.000 description 3
- CJWQYWQDLBZGPD-UHFFFAOYSA-N isoflavone Natural products C1=C(OC)C(OC)=CC(OC)=C1C1=COC2=C(C=CC(C)(C)O3)C3=C(OC)C=C2C1=O CJWQYWQDLBZGPD-UHFFFAOYSA-N 0.000 description 3
- 235000008696 isoflavones Nutrition 0.000 description 3
- 229940100554 isononyl isononanoate Drugs 0.000 description 3
- 239000003410 keratolytic agent Substances 0.000 description 3
- 235000012902 lepidium meyenii Nutrition 0.000 description 3
- 235000019136 lipoic acid Nutrition 0.000 description 3
- 235000019713 millet Nutrition 0.000 description 3
- 235000010755 mineral Nutrition 0.000 description 3
- 239000011707 mineral Substances 0.000 description 3
- 229930003658 monoterpene Natural products 0.000 description 3
- 235000002577 monoterpenes Nutrition 0.000 description 3
- 229960003966 nicotinamide Drugs 0.000 description 3
- 235000005152 nicotinamide Nutrition 0.000 description 3
- 239000011570 nicotinamide Substances 0.000 description 3
- 238000010606 normalization Methods 0.000 description 3
- AERBNCYCJBRYDG-KSZLIROESA-N phytosphingosine Chemical compound CCCCCCCCCCCCCC[C@@H](O)[C@@H](O)[C@@H](N)CO AERBNCYCJBRYDG-KSZLIROESA-N 0.000 description 3
- 229940033329 phytosphingosine Drugs 0.000 description 3
- 230000019612 pigmentation Effects 0.000 description 3
- 229960005330 pimecrolimus Drugs 0.000 description 3
- KASDHRXLYQOAKZ-ZPSXYTITSA-N pimecrolimus Chemical compound C/C([C@H]1OC(=O)[C@@H]2CCCCN2C(=O)C(=O)[C@]2(O)O[C@@H]([C@H](C[C@H]2C)OC)[C@@H](OC)C[C@@H](C)C/C(C)=C/[C@H](C(C[C@H](O)[C@H]1C)=O)CC)=C\[C@@H]1CC[C@@H](Cl)[C@H](OC)C1 KASDHRXLYQOAKZ-ZPSXYTITSA-N 0.000 description 3
- 235000002378 plant sterols Nutrition 0.000 description 3
- 230000000529 probiotic effect Effects 0.000 description 3
- 238000011160 research Methods 0.000 description 3
- 230000002207 retinal effect Effects 0.000 description 3
- 150000004492 retinoid derivatives Chemical class 0.000 description 3
- 235000009566 rice Nutrition 0.000 description 3
- 208000008742 seborrheic dermatitis Diseases 0.000 description 3
- 239000011780 sodium chloride Substances 0.000 description 3
- 239000007901 soft capsule Substances 0.000 description 3
- 239000011593 sulfur Substances 0.000 description 3
- 229910052717 sulfur Inorganic materials 0.000 description 3
- 230000000475 sunscreen effect Effects 0.000 description 3
- 239000000516 sunscreening agent Substances 0.000 description 3
- 229960001967 tacrolimus Drugs 0.000 description 3
- QJJXYPPXXYFBGM-SHYZHZOCSA-N tacrolimus Natural products CO[C@H]1C[C@H](CC[C@@H]1O)C=C(C)[C@H]2OC(=O)[C@H]3CCCCN3C(=O)C(=O)[C@@]4(O)O[C@@H]([C@H](C[C@H]4C)OC)[C@@H](C[C@H](C)CC(=C[C@@H](CC=C)C(=O)C[C@H](O)[C@H]2C)C)OC QJJXYPPXXYFBGM-SHYZHZOCSA-N 0.000 description 3
- 229960002663 thioctic acid Drugs 0.000 description 3
- 229960000984 tocofersolan Drugs 0.000 description 3
- LENZDBCJOHFCAS-UHFFFAOYSA-N tris Chemical compound OCC(N)(CO)CO LENZDBCJOHFCAS-UHFFFAOYSA-N 0.000 description 3
- 229960000281 trometamol Drugs 0.000 description 3
- 239000011670 zinc gluconate Substances 0.000 description 3
- 235000011478 zinc gluconate Nutrition 0.000 description 3
- 229960000306 zinc gluconate Drugs 0.000 description 3
- 235000004835 α-tocopherol Nutrition 0.000 description 3
- 239000002076 α-tocopherol Substances 0.000 description 3
- OENHQHLEOONYIE-JLTXGRSLSA-N β-Carotene Chemical compound CC=1CCCC(C)(C)C=1\C=C\C(\C)=C\C=C\C(\C)=C\C=C\C=C(/C)\C=C\C=C(/C)\C=C\C1=C(C)CCCC1(C)C OENHQHLEOONYIE-JLTXGRSLSA-N 0.000 description 3
- PFTAWBLQPZVEMU-DZGCQCFKSA-N (+)-catechin Chemical compound C1([C@H]2OC3=CC(O)=CC(O)=C3C[C@@H]2O)=CC=C(O)C(O)=C1 PFTAWBLQPZVEMU-DZGCQCFKSA-N 0.000 description 2
- DYLPEFGBWGEFBB-OSFYFWSMSA-N (+)-β-cedrene Chemical compound C1[C@]23[C@H](C)CC[C@H]3C(C)(C)[C@@H]1C(=C)CC2 DYLPEFGBWGEFBB-OSFYFWSMSA-N 0.000 description 2
- RGZSQWQPBWRIAQ-CABCVRRESA-N (-)-alpha-Bisabolol Chemical compound CC(C)=CCC[C@](C)(O)[C@H]1CCC(C)=CC1 RGZSQWQPBWRIAQ-CABCVRRESA-N 0.000 description 2
- KWGRBVOPPLSCSI-WPRPVWTQSA-N (-)-ephedrine Chemical compound CN[C@@H](C)[C@H](O)C1=CC=CC=C1 KWGRBVOPPLSCSI-WPRPVWTQSA-N 0.000 description 2
- 239000001500 (2R)-6-methyl-2-[(1R)-4-methyl-1-cyclohex-3-enyl]hept-5-en-2-ol Substances 0.000 description 2
- SGKRLCUYIXIAHR-AKNGSSGZSA-N (4s,4ar,5s,5ar,6r,12ar)-4-(dimethylamino)-1,5,10,11,12a-pentahydroxy-6-methyl-3,12-dioxo-4a,5,5a,6-tetrahydro-4h-tetracene-2-carboxamide Chemical compound C1=CC=C2[C@H](C)[C@@H]([C@H](O)[C@@H]3[C@](C(O)=C(C(N)=O)C(=O)[C@H]3N(C)C)(O)C3=O)C3=C(O)C2=C1O SGKRLCUYIXIAHR-AKNGSSGZSA-N 0.000 description 2
- PHIQHXFUZVPYII-ZCFIWIBFSA-N (R)-carnitine Chemical compound C[N+](C)(C)C[C@H](O)CC([O-])=O PHIQHXFUZVPYII-ZCFIWIBFSA-N 0.000 description 2
- AGBQKNBQESQNJD-SSDOTTSWSA-N (R)-lipoic acid Chemical compound OC(=O)CCCC[C@@H]1CCSS1 AGBQKNBQESQNJD-SSDOTTSWSA-N 0.000 description 2
- BJEPYKJPYRNKOW-REOHCLBHSA-N (S)-malic acid Chemical compound OC(=O)[C@@H](O)CC(O)=O BJEPYKJPYRNKOW-REOHCLBHSA-N 0.000 description 2
- PKJBRKTYYNRVSN-UHFFFAOYSA-N 10-(aminomethyl)-9,10-dihydroanthracene-1,2-diol Chemical compound OC1=CC=C2C(CN)C3=CC=CC=C3CC2=C1O PKJBRKTYYNRVSN-UHFFFAOYSA-N 0.000 description 2
- MPDGHEJMBKOTSU-YKLVYJNSSA-N 18beta-glycyrrhetic acid Chemical compound C([C@H]1C2=CC(=O)[C@H]34)[C@@](C)(C(O)=O)CC[C@]1(C)CC[C@@]2(C)[C@]4(C)CC[C@@H]1[C@]3(C)CC[C@H](O)C1(C)C MPDGHEJMBKOTSU-YKLVYJNSSA-N 0.000 description 2
- ZEMPKEQAKRGZGQ-AAKVHIHISA-N 2,3-bis[[(z)-12-hydroxyoctadec-9-enoyl]oxy]propyl (z)-12-hydroxyoctadec-9-enoate Chemical compound CCCCCCC(O)C\C=C/CCCCCCCC(=O)OCC(OC(=O)CCCCCCC\C=C/CC(O)CCCCCC)COC(=O)CCCCCCC\C=C/CC(O)CCCCCC ZEMPKEQAKRGZGQ-AAKVHIHISA-N 0.000 description 2
- CHHHXKFHOYLYRE-UHFFFAOYSA-M 2,4-Hexadienoic acid, potassium salt (1:1), (2E,4E)- Chemical compound [K+].CC=CC=CC([O-])=O CHHHXKFHOYLYRE-UHFFFAOYSA-M 0.000 description 2
- KIHBGTRZFAVZRV-UHFFFAOYSA-N 2-hydroxyoctadecanoic acid Chemical class CCCCCCCCCCCCCCCCC(O)C(O)=O KIHBGTRZFAVZRV-UHFFFAOYSA-N 0.000 description 2
- LEEDMQGKBNGPDN-UHFFFAOYSA-N 2-methylnonadecane Chemical compound CCCCCCCCCCCCCCCCCC(C)C LEEDMQGKBNGPDN-UHFFFAOYSA-N 0.000 description 2
- SATHPVQTSSUFFW-UHFFFAOYSA-N 4-[6-[(3,5-dihydroxy-4-methoxyoxan-2-yl)oxymethyl]-3,5-dihydroxy-4-methoxyoxan-2-yl]oxy-2-(hydroxymethyl)-6-methyloxane-3,5-diol Chemical compound OC1C(OC)C(O)COC1OCC1C(O)C(OC)C(O)C(OC2C(C(CO)OC(C)C2O)O)O1 SATHPVQTSSUFFW-UHFFFAOYSA-N 0.000 description 2
- PNWSHHILERSSLF-UHFFFAOYSA-N 4-methylbenzene-1,3-dicarboxylic acid Chemical compound CC1=CC=C(C(O)=O)C=C1C(O)=O PNWSHHILERSSLF-UHFFFAOYSA-N 0.000 description 2
- 239000002677 5-alpha reductase inhibitor Substances 0.000 description 2
- 244000235603 Acacia catechu Species 0.000 description 2
- WBZFUFAFFUEMEI-UHFFFAOYSA-M Acesulfame k Chemical compound [K+].CC1=CC(=O)[N-]S(=O)(=O)O1 WBZFUFAFFUEMEI-UHFFFAOYSA-M 0.000 description 2
- 229910018134 Al-Mg Inorganic materials 0.000 description 2
- 229910018467 Al—Mg Inorganic materials 0.000 description 2
- 239000001904 Arabinogalactan Substances 0.000 description 2
- 229920000189 Arabinogalactan Polymers 0.000 description 2
- IJGRMHOSHXDMSA-UHFFFAOYSA-N Atomic nitrogen Chemical compound N#N IJGRMHOSHXDMSA-UHFFFAOYSA-N 0.000 description 2
- 108010081589 Becaplermin Proteins 0.000 description 2
- 102100023995 Beta-nerve growth factor Human genes 0.000 description 2
- 239000004322 Butylated hydroxytoluene Substances 0.000 description 2
- NLZUEZXRPGMBCV-UHFFFAOYSA-N Butylhydroxytoluene Chemical compound CC1=CC(C(C)(C)C)=C(O)C(C(C)(C)C)=C1 NLZUEZXRPGMBCV-UHFFFAOYSA-N 0.000 description 2
- 239000004215 Carbon black (E152) Substances 0.000 description 2
- 235000004032 Centella asiatica Nutrition 0.000 description 2
- 244000146462 Centella asiatica Species 0.000 description 2
- HEDRZPFGACZZDS-UHFFFAOYSA-N Chloroform Chemical compound ClC(Cl)Cl HEDRZPFGACZZDS-UHFFFAOYSA-N 0.000 description 2
- VYZAMTAEIAYCRO-UHFFFAOYSA-N Chromium Chemical compound [Cr] VYZAMTAEIAYCRO-UHFFFAOYSA-N 0.000 description 2
- WNBCMONIPIJTSB-BGNCJLHMSA-N Cichoriin Natural products O([C@H]1[C@H](O)[C@@H](O)[C@@H](O)[C@@H](CO)O1)c1c(O)cc2c(OC(=O)C=C2)c1 WNBCMONIPIJTSB-BGNCJLHMSA-N 0.000 description 2
- 235000001258 Cinchona calisaya Nutrition 0.000 description 2
- 241000207199 Citrus Species 0.000 description 2
- 235000003363 Cornus mas Nutrition 0.000 description 2
- 240000006766 Cornus mas Species 0.000 description 2
- 241000125183 Crithmum maritimum Species 0.000 description 2
- 244000007835 Cyamopsis tetragonoloba Species 0.000 description 2
- 102100028717 Cytosolic 5'-nucleotidase 3A Human genes 0.000 description 2
- FBPFZTCFMRRESA-FSIIMWSLSA-N D-Glucitol Natural products OC[C@H](O)[C@H](O)[C@@H](O)[C@H](O)CO FBPFZTCFMRRESA-FSIIMWSLSA-N 0.000 description 2
- FBPFZTCFMRRESA-JGWLITMVSA-N D-glucitol Chemical compound OC[C@H](O)[C@@H](O)[C@H](O)[C@H](O)CO FBPFZTCFMRRESA-JGWLITMVSA-N 0.000 description 2
- RGHNJXZEOKUKBD-SQOUGZDYSA-M D-gluconate Chemical compound OC[C@@H](O)[C@@H](O)[C@H](O)[C@@H](O)C([O-])=O RGHNJXZEOKUKBD-SQOUGZDYSA-M 0.000 description 2
- GMTUGPYJRUMVTC-UHFFFAOYSA-N Daidzin Natural products OC(COc1ccc2C(=O)C(=COc2c1)c3ccc(O)cc3)C(O)C(O)C(O)C=O GMTUGPYJRUMVTC-UHFFFAOYSA-N 0.000 description 2
- KYQZWONCHDNPDP-UHFFFAOYSA-N Daidzoside Natural products OC1C(O)C(O)C(CO)OC1OC1=CC=C2C(=O)C(C=3C=CC(O)=CC=3)=COC2=C1 KYQZWONCHDNPDP-UHFFFAOYSA-N 0.000 description 2
- 201000004624 Dermatitis Diseases 0.000 description 2
- IAZDPXIOMUYVGZ-UHFFFAOYSA-N Dimethylsulphoxide Chemical compound CS(C)=O IAZDPXIOMUYVGZ-UHFFFAOYSA-N 0.000 description 2
- 206010013786 Dry skin Diseases 0.000 description 2
- ULGZDMOVFRHVEP-RWJQBGPGSA-N Erythromycin Chemical compound O([C@@H]1[C@@H](C)C(=O)O[C@@H]([C@@]([C@H](O)[C@@H](C)C(=O)[C@H](C)C[C@@](C)(O)[C@H](O[C@H]2[C@@H]([C@H](C[C@@H](C)O2)N(C)C)O)[C@H]1C)(C)O)CC)[C@H]1C[C@@](C)(OC)[C@@H](O)[C@H](C)O1 ULGZDMOVFRHVEP-RWJQBGPGSA-N 0.000 description 2
- 235000004692 Eucalyptus globulus Nutrition 0.000 description 2
- ZCOLJUOHXJRHDI-FZHKGVQDSA-N Genistein 7-O-glucoside Natural products O([C@H]1[C@H](O)[C@@H](O)[C@H](O)[C@H](CO)O1)c1cc(O)c2C(=O)C(c3ccc(O)cc3)=COc2c1 ZCOLJUOHXJRHDI-FZHKGVQDSA-N 0.000 description 2
- CJPNHKPXZYYCME-UHFFFAOYSA-N Genistin Natural products OCC1OC(Oc2ccc(O)c3OC(=CC(=O)c23)c4ccc(O)cc4)C(O)C(O)C1O CJPNHKPXZYYCME-UHFFFAOYSA-N 0.000 description 2
- 235000011201 Ginkgo Nutrition 0.000 description 2
- 235000010469 Glycine max Nutrition 0.000 description 2
- 244000068988 Glycine max Species 0.000 description 2
- MPDGHEJMBKOTSU-UHFFFAOYSA-N Glycyrrhetinsaeure Natural products C12C(=O)C=C3C4CC(C)(C(O)=O)CCC4(C)CCC3(C)C1(C)CCC1C2(C)CCC(O)C1(C)C MPDGHEJMBKOTSU-UHFFFAOYSA-N 0.000 description 2
- 241000208253 Gymnema sylvestre Species 0.000 description 2
- 241000221775 Hypocreales Species 0.000 description 2
- 108090000723 Insulin-Like Growth Factor I Proteins 0.000 description 2
- LPHGQDQBBGAPDZ-UHFFFAOYSA-N Isocaffeine Natural products CN1C(=O)N(C)C(=O)C2=C1N(C)C=N2 LPHGQDQBBGAPDZ-UHFFFAOYSA-N 0.000 description 2
- COLNVLDHVKWLRT-QMMMGPOBSA-N L-phenylalanine Chemical compound OC(=O)[C@@H](N)CC1=CC=CC=C1 COLNVLDHVKWLRT-QMMMGPOBSA-N 0.000 description 2
- 241000219745 Lupinus Species 0.000 description 2
- 241000218376 Magnoliales Species 0.000 description 2
- 108010025020 Nerve Growth Factor Proteins 0.000 description 2
- DCTLJGWMHPGCOS-UHFFFAOYSA-N Osajin Chemical compound C1=2C=CC(C)(C)OC=2C(CC=C(C)C)=C(O)C(C2=O)=C1OC=C2C1=CC=C(O)C=C1 DCTLJGWMHPGCOS-UHFFFAOYSA-N 0.000 description 2
- 239000008118 PEG 6000 Substances 0.000 description 2
- YCUNGEJJOMKCGZ-UHFFFAOYSA-N Pallidiflorin Natural products C1=CC(OC)=CC=C1C1=COC2=CC=CC(O)=C2C1=O YCUNGEJJOMKCGZ-UHFFFAOYSA-N 0.000 description 2
- 235000005035 Panax pseudoginseng ssp. pseudoginseng Nutrition 0.000 description 2
- 235000003140 Panax quinquefolius Nutrition 0.000 description 2
- 240000008440 Passiflora incarnata Species 0.000 description 2
- 235000011922 Passiflora incarnata Nutrition 0.000 description 2
- 235000000556 Paullinia cupana Nutrition 0.000 description 2
- 240000003444 Paullinia cupana Species 0.000 description 2
- ISWSIDIOOBJBQZ-UHFFFAOYSA-N Phenol Chemical compound OC1=CC=CC=C1 ISWSIDIOOBJBQZ-UHFFFAOYSA-N 0.000 description 2
- 102100040990 Platelet-derived growth factor subunit B Human genes 0.000 description 2
- 229920002584 Polyethylene Glycol 6000 Polymers 0.000 description 2
- DNIAPMSPPWPWGF-UHFFFAOYSA-N Propylene glycol Chemical compound CC(O)CO DNIAPMSPPWPWGF-UHFFFAOYSA-N 0.000 description 2
- 102100038280 Prostaglandin G/H synthase 2 Human genes 0.000 description 2
- REFJWTPEDVJJIY-UHFFFAOYSA-N Quercetin Chemical compound C=1C(O)=CC(O)=C(C(C=2O)=O)C=1OC=2C1=CC=C(O)C(O)=C1 REFJWTPEDVJJIY-UHFFFAOYSA-N 0.000 description 2
- 235000011552 Rhamnus crocea Nutrition 0.000 description 2
- 235000002357 Ribes grossularia Nutrition 0.000 description 2
- 244000171263 Ribes grossularia Species 0.000 description 2
- OUZCFMSJGDEXRT-UHFFFAOYSA-N Scandinone Natural products O=C1C=2C(OC)=C(CC=C(C)C)C=3OC(C)(C)C=CC=3C=2OC=C1C1=CC=C(O)C=C1 OUZCFMSJGDEXRT-UHFFFAOYSA-N 0.000 description 2
- 241000758724 Schisandraceae Species 0.000 description 2
- 206010039793 Seborrhoeic dermatitis Diseases 0.000 description 2
- XUIMIQQOPSSXEZ-UHFFFAOYSA-N Silicon Chemical compound [Si] XUIMIQQOPSSXEZ-UHFFFAOYSA-N 0.000 description 2
- 244000044822 Simmondsia californica Species 0.000 description 2
- 235000004433 Simmondsia californica Nutrition 0.000 description 2
- HEMHJVSKTPXQMS-UHFFFAOYSA-M Sodium hydroxide Chemical compound [OH-].[Na+] HEMHJVSKTPXQMS-UHFFFAOYSA-M 0.000 description 2
- 102000013275 Somatomedins Human genes 0.000 description 2
- 102000019197 Superoxide Dismutase Human genes 0.000 description 2
- 108010012715 Superoxide dismutase Proteins 0.000 description 2
- FEWJPZIEWOKRBE-UHFFFAOYSA-N Tartaric acid Natural products [H+].[H+].[O-]C(=O)C(O)C(O)C([O-])=O FEWJPZIEWOKRBE-UHFFFAOYSA-N 0.000 description 2
- 206010043189 Telangiectasia Diseases 0.000 description 2
- 208000002474 Tinea Diseases 0.000 description 2
- 241000130764 Tinea Species 0.000 description 2
- XSQUKJJJFZCRTK-UHFFFAOYSA-N Urea Chemical compound NC(N)=O XSQUKJJJFZCRTK-UHFFFAOYSA-N 0.000 description 2
- 241000759263 Ventia crocea Species 0.000 description 2
- FPIPGXGPPPQFEQ-BOOMUCAASA-N Vitamin A Natural products OC/C=C(/C)\C=C\C=C(\C)/C=C/C1=C(C)CCCC1(C)C FPIPGXGPPPQFEQ-BOOMUCAASA-N 0.000 description 2
- 229930003270 Vitamin B Natural products 0.000 description 2
- 235000009392 Vitis Nutrition 0.000 description 2
- 241000219095 Vitis Species 0.000 description 2
- OGQICQVSFDPSEI-UHFFFAOYSA-N Zorac Chemical compound N1=CC(C(=O)OCC)=CC=C1C#CC1=CC=C(SCCC2(C)C)C2=C1 OGQICQVSFDPSEI-UHFFFAOYSA-N 0.000 description 2
- 238000010521 absorption reaction Methods 0.000 description 2
- 235000010358 acesulfame potassium Nutrition 0.000 description 2
- 229960004998 acesulfame potassium Drugs 0.000 description 2
- 239000000619 acesulfame-K Substances 0.000 description 2
- 239000000556 agonist Substances 0.000 description 2
- 235000011399 aloe vera Nutrition 0.000 description 2
- 229940061720 alpha hydroxy acid Drugs 0.000 description 2
- 150000001280 alpha hydroxy acids Chemical class 0.000 description 2
- RGZSQWQPBWRIAQ-LSDHHAIUSA-N alpha-Bisabolol Natural products CC(C)=CCC[C@@](C)(O)[C@@H]1CCC(C)=CC1 RGZSQWQPBWRIAQ-LSDHHAIUSA-N 0.000 description 2
- BJEPYKJPYRNKOW-UHFFFAOYSA-N alpha-hydroxysuccinic acid Natural products OC(=O)C(O)CC(O)=O BJEPYKJPYRNKOW-UHFFFAOYSA-N 0.000 description 2
- 230000003321 amplification Effects 0.000 description 2
- 239000010775 animal oil Substances 0.000 description 2
- 230000003255 anti-acne Effects 0.000 description 2
- 230000000843 anti-fungal effect Effects 0.000 description 2
- 229940121375 antifungal agent Drugs 0.000 description 2
- 239000003443 antiviral agent Substances 0.000 description 2
- 235000019312 arabinogalactan Nutrition 0.000 description 2
- YZXBAPSDXZZRGB-DOFZRALJSA-N arachidonic acid Chemical compound CCCCC\C=C/C\C=C/C\C=C/C\C=C/CCCC(O)=O YZXBAPSDXZZRGB-DOFZRALJSA-N 0.000 description 2
- 201000008937 atopic dermatitis Diseases 0.000 description 2
- 230000004888 barrier function Effects 0.000 description 2
- 239000002585 base Substances 0.000 description 2
- HYNPZTKLUNHGPM-KKERQHFVSA-N becaplermin Chemical group CC[C@H](C)[C@@H](C(=O)N[C@@H](Cc1ccccc1)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](C)C(=O)N[C@@H]([C@@H](C)O)C(=O)N[C@@H](C(C)C)C(=O)N[C@@H]([C@@H](C)O)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCC(=O)O)C(=O)N[C@@H](CC(=O)O)C(=O)N[C@@H](Cc2cnc[nH]2)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](C)C(=O)N[C@@H](CS)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CS)C(=O)N[C@@H](CCC(=O)O)C(=O)N[C@@H]([C@@H](C)O)C(=O)N[C@@H](C(C)C)C(=O)N[C@@H](C)C(=O)N[C@@H](C)C(=O)N[C@@H](C)C(=O)N[C@@H](CCCNC(=N)N)C(=O)N3CCC[C@H]3C(=O)N[C@@H](C(C)C)C(=O)N[C@@H]([C@@H](C)O)C(=O)O)NC(=O)[C@@H]4CCCN4C(=O)[C@H](CCCCN)NC(=O)[C@H](CCCCN)NC(=O)[C@H](CCCNC(=N)N)NC(=O)[C@H](C(C)C)NC(=O)[C@H]([C@@H](C)CC)NC(=O)[C@H](CCC(=O)O)NC(=O)[C@H]([C@@H](C)CC)NC(=O)[C@H](CCCCN)NC(=O)[C@H](CCCNC(=N)N)NC(=O)[C@H](C(C)C)NC(=O)[C@H](CCC(=O)N)NC(=O)[C@H](C(C)C)NC(=O)[C@@H]5CCCN5C(=O)[C@H](CCCNC(=N)N)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CCC(=O)N)NC(=O)[C@H](C(C)C)NC(=O)[C@H](CCC(=O)N)NC(=O)[C@H]([C@@H](C)O)NC(=O)[C@@H]6CCCN6C(=O)[C@H](CCCNC(=N)N)NC(=O)[C@H](CS)NC(=O)[C@H](CCC(=O)N)NC(=O)[C@H](C(C)C)NC(=O)[C@H](CC(=O)N)NC(=O)[C@H](CCCNC(=N)N)NC(=O)[C@H](CC(=O)N)NC(=O)[C@H](CC(=O)N)NC(=O)[C@H](CS)NC(=O)[C@H](CS)NC(=O)CNC(=O)[C@H](CO)NC(=O)[C@H](CS)NC(=O)[C@H](CCCNC(=N)N)NC(=O)[C@H](CCC(=O)N)NC(=O)[C@H](C(C)C)NC(=O)[C@H](CCC(=O)O)NC(=O)[C@H](C(C)C)NC(=O)[C@H](CS)NC(=O)[C@H](CCCNC(=N)N)NC(=O)[C@@H]7CCCN7C(=O)[C@H](Cc8c[nH]c9c8cccc9)NC(=O)[C@H](C(C)C)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](Cc1ccccc1)NC(=O)[C@H](CC(=O)N)NC(=O)[C@H](C)NC(=O)[C@H](CC(=O)N)NC(=O)[C@H]([C@@H](C)O)NC(=O)[C@H](CCCNC(=N)N)NC(=O)[C@H](CC(=O)O)NC(=O)[C@H]([C@@H](C)CC)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CCCNC(=N)N)NC(=O)[C@H](CCCNC(=N)N)NC(=O)[C@H](CO)NC(=O)[C@H]([C@@H](C)CC)NC(=O)[C@H](CCC(=O)O)NC(=O)[C@H](Cc1ccccc1)NC(=O)[C@H](C(C)C)NC(=O)[C@H](CCC(=O)O)NC(=O)[C@H]([C@@H](C)O)NC(=O)[C@H](CCCNC(=N)N)NC(=O)[C@H]([C@@H](C)O)NC(=O)[C@H](CCCCN)NC(=O)[C@H](CS)NC(=O)[C@H](CCC(=O)O)NC(=O)[C@H](C)NC(=O)[C@H]([C@@H](C)CC)NC(=O)[C@H](CCSC)NC(=O)[C@H](C)NC(=O)[C@@H]1CCCN1C(=O)[C@H](CCC(=O)O)NC(=O)[C@H](C)NC(=O)[C@H]([C@@H](C)CC)NC(=O)[C@H]([C@@H](C)O)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CO)NC(=O)CNC(=O)[C@H](CC(C)C)NC(=O)[C@H](CO)N HYNPZTKLUNHGPM-KKERQHFVSA-N 0.000 description 2
- 229960004787 becaplermin Drugs 0.000 description 2
- 230000008901 benefit Effects 0.000 description 2
- WPYMKLBDIGXBTP-UHFFFAOYSA-N benzoic acid Chemical compound OC(=O)C1=CC=CC=C1 WPYMKLBDIGXBTP-UHFFFAOYSA-N 0.000 description 2
- 235000021028 berry Nutrition 0.000 description 2
- 235000015895 biscuits Nutrition 0.000 description 2
- 235000019282 butylated hydroxyanisole Nutrition 0.000 description 2
- 235000010354 butylated hydroxytoluene Nutrition 0.000 description 2
- 229940095259 butylated hydroxytoluene Drugs 0.000 description 2
- 229960001948 caffeine Drugs 0.000 description 2
- VJEONQKOZGKCAK-UHFFFAOYSA-N caffeine Natural products CN1C(=O)N(C)C(=O)C2=C1C=CN2C VJEONQKOZGKCAK-UHFFFAOYSA-N 0.000 description 2
- FDSDTBUPSURDBL-LOFNIBRQSA-N canthaxanthin Chemical compound CC=1C(=O)CCC(C)(C)C=1/C=C/C(/C)=C/C=C/C(/C)=C/C=C/C=C(C)C=CC=C(C)C=CC1=C(C)C(=O)CCC1(C)C FDSDTBUPSURDBL-LOFNIBRQSA-N 0.000 description 2
- 239000002775 capsule Substances 0.000 description 2
- 229910052799 carbon Inorganic materials 0.000 description 2
- 239000001569 carbon dioxide Substances 0.000 description 2
- 229910002092 carbon dioxide Inorganic materials 0.000 description 2
- 230000010261 cell growth Effects 0.000 description 2
- 239000003638 chemical reducing agent Substances 0.000 description 2
- 235000010675 chips/crisps Nutrition 0.000 description 2
- 239000011651 chromium Substances 0.000 description 2
- 229910052804 chromium Inorganic materials 0.000 description 2
- LOUPRKONTZGTKE-UHFFFAOYSA-N cinchonine Natural products C1C(C(C2)C=C)CCN2C1C(O)C1=CC=NC2=CC=C(OC)C=C21 LOUPRKONTZGTKE-UHFFFAOYSA-N 0.000 description 2
- 229960002303 citric acid monohydrate Drugs 0.000 description 2
- 235000020186 condensed milk Nutrition 0.000 description 2
- 230000001054 cortical effect Effects 0.000 description 2
- 239000003246 corticosteroid Substances 0.000 description 2
- 239000006184 cosolvent Substances 0.000 description 2
- 239000006071 cream Substances 0.000 description 2
- XUJNEKJLAYXESH-UHFFFAOYSA-N cysteine Natural products SCC(N)C(O)=O XUJNEKJLAYXESH-UHFFFAOYSA-N 0.000 description 2
- 235000018417 cysteine Nutrition 0.000 description 2
- 235000007240 daidzein Nutrition 0.000 description 2
- KYQZWONCHDNPDP-QNDFHXLGSA-N daidzein 7-O-beta-D-glucoside Chemical compound O[C@@H]1[C@@H](O)[C@H](O)[C@@H](CO)O[C@H]1OC1=CC=C2C(=O)C(C=3C=CC(O)=CC=3)=COC2=C1 KYQZWONCHDNPDP-QNDFHXLGSA-N 0.000 description 2
- YOCDGWMCBBMMGJ-UHFFFAOYSA-N delta-cadinene Natural products C1C=C(C)CC2C(C(C)C)CCC(=C)C21 YOCDGWMCBBMMGJ-UHFFFAOYSA-N 0.000 description 2
- 239000007854 depigmenting agent Substances 0.000 description 2
- 230000004069 differentiation Effects 0.000 description 2
- RXKJFZQQPQGTFL-UHFFFAOYSA-N dihydroxyacetone Chemical compound OCC(=O)CO RXKJFZQQPQGTFL-UHFFFAOYSA-N 0.000 description 2
- SNRUBQQJIBEYMU-UHFFFAOYSA-N dodecane Chemical compound CCCCCCCCCCCC SNRUBQQJIBEYMU-UHFFFAOYSA-N 0.000 description 2
- POULHZVOKOAJMA-UHFFFAOYSA-N dodecanoic acid Chemical compound CCCCCCCCCCCC(O)=O POULHZVOKOAJMA-UHFFFAOYSA-N 0.000 description 2
- 239000002552 dosage form Substances 0.000 description 2
- 229960003722 doxycycline Drugs 0.000 description 2
- 230000002500 effect on skin Effects 0.000 description 2
- 229960003720 enoxolone Drugs 0.000 description 2
- 231100000321 erythema Toxicity 0.000 description 2
- 229940093496 esculin Drugs 0.000 description 2
- AWRMZKLXZLNBBK-UHFFFAOYSA-N esculin Natural products OC1OC(COc2cc3C=CC(=O)Oc3cc2O)C(O)C(O)C1O AWRMZKLXZLNBBK-UHFFFAOYSA-N 0.000 description 2
- 238000011156 evaluation Methods 0.000 description 2
- 238000001704 evaporation Methods 0.000 description 2
- 230000002349 favourable effect Effects 0.000 description 2
- 239000000835 fiber Substances 0.000 description 2
- 210000002950 fibroblast Anatomy 0.000 description 2
- 238000001914 filtration Methods 0.000 description 2
- OVBPIULPVIDEAO-LBPRGKRZSA-N folic acid Chemical compound C=1N=C2NC(N)=NC(=O)C2=NC=1CNC1=CC=C(C(=O)N[C@@H](CCC(O)=O)C(O)=O)C=C1 OVBPIULPVIDEAO-LBPRGKRZSA-N 0.000 description 2
- 235000021433 fructose syrup Nutrition 0.000 description 2
- 235000015203 fruit juice Nutrition 0.000 description 2
- LNTHITQWFMADLM-UHFFFAOYSA-N gallic acid Chemical compound OC(=O)C1=CC(O)=C(O)C(O)=C1 LNTHITQWFMADLM-UHFFFAOYSA-N 0.000 description 2
- 210000004392 genitalia Anatomy 0.000 description 2
- 229940050410 gluconate Drugs 0.000 description 2
- 235000001727 glucose Nutrition 0.000 description 2
- 239000003292 glue Substances 0.000 description 2
- RWSXRVCMGQZWBV-WDSKDSINSA-N glutathione Chemical compound OC(=O)[C@@H](N)CCC(=O)N[C@@H](CS)C(=O)NCC(O)=O RWSXRVCMGQZWBV-WDSKDSINSA-N 0.000 description 2
- 235000003969 glutathione Nutrition 0.000 description 2
- 229960003180 glutathione Drugs 0.000 description 2
- GWDFJIBHVSYXQL-SYTFOFBDSA-N gomisin o Chemical compound COC1=C2C=3C(OC)=C(OC)C(OC)=CC=3[C@H](O)[C@@H](C)[C@@H](C)CC2=CC2=C1OCO2 GWDFJIBHVSYXQL-SYTFOFBDSA-N 0.000 description 2
- DXTIKTAIYCJTII-UHFFFAOYSA-N guanidine acetate Chemical compound CC([O-])=O.NC([NH3+])=N DXTIKTAIYCJTII-UHFFFAOYSA-N 0.000 description 2
- 238000004128 high performance liquid chromatography Methods 0.000 description 2
- 229930195733 hydrocarbon Natural products 0.000 description 2
- JYGXADMDTFJGBT-VWUMJDOOSA-N hydrocortisone Chemical compound O=C1CC[C@]2(C)[C@H]3[C@@H](O)C[C@](C)([C@@](CC4)(O)C(=O)CO)[C@@H]4[C@@H]3CCC2=C1 JYGXADMDTFJGBT-VWUMJDOOSA-N 0.000 description 2
- BJRNKVDFDLYUGJ-RMPHRYRLSA-N hydroquinone O-beta-D-glucopyranoside Chemical compound O[C@@H]1[C@@H](O)[C@H](O)[C@@H](CO)O[C@H]1OC1=CC=C(O)C=C1 BJRNKVDFDLYUGJ-RMPHRYRLSA-N 0.000 description 2
- 150000001261 hydroxy acids Chemical class 0.000 description 2
- WGCNASOHLSPBMP-UHFFFAOYSA-N hydroxyacetaldehyde Natural products OCC=O WGCNASOHLSPBMP-UHFFFAOYSA-N 0.000 description 2
- 229960000905 indomethacin Drugs 0.000 description 2
- 230000015788 innate immune response Effects 0.000 description 2
- NOESYZHRGYRDHS-UHFFFAOYSA-N insulin Chemical compound N1C(=O)C(NC(=O)C(CCC(N)=O)NC(=O)C(CCC(O)=O)NC(=O)C(C(C)C)NC(=O)C(NC(=O)CN)C(C)CC)CSSCC(C(NC(CO)C(=O)NC(CC(C)C)C(=O)NC(CC=2C=CC(O)=CC=2)C(=O)NC(CCC(N)=O)C(=O)NC(CC(C)C)C(=O)NC(CCC(O)=O)C(=O)NC(CC(N)=O)C(=O)NC(CC=2C=CC(O)=CC=2)C(=O)NC(CSSCC(NC(=O)C(C(C)C)NC(=O)C(CC(C)C)NC(=O)C(CC=2C=CC(O)=CC=2)NC(=O)C(CC(C)C)NC(=O)C(C)NC(=O)C(CCC(O)=O)NC(=O)C(C(C)C)NC(=O)C(CC(C)C)NC(=O)C(CC=2NC=NC=2)NC(=O)C(CO)NC(=O)CNC2=O)C(=O)NCC(=O)NC(CCC(O)=O)C(=O)NC(CCCNC(N)=N)C(=O)NCC(=O)NC(CC=3C=CC=CC=3)C(=O)NC(CC=3C=CC=CC=3)C(=O)NC(CC=3C=CC(O)=CC=3)C(=O)NC(C(C)O)C(=O)N3C(CCC3)C(=O)NC(CCCCN)C(=O)NC(C)C(O)=O)C(=O)NC(CC(N)=O)C(O)=O)=O)NC(=O)C(C(C)CC)NC(=O)C(CO)NC(=O)C(C(C)O)NC(=O)C1CSSCC2NC(=O)C(CC(C)C)NC(=O)C(NC(=O)C(CCC(N)=O)NC(=O)C(CC(N)=O)NC(=O)C(NC(=O)C(N)CC=1C=CC=CC=1)C(C)C)CC1=CN=CN1 NOESYZHRGYRDHS-UHFFFAOYSA-N 0.000 description 2
- 239000004310 lactic acid Substances 0.000 description 2
- 235000014655 lactic acid Nutrition 0.000 description 2
- 125000000400 lauroyl group Chemical group O=C([*])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])[H] 0.000 description 2
- 230000004132 lipogenesis Effects 0.000 description 2
- 208000019423 liver disease Diseases 0.000 description 2
- PKGKOZOYXQMJNG-UHFFFAOYSA-N lupeol Natural products CC(=C)C1CC2C(C)(CCC3C4(C)CCC5C(C)(C)C(O)CCC5(C)C4CCC23C)C1 PKGKOZOYXQMJNG-UHFFFAOYSA-N 0.000 description 2
- MQYXUWHLBZFQQO-QGTGJCAVSA-N lupeol Chemical compound C1C[C@H](O)C(C)(C)[C@@H]2CC[C@@]3(C)[C@]4(C)CC[C@@]5(C)CC[C@@H](C(=C)C)[C@@H]5[C@H]4CC[C@@H]3[C@]21C MQYXUWHLBZFQQO-QGTGJCAVSA-N 0.000 description 2
- 239000001630 malic acid Substances 0.000 description 2
- 235000011090 malic acid Nutrition 0.000 description 2
- 230000007246 mechanism Effects 0.000 description 2
- 238000002156 mixing Methods 0.000 description 2
- JXTPJDDICSTXJX-UHFFFAOYSA-N n-Triacontane Natural products CCCCCCCCCCCCCCCCCCCCCCCCCCCCCC JXTPJDDICSTXJX-UHFFFAOYSA-N 0.000 description 2
- 229940053128 nerve growth factor Drugs 0.000 description 2
- 230000001537 neural effect Effects 0.000 description 2
- 239000000041 non-steroidal anti-inflammatory agent Substances 0.000 description 2
- 229940021182 non-steroidal anti-inflammatory drug Drugs 0.000 description 2
- 238000003199 nucleic acid amplification method Methods 0.000 description 2
- 230000035764 nutrition Effects 0.000 description 2
- OQILCOQZDHPEAZ-UHFFFAOYSA-N octyl palmitate Chemical compound CCCCCCCCCCCCCCCC(=O)OCCCCCCCC OQILCOQZDHPEAZ-UHFFFAOYSA-N 0.000 description 2
- 235000020660 omega-3 fatty acid Nutrition 0.000 description 2
- AHLBNYSZXLDEJQ-FWEHEUNISA-N orlistat Chemical compound CCCCCCCCCCC[C@H](OC(=O)[C@H](CC(C)C)NC=O)C[C@@H]1OC(=O)[C@H]1CCCCCC AHLBNYSZXLDEJQ-FWEHEUNISA-N 0.000 description 2
- 229960001243 orlistat Drugs 0.000 description 2
- WYWIFABBXFUGLM-UHFFFAOYSA-N oxymetazoline Chemical compound CC1=CC(C(C)(C)C)=C(O)C(C)=C1CC1=NCCN1 WYWIFABBXFUGLM-UHFFFAOYSA-N 0.000 description 2
- SECPZKHBENQXJG-FPLPWBNLSA-N palmitoleic acid Chemical compound CCCCCC\C=C/CCCCCCCC(O)=O SECPZKHBENQXJG-FPLPWBNLSA-N 0.000 description 2
- 229960005190 phenylalanine Drugs 0.000 description 2
- 230000000886 photobiology Effects 0.000 description 2
- 230000003711 photoprotective effect Effects 0.000 description 2
- 229960005095 pioglitazone Drugs 0.000 description 2
- 239000004302 potassium sorbate Substances 0.000 description 2
- 235000010241 potassium sorbate Nutrition 0.000 description 2
- 229940069338 potassium sorbate Drugs 0.000 description 2
- 235000013406 prebiotics Nutrition 0.000 description 2
- 230000008569 process Effects 0.000 description 2
- 238000011002 quantification Methods 0.000 description 2
- 238000004445 quantitative analysis Methods 0.000 description 2
- 125000001453 quaternary ammonium group Chemical group 0.000 description 2
- 229960000948 quinine Drugs 0.000 description 2
- 238000003753 real-time PCR Methods 0.000 description 2
- 238000010839 reverse transcription Methods 0.000 description 2
- 229960004586 rosiglitazone Drugs 0.000 description 2
- 235000015067 sauces Nutrition 0.000 description 2
- 210000004761 scalp Anatomy 0.000 description 2
- 238000007790 scraping Methods 0.000 description 2
- 150000004354 sesquiterpene derivatives Chemical class 0.000 description 2
- 239000002453 shampoo Substances 0.000 description 2
- 229910052710 silicon Inorganic materials 0.000 description 2
- 239000010703 silicon Substances 0.000 description 2
- 235000020183 skimmed milk Nutrition 0.000 description 2
- 208000017520 skin disease Diseases 0.000 description 2
- 239000011734 sodium Substances 0.000 description 2
- HELHAJAZNSDZJO-OLXYHTOASA-L sodium L-tartrate Chemical compound [Na+].[Na+].[O-]C(=O)[C@H](O)[C@@H](O)C([O-])=O HELHAJAZNSDZJO-OLXYHTOASA-L 0.000 description 2
- PPASLZSBLFJQEF-RKJRWTFHSA-M sodium ascorbate Substances [Na+].OC[C@@H](O)[C@H]1OC(=O)C(O)=C1[O-] PPASLZSBLFJQEF-RKJRWTFHSA-M 0.000 description 2
- 229960005055 sodium ascorbate Drugs 0.000 description 2
- 239000001509 sodium citrate Substances 0.000 description 2
- 239000001433 sodium tartrate Substances 0.000 description 2
- 229960002167 sodium tartrate Drugs 0.000 description 2
- 235000011004 sodium tartrates Nutrition 0.000 description 2
- 239000000600 sorbitol Substances 0.000 description 2
- 235000010356 sorbitol Nutrition 0.000 description 2
- 229940032094 squalane Drugs 0.000 description 2
- WNIFXKPDILJURQ-UHFFFAOYSA-N stearyl glycyrrhizinate Natural products C1CC(O)C(C)(C)C2CCC3(C)C4(C)CCC5(C)CCC(C(=O)OCCCCCCCCCCCCCCCCCC)(C)CC5C4=CC(=O)C3C21C WNIFXKPDILJURQ-UHFFFAOYSA-N 0.000 description 2
- 230000000638 stimulation Effects 0.000 description 2
- 230000035882 stress Effects 0.000 description 2
- 239000004094 surface-active agent Substances 0.000 description 2
- 235000019605 sweet taste sensations Nutrition 0.000 description 2
- 239000011975 tartaric acid Substances 0.000 description 2
- 235000002906 tartaric acid Nutrition 0.000 description 2
- 229960000565 tazarotene Drugs 0.000 description 2
- 208000009056 telangiectasis Diseases 0.000 description 2
- YAPQBXQYLJRXSA-UHFFFAOYSA-N theobromine Chemical compound CN1C(=O)NC(=O)C2=C1N=CN2C YAPQBXQYLJRXSA-UHFFFAOYSA-N 0.000 description 2
- 229960000278 theophylline Drugs 0.000 description 2
- 238000004809 thin layer chromatography Methods 0.000 description 2
- MGSRCZKZVOBKFT-UHFFFAOYSA-N thymol Chemical compound CC(C)C1=CC=C(C)C=C1O MGSRCZKZVOBKFT-UHFFFAOYSA-N 0.000 description 2
- 210000001519 tissue Anatomy 0.000 description 2
- 239000004408 titanium dioxide Substances 0.000 description 2
- 239000011731 tocotrienol Substances 0.000 description 2
- HRXKRNGNAMMEHJ-UHFFFAOYSA-K trisodium citrate Chemical compound [Na+].[Na+].[Na+].[O-]C(=O)CC(O)(CC([O-])=O)C([O-])=O HRXKRNGNAMMEHJ-UHFFFAOYSA-K 0.000 description 2
- 229940038773 trisodium citrate Drugs 0.000 description 2
- 150000003648 triterpenes Chemical class 0.000 description 2
- 229960004441 tyrosine Drugs 0.000 description 2
- 208000019553 vascular disease Diseases 0.000 description 2
- 229940099259 vaseline Drugs 0.000 description 2
- 230000000283 vasomotion Effects 0.000 description 2
- 235000013311 vegetables Nutrition 0.000 description 2
- 235000014348 vinaigrettes Nutrition 0.000 description 2
- 235000019155 vitamin A Nutrition 0.000 description 2
- 239000011719 vitamin A Substances 0.000 description 2
- 235000019156 vitamin B Nutrition 0.000 description 2
- 229940045997 vitamin a Drugs 0.000 description 2
- 150000003722 vitamin derivatives Chemical class 0.000 description 2
- 238000005406 washing Methods 0.000 description 2
- PICXIOQBANWBIZ-UHFFFAOYSA-N zinc;1-oxidopyridine-2-thione Chemical compound [Zn+2].[O-]N1C=CC=CC1=S.[O-]N1C=CC=CC1=S PICXIOQBANWBIZ-UHFFFAOYSA-N 0.000 description 2
- 238000010153 Šidák test Methods 0.000 description 2
- WRHGORWNJGOVQY-KKUMJFAQSA-N (+)-gamma-cadinene Chemical compound C1CC(C)=C[C@H]2[C@H](C(C)C)CCC(=C)[C@@H]21 WRHGORWNJGOVQY-KKUMJFAQSA-N 0.000 description 1
- FUCYIEXQVQJBKY-ZFWWWQNUSA-N (+)-δ-Cadinene Chemical compound C1CC(C)=C[C@H]2[C@H](C(C)C)CCC(C)=C21 FUCYIEXQVQJBKY-ZFWWWQNUSA-N 0.000 description 1
- KZJWDPNRJALLNS-VPUBHVLGSA-N (-)-beta-Sitosterol Natural products O[C@@H]1CC=2[C@@](C)([C@@H]3[C@H]([C@H]4[C@@](C)([C@H]([C@H](CC[C@@H](C(C)C)CC)C)CC4)CC3)CC=2)CC1 KZJWDPNRJALLNS-VPUBHVLGSA-N 0.000 description 1
- QGVLYPPODPLXMB-UBTYZVCOSA-N (1aR,1bS,4aR,7aS,7bS,8R,9R,9aS)-4a,7b,9,9a-tetrahydroxy-3-(hydroxymethyl)-1,1,6,8-tetramethyl-1,1a,1b,4,4a,7a,7b,8,9,9a-decahydro-5H-cyclopropa[3,4]benzo[1,2-e]azulen-5-one Chemical compound C1=C(CO)C[C@]2(O)C(=O)C(C)=C[C@H]2[C@@]2(O)[C@H](C)[C@@H](O)[C@@]3(O)C(C)(C)[C@H]3[C@@H]21 QGVLYPPODPLXMB-UBTYZVCOSA-N 0.000 description 1
- HEOCBCNFKCOKBX-RELGSGGGSA-N (1s,2e,4r)-4,7,7-trimethyl-2-[(4-methylphenyl)methylidene]bicyclo[2.2.1]heptan-3-one Chemical compound C1=CC(C)=CC=C1\C=C/1C(=O)[C@]2(C)CC[C@H]\1C2(C)C HEOCBCNFKCOKBX-RELGSGGGSA-N 0.000 description 1
- RRKODOZNUZCUBN-CCAGOZQPSA-N (1z,3z)-cycloocta-1,3-diene Chemical group C1CC\C=C/C=C\C1 RRKODOZNUZCUBN-CCAGOZQPSA-N 0.000 description 1
- CSVWWLUMXNHWSU-UHFFFAOYSA-N (22E)-(24xi)-24-ethyl-5alpha-cholest-22-en-3beta-ol Natural products C1CC2CC(O)CCC2(C)C2C1C1CCC(C(C)C=CC(CC)C(C)C)C1(C)CC2 CSVWWLUMXNHWSU-UHFFFAOYSA-N 0.000 description 1
- XFZJEEAOWLFHDH-UHFFFAOYSA-N (2R,2'R,3R,3'R,4R)-3,3',4',5,7-Pentahydroxyflavan(48)-3,3',4',5,7-pentahydroxyflavan Natural products C=12OC(C=3C=C(O)C(O)=CC=3)C(O)CC2=C(O)C=C(O)C=1C(C1=C(O)C=C(O)C=C1O1)C(O)C1C1=CC=C(O)C(O)=C1 XFZJEEAOWLFHDH-UHFFFAOYSA-N 0.000 description 1
- XMAYWYJOQHXEEK-OZXSUGGESA-N (2R,4S)-ketoconazole Chemical compound C1CN(C(=O)C)CCN1C(C=C1)=CC=C1OC[C@@H]1O[C@@](CN2C=NC=C2)(C=2C(=CC(Cl)=CC=2)Cl)OC1 XMAYWYJOQHXEEK-OZXSUGGESA-N 0.000 description 1
- FYGDTMLNYKFZSV-URKRLVJHSA-N (2s,3r,4s,5s,6r)-2-[(2r,4r,5r,6s)-4,5-dihydroxy-2-(hydroxymethyl)-6-[(2r,4r,5r,6s)-4,5,6-trihydroxy-2-(hydroxymethyl)oxan-3-yl]oxyoxan-3-yl]oxy-6-(hydroxymethyl)oxane-3,4,5-triol Chemical compound O[C@@H]1[C@@H](O)[C@H](O)[C@@H](CO)O[C@H]1OC1[C@@H](CO)O[C@@H](OC2[C@H](O[C@H](O)[C@H](O)[C@H]2O)CO)[C@H](O)[C@H]1O FYGDTMLNYKFZSV-URKRLVJHSA-N 0.000 description 1
- FFTVPQUHLQBXQZ-KVUCHLLUSA-N (4s,4as,5ar,12ar)-4,7-bis(dimethylamino)-1,10,11,12a-tetrahydroxy-3,12-dioxo-4a,5,5a,6-tetrahydro-4h-tetracene-2-carboxamide Chemical compound C1C2=C(N(C)C)C=CC(O)=C2C(O)=C2[C@@H]1C[C@H]1[C@H](N(C)C)C(=O)C(C(N)=O)=C(O)[C@@]1(O)C2=O FFTVPQUHLQBXQZ-KVUCHLLUSA-N 0.000 description 1
- FRWNAQDBODEVAL-VMPITWQZSA-N (5e)-5-[(4-nitrophenyl)methylidene]-2-sulfanylidene-1,3-thiazolidin-4-one Chemical compound C1=CC([N+](=O)[O-])=CC=C1\C=C\1C(=O)NC(=S)S/1 FRWNAQDBODEVAL-VMPITWQZSA-N 0.000 description 1
- 239000001306 (7E,9E,11E,13E)-pentadeca-7,9,11,13-tetraen-1-ol Substances 0.000 description 1
- ALSTYHKOOCGGFT-KTKRTIGZSA-N (9Z)-octadecen-1-ol Chemical compound CCCCCCCC\C=C/CCCCCCCCO ALSTYHKOOCGGFT-KTKRTIGZSA-N 0.000 description 1
- MINDHVHHQZYEEK-UHFFFAOYSA-N (E)-(2S,3R,4R,5S)-5-[(2S,3S,4S,5S)-2,3-epoxy-5-hydroxy-4-methylhexyl]tetrahydro-3,4-dihydroxy-(beta)-methyl-2H-pyran-2-crotonic acid ester with 9-hydroxynonanoic acid Natural products CC(O)C(C)C1OC1CC1C(O)C(O)C(CC(C)=CC(=O)OCCCCCCCCC(O)=O)OC1 MINDHVHHQZYEEK-UHFFFAOYSA-N 0.000 description 1
- DSSYKIVIOFKYAU-XCBNKYQSSA-N (R)-camphor Chemical compound C1C[C@@]2(C)C(=O)C[C@@H]1C2(C)C DSSYKIVIOFKYAU-XCBNKYQSSA-N 0.000 description 1
- FDHNLHLOJLLXDH-JIYHLSBYSA-N (e)-3-(3-hydroxy-4-methoxyphenyl)-1-[2-hydroxy-6-methoxy-4-[(2s,3r,4s,5s,6r)-3,4,5-trihydroxy-6-[[(2r,3r,4r,5r,6s)-3,4,5-trihydroxy-6-methyloxan-2-yl]oxymethyl]oxan-2-yl]oxyphenyl]prop-2-en-1-one Chemical compound C1=C(O)C(OC)=CC=C1\C=C\C(=O)C(C(=C1)OC)=C(O)C=C1O[C@H]1[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO[C@H]2[C@@H]([C@H](O)[C@@H](O)[C@H](C)O2)O)O1 FDHNLHLOJLLXDH-JIYHLSBYSA-N 0.000 description 1
- NKJOXAZJBOMXID-UHFFFAOYSA-N 1,1'-Oxybisoctane Chemical compound CCCCCCCCOCCCCCCCC NKJOXAZJBOMXID-UHFFFAOYSA-N 0.000 description 1
- NAOLWIGVYRIGTP-UHFFFAOYSA-N 1,3,5-trihydroxyanthracene-9,10-dione Chemical compound C1=CC(O)=C2C(=O)C3=CC(O)=CC(O)=C3C(=O)C2=C1 NAOLWIGVYRIGTP-UHFFFAOYSA-N 0.000 description 1
- 150000005207 1,3-dihydroxybenzenes Chemical class 0.000 description 1
- OWEGWHBOCFMBLP-UHFFFAOYSA-N 1-(4-chlorophenoxy)-1-(1H-imidazol-1-yl)-3,3-dimethylbutan-2-one Chemical compound C1=CN=CN1C(C(=O)C(C)(C)C)OC1=CC=C(Cl)C=C1 OWEGWHBOCFMBLP-UHFFFAOYSA-N 0.000 description 1
- LEZWWPYKPKIXLL-UHFFFAOYSA-N 1-{2-(4-chlorobenzyloxy)-2-(2,4-dichlorophenyl)ethyl}imidazole Chemical group C1=CC(Cl)=CC=C1COC(C=1C(=CC(Cl)=CC=1)Cl)CN1C=NC=C1 LEZWWPYKPKIXLL-UHFFFAOYSA-N 0.000 description 1
- QMNWYGTWTXOQTP-UHFFFAOYSA-N 1h-triazin-6-one Chemical compound O=C1C=CN=NN1 QMNWYGTWTXOQTP-UHFFFAOYSA-N 0.000 description 1
- 239000000263 2,3-dihydroxypropyl (Z)-octadec-9-enoate Substances 0.000 description 1
- SPCKHVPPRJWQRZ-UHFFFAOYSA-N 2-benzhydryloxy-n,n-dimethylethanamine;2-hydroxypropane-1,2,3-tricarboxylic acid Chemical compound OC(=O)CC(O)(C(O)=O)CC(O)=O.C=1C=CC=CC=1C(OCCN(C)C)C1=CC=CC=C1 SPCKHVPPRJWQRZ-UHFFFAOYSA-N 0.000 description 1
- NCIAZCLIFWUDPR-UHFFFAOYSA-N 2-butyl-3,4,5,6-tetramethylphenol Chemical compound CCCCC1=C(C)C(C)=C(C)C(C)=C1O NCIAZCLIFWUDPR-UHFFFAOYSA-N 0.000 description 1
- TWNJSZBYPPKSFE-BAYNMDCWSA-M 2-hydroxypropyl-[2-[2-hydroxypropyl-[2-[(e)-octadec-9-enoyl]oxypropyl]amino]ethyl]-methyl-[2-[(e)-octadec-10-enoyl]oxypropyl]azanium;methyl sulfate Chemical compound COS([O-])(=O)=O.CCCCCCCC\C=C\CCCCCCCC(=O)OC(C)CN(CC(C)O)CC[N+](C)(CC(C)O)CC(C)OC(=O)CCCCCCCC\C=C\CCCCCCC TWNJSZBYPPKSFE-BAYNMDCWSA-M 0.000 description 1
- GJJVAFUKOBZPCB-UHFFFAOYSA-N 2-methyl-2-(4,8,12-trimethyltrideca-3,7,11-trienyl)-3,4-dihydrochromen-6-ol Chemical compound OC1=CC=C2OC(CCC=C(C)CCC=C(C)CCC=C(C)C)(C)CCC2=C1 GJJVAFUKOBZPCB-UHFFFAOYSA-N 0.000 description 1
- QWGRWMMWNDWRQN-UHFFFAOYSA-N 2-methylpropane-1,3-diol Chemical compound OCC(C)CO QWGRWMMWNDWRQN-UHFFFAOYSA-N 0.000 description 1
- KLEXDBGYSOIREE-UHFFFAOYSA-N 24xi-n-propylcholesterol Natural products C1C=C2CC(O)CCC2(C)C2C1C1CCC(C(C)CCC(CCC)C(C)C)C1(C)CC2 KLEXDBGYSOIREE-UHFFFAOYSA-N 0.000 description 1
- QNMKGMUGYVWVFQ-UHFFFAOYSA-N 2alpha-Hydroxyursolic acid Natural products CC12CC(O)C(O)C(C)(C)C1CCC1(C)C2CC=C2C3C(C)C(C)(C)CCC3(C(O)=O)CCC21C QNMKGMUGYVWVFQ-UHFFFAOYSA-N 0.000 description 1
- APIXJSLKIYYUKG-UHFFFAOYSA-N 3 Isobutyl 1 methylxanthine Chemical compound O=C1N(C)C(=O)N(CC(C)C)C2=C1N=CN2 APIXJSLKIYYUKG-UHFFFAOYSA-N 0.000 description 1
- MIDXCONKKJTLDX-UHFFFAOYSA-N 3,5-dimethylcyclopentane-1,2-dione Chemical compound CC1CC(C)C(=O)C1=O MIDXCONKKJTLDX-UHFFFAOYSA-N 0.000 description 1
- XKRGXCUZHCDBHJ-UHFFFAOYSA-N 3-ethyloctan-3-amine Chemical compound CCCCCC(N)(CC)CC XKRGXCUZHCDBHJ-UHFFFAOYSA-N 0.000 description 1
- RZRNAYUHWVFMIP-GDCKJWNLSA-N 3-oleoyl-sn-glycerol Chemical compound CCCCCCCC\C=C/CCCCCCCC(=O)OC[C@H](O)CO RZRNAYUHWVFMIP-GDCKJWNLSA-N 0.000 description 1
- AJBZENLMTKDAEK-UHFFFAOYSA-N 3a,5a,5b,8,8,11a-hexamethyl-1-prop-1-en-2-yl-1,2,3,4,5,6,7,7a,9,10,11,11b,12,13,13a,13b-hexadecahydrocyclopenta[a]chrysene-4,9-diol Chemical compound CC12CCC(O)C(C)(C)C1CCC(C1(C)CC3O)(C)C2CCC1C1C3(C)CCC1C(=C)C AJBZENLMTKDAEK-UHFFFAOYSA-N 0.000 description 1
- TZSXPFCNIIPDDY-UHFFFAOYSA-N 4-ethyltriazine Chemical compound CCC1=CC=NN=N1 TZSXPFCNIIPDDY-UHFFFAOYSA-N 0.000 description 1
- JOOXCMJARBKPKM-UHFFFAOYSA-N 4-oxopentanoic acid Chemical compound CC(=O)CCC(O)=O JOOXCMJARBKPKM-UHFFFAOYSA-N 0.000 description 1
- YVMBAUWDIGJRNY-BESUKNQGSA-N 4o8o7q7iu4 Chemical compound C1C(=O)C[C@H](O)\C=C(/C)\C=C\CNC(=O)\C=C\[C@@H](C)[C@@H](C(C)C)OC(=O)C2=CCCN2C(=O)C2=COC1=N2.N([C@@H]1C(=O)N[C@@H](C(N2CCC[C@H]2C(=O)N(C)[C@@H](CC=2C=CC(=CC=2)N(C)C)C(=O)N2CCC(=O)C[C@H]2C(=O)N[C@H](C(=O)O[C@@H]1C)C=1C=CC=CC=1)=O)CC)C(=O)C1=NC=CC=C1O YVMBAUWDIGJRNY-BESUKNQGSA-N 0.000 description 1
- ZGHOATLFXGBJGZ-UHFFFAOYSA-N 5-[4-(1,3-benzodioxol-5-yl)-2,3-dimethylbutyl]-2,3-dimethoxyphenol Chemical compound OC1=C(OC)C(OC)=CC(CC(C)C(C)CC=2C=C3OCOC3=CC=2)=C1 ZGHOATLFXGBJGZ-UHFFFAOYSA-N 0.000 description 1
- SQDAZGGFXASXDW-UHFFFAOYSA-N 5-bromo-2-(trifluoromethoxy)pyridine Chemical compound FC(F)(F)OC1=CC=C(Br)C=N1 SQDAZGGFXASXDW-UHFFFAOYSA-N 0.000 description 1
- BGEBZHIAGXMEMV-UHFFFAOYSA-N 5-methoxypsoralen Chemical compound O1C(=O)C=CC2=C1C=C1OC=CC1=C2OC BGEBZHIAGXMEMV-UHFFFAOYSA-N 0.000 description 1
- ODHCTXKNWHHXJC-VKHMYHEASA-N 5-oxo-L-proline Chemical compound OC(=O)[C@@H]1CCC(=O)N1 ODHCTXKNWHHXJC-VKHMYHEASA-N 0.000 description 1
- FCKUBAVAZWFDNQ-UHFFFAOYSA-N 5-oxopyrrolidine-2-carboxylic acid zinc Chemical compound [Zn].OC(=O)C1CCC(=O)N1 FCKUBAVAZWFDNQ-UHFFFAOYSA-N 0.000 description 1
- OMGPNSFUSJHLFT-UHFFFAOYSA-N 6-anilinopyridine-3-carboxylic acid Chemical compound N1=CC(C(=O)O)=CC=C1NC1=CC=CC=C1 OMGPNSFUSJHLFT-UHFFFAOYSA-N 0.000 description 1
- BUNGCZLFHHXKBX-UHFFFAOYSA-N 8-methoxypsoralen Natural products C1=CC(=O)OC2=C1C=C1CCOC1=C2OC BUNGCZLFHHXKBX-UHFFFAOYSA-N 0.000 description 1
- 235000006020 Acacia catechu Nutrition 0.000 description 1
- 244000205574 Acorus calamus Species 0.000 description 1
- 235000006480 Acorus calamus Nutrition 0.000 description 1
- 244000001632 Acorus gramineus Species 0.000 description 1
- 241001119624 Aesculus chinensis Species 0.000 description 1
- 241000157280 Aesculus hippocastanum Species 0.000 description 1
- 241001116389 Aloe Species 0.000 description 1
- 244000144927 Aloe barbadensis Species 0.000 description 1
- 235000002961 Aloe barbadensis Nutrition 0.000 description 1
- 229940077274 Alpha glucosidase inhibitor Drugs 0.000 description 1
- 241000219317 Amaranthaceae Species 0.000 description 1
- 235000005750 Ammi majus Nutrition 0.000 description 1
- 244000160914 Ammi majus Species 0.000 description 1
- 244000144725 Amygdalus communis Species 0.000 description 1
- 235000011437 Amygdalus communis Nutrition 0.000 description 1
- UIERETOOQGIECD-UHFFFAOYSA-N Angelic acid Natural products CC=C(C)C(O)=O UIERETOOQGIECD-UHFFFAOYSA-N 0.000 description 1
- 235000019737 Animal fat Nutrition 0.000 description 1
- 102000044503 Antimicrobial Peptides Human genes 0.000 description 1
- 108700042778 Antimicrobial Peptides Proteins 0.000 description 1
- 240000007087 Apium graveolens Species 0.000 description 1
- 235000015849 Apium graveolens Dulce Group Nutrition 0.000 description 1
- 235000010591 Appio Nutrition 0.000 description 1
- 235000006226 Areca catechu Nutrition 0.000 description 1
- 241001480043 Arthrodermataceae Species 0.000 description 1
- 108010011485 Aspartame Proteins 0.000 description 1
- 239000005711 Benzoic acid Substances 0.000 description 1
- 229920002498 Beta-glucan Polymers 0.000 description 1
- 229940123208 Biguanide Drugs 0.000 description 1
- XNCOSPRUTUOJCJ-UHFFFAOYSA-N Biguanide Chemical compound NC(N)=NC(N)=N XNCOSPRUTUOJCJ-UHFFFAOYSA-N 0.000 description 1
- LSNNMFCWUKXFEE-UHFFFAOYSA-M Bisulfite Chemical compound OS([O-])=O LSNNMFCWUKXFEE-UHFFFAOYSA-M 0.000 description 1
- 240000004355 Borago officinalis Species 0.000 description 1
- 235000007689 Borago officinalis Nutrition 0.000 description 1
- 238000009010 Bradford assay Methods 0.000 description 1
- 240000007124 Brassica oleracea Species 0.000 description 1
- 235000003899 Brassica oleracea var acephala Nutrition 0.000 description 1
- 235000011301 Brassica oleracea var capitata Nutrition 0.000 description 1
- 235000001169 Brassica oleracea var oleracea Nutrition 0.000 description 1
- 108010004032 Bromelains Proteins 0.000 description 1
- 239000004255 Butylated hydroxyanisole Substances 0.000 description 1
- CTMGYVXDOVJJQM-UHFFFAOYSA-N C(CCCCCCCCCC)C1=C(C(=O)O)C=CC(C1C(=O)O)(C)CO Chemical compound C(CCCCCCCCCC)C1=C(C(=O)O)C=CC(C1C(=O)O)(C)CO CTMGYVXDOVJJQM-UHFFFAOYSA-N 0.000 description 1
- 235000003880 Calendula Nutrition 0.000 description 1
- 240000001432 Calendula officinalis Species 0.000 description 1
- OKTJSMMVPCPJKN-UHFFFAOYSA-N Carbon Chemical compound [C] OKTJSMMVPCPJKN-UHFFFAOYSA-N 0.000 description 1
- QRYRORQUOLYVBU-VBKZILBWSA-N Carnosic acid Natural products CC([C@@H]1CC2)(C)CCC[C@]1(C(O)=O)C1=C2C=C(C(C)C)C(O)=C1O QRYRORQUOLYVBU-VBKZILBWSA-N 0.000 description 1
- 108010087806 Carnosine Proteins 0.000 description 1
- WLYGSPLCNKYESI-RSUQVHIMSA-N Carthamin Chemical compound O[C@@H]1[C@@H](O)[C@H](O)[C@@H](CO)O[C@H]1[C@@]1(O)C(O)=C(C(=O)\C=C\C=2C=CC(O)=CC=2)C(=O)C(\C=C\2C([C@](O)([C@H]3[C@@H]([C@@H](O)[C@H](O)[C@@H](CO)O3)O)C(O)=C(C(=O)\C=C\C=3C=CC(O)=CC=3)C/2=O)=O)=C1O WLYGSPLCNKYESI-RSUQVHIMSA-N 0.000 description 1
- 241000208809 Carthamus Species 0.000 description 1
- 102100035882 Catalase Human genes 0.000 description 1
- 108010053835 Catalase Proteins 0.000 description 1
- 229920001661 Chitosan Polymers 0.000 description 1
- 206010008570 Chloasma Diseases 0.000 description 1
- GHXZTYHSJHQHIJ-UHFFFAOYSA-N Chlorhexidine Chemical compound C=1C=C(Cl)C=CC=1NC(N)=NC(N)=NCCCCCCN=C(N)N=C(N)NC1=CC=C(Cl)C=C1 GHXZTYHSJHQHIJ-UHFFFAOYSA-N 0.000 description 1
- 229920001287 Chondroitin sulfate Polymers 0.000 description 1
- 208000017667 Chronic Disease Diseases 0.000 description 1
- 244000182633 Cinchona succirubra Species 0.000 description 1
- 235000006768 Cinchona succirubra Nutrition 0.000 description 1
- LPZCCMIISIBREI-MTFRKTCUSA-N Citrostadienol Natural products CC=C(CC[C@@H](C)[C@H]1CC[C@H]2C3=CC[C@H]4[C@H](C)[C@@H](O)CC[C@]4(C)[C@H]3CC[C@]12C)C(C)C LPZCCMIISIBREI-MTFRKTCUSA-N 0.000 description 1
- 235000007716 Citrus aurantium Nutrition 0.000 description 1
- 240000003791 Citrus myrtifolia Species 0.000 description 1
- 235000000228 Citrus myrtifolia Nutrition 0.000 description 1
- 235000016646 Citrus taiwanica Nutrition 0.000 description 1
- 206010011224 Cough Diseases 0.000 description 1
- 102000016736 Cyclin Human genes 0.000 description 1
- 108050006400 Cyclin Proteins 0.000 description 1
- 108010037462 Cyclooxygenase 2 Proteins 0.000 description 1
- PMATZTZNYRCHOR-CGLBZJNRSA-N Cyclosporin A Chemical compound CC[C@@H]1NC(=O)[C@H]([C@H](O)[C@H](C)C\C=C\C)N(C)C(=O)[C@H](C(C)C)N(C)C(=O)[C@H](CC(C)C)N(C)C(=O)[C@H](CC(C)C)N(C)C(=O)[C@@H](C)NC(=O)[C@H](C)NC(=O)[C@H](CC(C)C)N(C)C(=O)[C@H](C(C)C)NC(=O)[C@H](CC(C)C)N(C)C(=O)CN(C)C1=O PMATZTZNYRCHOR-CGLBZJNRSA-N 0.000 description 1
- 229930105110 Cyclosporin A Natural products 0.000 description 1
- 108010036949 Cyclosporine Proteins 0.000 description 1
- AUNGANRZJHBGPY-UHFFFAOYSA-N D-Lyxoflavin Natural products OCC(O)C(O)C(O)CN1C=2C=C(C)C(C)=CC=2N=C2C1=NC(=O)NC2=O AUNGANRZJHBGPY-UHFFFAOYSA-N 0.000 description 1
- MQJKPEGWNLWLTK-UHFFFAOYSA-N Dapsone Chemical compound C1=CC(N)=CC=C1S(=O)(=O)C1=CC=C(N)C=C1 MQJKPEGWNLWLTK-UHFFFAOYSA-N 0.000 description 1
- ARVGMISWLZPBCH-UHFFFAOYSA-N Dehydro-beta-sitosterol Natural products C1C(O)CCC2(C)C(CCC3(C(C(C)CCC(CC)C(C)C)CCC33)C)C3=CC=C21 ARVGMISWLZPBCH-UHFFFAOYSA-N 0.000 description 1
- 206010012434 Dermatitis allergic Diseases 0.000 description 1
- 206010012438 Dermatitis atopic Diseases 0.000 description 1
- 206010012442 Dermatitis contact Diseases 0.000 description 1
- 206010012444 Dermatitis diaper Diseases 0.000 description 1
- 206010048768 Dermatosis Diseases 0.000 description 1
- 229920001353 Dextrin Polymers 0.000 description 1
- 239000004375 Dextrin Substances 0.000 description 1
- 208000003105 Diaper Rash Diseases 0.000 description 1
- 206010012735 Diarrhoea Diseases 0.000 description 1
- 239000003109 Disodium ethylene diamine tetraacetate Substances 0.000 description 1
- 229940097420 Diuretic Drugs 0.000 description 1
- 244000133098 Echinacea angustifolia Species 0.000 description 1
- 102000002322 Egg Proteins Human genes 0.000 description 1
- 108010000912 Egg Proteins Proteins 0.000 description 1
- AFSDNFLWKVMVRB-UHFFFAOYSA-N Ellagic acid Chemical compound OC1=C(O)C(OC2=O)=C3C4=C2C=C(O)C(O)=C4OC(=O)C3=C1 AFSDNFLWKVMVRB-UHFFFAOYSA-N 0.000 description 1
- ATJXMQHAMYVHRX-CPCISQLKSA-N Ellagic acid Natural products OC1=C(O)[C@H]2OC(=O)c3cc(O)c(O)c4OC(=O)C(=C1)[C@H]2c34 ATJXMQHAMYVHRX-CPCISQLKSA-N 0.000 description 1
- 229920002079 Ellagic acid Polymers 0.000 description 1
- 102400000686 Endothelin-1 Human genes 0.000 description 1
- 101800004490 Endothelin-1 Proteins 0.000 description 1
- 241000239366 Euphausiacea Species 0.000 description 1
- 208000002306 Eye Manifestations Diseases 0.000 description 1
- 102000003974 Fibroblast growth factor 2 Human genes 0.000 description 1
- 108090000379 Fibroblast growth factor 2 Proteins 0.000 description 1
- 241000883990 Flabellum Species 0.000 description 1
- 206010016936 Folliculitis Diseases 0.000 description 1
- 229940123457 Free radical scavenger Drugs 0.000 description 1
- 229930091371 Fructose Natural products 0.000 description 1
- 239000005715 Fructose Substances 0.000 description 1
- RFSUNEUAIZKAJO-ARQDHWQXSA-N Fructose Chemical compound OC[C@H]1O[C@](O)(CO)[C@@H](O)[C@@H]1O RFSUNEUAIZKAJO-ARQDHWQXSA-N 0.000 description 1
- 241000233866 Fungi Species 0.000 description 1
- IECPWNUMDGFDKC-UHFFFAOYSA-N Fusicsaeure Natural products C12C(O)CC3C(=C(CCC=C(C)C)C(O)=O)C(OC(C)=O)CC3(C)C1(C)CCC1C2(C)CCC(O)C1C IECPWNUMDGFDKC-UHFFFAOYSA-N 0.000 description 1
- 241000287828 Gallus gallus Species 0.000 description 1
- 101150112014 Gapdh gene Proteins 0.000 description 1
- 235000000885 Garcinia xanthochymus Nutrition 0.000 description 1
- 244000119461 Garcinia xanthochymus Species 0.000 description 1
- GWDFJIBHVSYXQL-CLUVUEOHSA-N Gomisin O Natural products O(C)c1c(OC)c2-c3c(OC)c4OCOc4cc3C[C@@H](C)[C@@H](C)[C@H](O)c2cc1OC GWDFJIBHVSYXQL-CLUVUEOHSA-N 0.000 description 1
- 108010051696 Growth Hormone Proteins 0.000 description 1
- 241000208690 Hamamelis Species 0.000 description 1
- 208000005176 Hepatitis C Diseases 0.000 description 1
- 206010020112 Hirsutism Diseases 0.000 description 1
- 102100032742 Histone-lysine N-methyltransferase SETD2 Human genes 0.000 description 1
- 101000654725 Homo sapiens Histone-lysine N-methyltransferase SETD2 Proteins 0.000 description 1
- ZMJBYMUCKBYSCP-UHFFFAOYSA-N Hydroxycitric acid Chemical compound OC(=O)C(O)C(O)(C(O)=O)CC(O)=O ZMJBYMUCKBYSCP-UHFFFAOYSA-N 0.000 description 1
- DGAQECJNVWCQMB-PUAWFVPOSA-M Ilexoside XXIX Chemical compound C[C@@H]1CC[C@@]2(CC[C@@]3(C(=CC[C@H]4[C@]3(CC[C@@H]5[C@@]4(CC[C@@H](C5(C)C)OS(=O)(=O)[O-])C)C)[C@@H]2[C@]1(C)O)C)C(=O)O[C@H]6[C@@H]([C@H]([C@@H]([C@H](O6)CO)O)O)O.[Na+] DGAQECJNVWCQMB-PUAWFVPOSA-M 0.000 description 1
- 206010061598 Immunodeficiency Diseases 0.000 description 1
- 208000029462 Immunodeficiency disease Diseases 0.000 description 1
- 208000006877 Insect Bites and Stings Diseases 0.000 description 1
- 102000004877 Insulin Human genes 0.000 description 1
- 108090001061 Insulin Proteins 0.000 description 1
- 206010022489 Insulin Resistance Diseases 0.000 description 1
- 102000006992 Interferon-alpha Human genes 0.000 description 1
- 108010047761 Interferon-alpha Proteins 0.000 description 1
- 102000000589 Interleukin-1 Human genes 0.000 description 1
- 108010002352 Interleukin-1 Proteins 0.000 description 1
- SHGAZHPCJJPHSC-NUEINMDLSA-N Isotretinoin Chemical compound OC(=O)C=C(C)/C=C/C=C(C)C=CC1=C(C)CCCC1(C)C SHGAZHPCJJPHSC-NUEINMDLSA-N 0.000 description 1
- 101150028679 KLK5 gene Proteins 0.000 description 1
- XUJNEKJLAYXESH-REOHCLBHSA-N L-Cysteine Chemical compound SC[C@H](N)C(O)=O XUJNEKJLAYXESH-REOHCLBHSA-N 0.000 description 1
- WTDRDQBEARUVNC-LURJTMIESA-N L-DOPA Chemical compound OC(=O)[C@@H](N)CC1=CC=C(O)C(O)=C1 WTDRDQBEARUVNC-LURJTMIESA-N 0.000 description 1
- WTDRDQBEARUVNC-UHFFFAOYSA-N L-Dopa Natural products OC(=O)C(N)CC1=CC=C(O)C(O)=C1 WTDRDQBEARUVNC-UHFFFAOYSA-N 0.000 description 1
- PWKSKIMOESPYIA-BYPYZUCNSA-N L-N-acetyl-Cysteine Chemical compound CC(=O)N[C@@H](CS)C(O)=O PWKSKIMOESPYIA-BYPYZUCNSA-N 0.000 description 1
- LEVWYRKDKASIDU-IMJSIDKUSA-N L-cystine Chemical compound [O-]C(=O)[C@@H]([NH3+])CSSC[C@H]([NH3+])C([O-])=O LEVWYRKDKASIDU-IMJSIDKUSA-N 0.000 description 1
- FFEARJCKVFRZRR-BYPYZUCNSA-N L-methionine Chemical compound CSCC[C@H](N)C(O)=O FFEARJCKVFRZRR-BYPYZUCNSA-N 0.000 description 1
- FBOZXECLQNJBKD-ZDUSSCGKSA-N L-methotrexate Chemical compound C=1N=C2N=C(N)N=C(N)C2=NC=1CN(C)C1=CC=C(C(=O)N[C@@H](CCC(O)=O)C(O)=O)C=C1 FBOZXECLQNJBKD-ZDUSSCGKSA-N 0.000 description 1
- 240000000161 Lagerstroemia indica Species 0.000 description 1
- 244000198896 Lagerstroemia speciosa Species 0.000 description 1
- 241001598113 Laminaria digitata Species 0.000 description 1
- 229920002884 Laureth 4 Polymers 0.000 description 1
- 239000005639 Lauric acid Substances 0.000 description 1
- 241000801118 Lepidium Species 0.000 description 1
- DRDRYGIIYOPBBZ-XBXARRHUSA-N Licochalcone B Natural products COC1=C(O)C(O)=CC=C1\C=C\C(=O)C1=CC=C(O)C=C1 DRDRYGIIYOPBBZ-XBXARRHUSA-N 0.000 description 1
- WBDNTJSRHDSPSR-UHFFFAOYSA-N Licochalcone C Natural products C1=CC(O)=C(CC=C(C)C)C(OC)=C1C=CC(=O)C1=CC=C(O)C=C1 WBDNTJSRHDSPSR-UHFFFAOYSA-N 0.000 description 1
- 235000015459 Lycium barbarum Nutrition 0.000 description 1
- 244000241838 Lycium barbarum Species 0.000 description 1
- 235000019493 Macadamia oil Nutrition 0.000 description 1
- 241000514745 Mactra Species 0.000 description 1
- 208000002720 Malnutrition Diseases 0.000 description 1
- 244000070406 Malus silvestris Species 0.000 description 1
- PWHULOQIROXLJO-UHFFFAOYSA-N Manganese Chemical compound [Mn] PWHULOQIROXLJO-UHFFFAOYSA-N 0.000 description 1
- 241000378467 Melaleuca Species 0.000 description 1
- 208000003351 Melanosis Diseases 0.000 description 1
- LSDPWZHWYPCBBB-UHFFFAOYSA-N Methanethiol Chemical compound SC LSDPWZHWYPCBBB-UHFFFAOYSA-N 0.000 description 1
- QXKHYNVANLEOEG-UHFFFAOYSA-N Methoxsalen Chemical compound C1=CC(=O)OC2=C1C=C1C=COC1=C2OC QXKHYNVANLEOEG-UHFFFAOYSA-N 0.000 description 1
- 241000978725 Mimosa tenuiflora Species 0.000 description 1
- 244000302512 Momordica charantia Species 0.000 description 1
- 235000009811 Momordica charantia Nutrition 0.000 description 1
- OVBPIULPVIDEAO-UHFFFAOYSA-N N-Pteroyl-L-glutaminsaeure Natural products C=1N=C2NC(N)=NC(=O)C2=NC=1CNC1=CC=C(C(=O)NC(CCC(O)=O)C(O)=O)C=C1 OVBPIULPVIDEAO-UHFFFAOYSA-N 0.000 description 1
- CQOVPNPJLQNMDC-UHFFFAOYSA-N N-beta-alanyl-L-histidine Natural products NCCC(=O)NC(C(O)=O)CC1=CN=CN1 CQOVPNPJLQNMDC-UHFFFAOYSA-N 0.000 description 1
- 206010029113 Neovascularisation Diseases 0.000 description 1
- 108090000189 Neuropeptides Proteins 0.000 description 1
- 102000003797 Neuropeptides Human genes 0.000 description 1
- 235000002637 Nicotiana tabacum Nutrition 0.000 description 1
- 244000061176 Nicotiana tabacum Species 0.000 description 1
- GRYLNZFGIOXLOG-UHFFFAOYSA-N Nitric acid Chemical compound O[N+]([O-])=O GRYLNZFGIOXLOG-UHFFFAOYSA-N 0.000 description 1
- QLDNWJOJCDIMKK-UHFFFAOYSA-N Obtusifoliol Natural products CC12CCC(O)C(C)C1CCC1=C2CCC2(C)C(C(C)CCC(=C)C(C)C)CCC21 QLDNWJOJCDIMKK-UHFFFAOYSA-N 0.000 description 1
- YBGZDTIWKVFICR-JLHYYAGUSA-N Octyl 4-methoxycinnamic acid Chemical compound CCCCC(CC)COC(=O)\C=C\C1=CC=C(OC)C=C1 YBGZDTIWKVFICR-JLHYYAGUSA-N 0.000 description 1
- 229910019142 PO4 Inorganic materials 0.000 description 1
- 238000009193 PUVA therapy Methods 0.000 description 1
- 235000021319 Palmitoleic acid Nutrition 0.000 description 1
- 235000002789 Panax ginseng Nutrition 0.000 description 1
- 108090000526 Papain Proteins 0.000 description 1
- 235000000466 Passiflora suberosa Nutrition 0.000 description 1
- 229930182555 Penicillin Natural products 0.000 description 1
- JGSARLDLIJGVTE-MBNYWOFBSA-N Penicillin G Chemical compound N([C@H]1[C@H]2SC([C@@H](N2C1=O)C(O)=O)(C)C)C(=O)CC1=CC=CC=C1 JGSARLDLIJGVTE-MBNYWOFBSA-N 0.000 description 1
- 102000035195 Peptidases Human genes 0.000 description 1
- 102100038831 Peroxisome proliferator-activated receptor alpha Human genes 0.000 description 1
- 241000241627 Pfaffia Species 0.000 description 1
- OOUTWVMJGMVRQF-DOYZGLONSA-N Phoenicoxanthin Natural products CC(=C/C=C/C=C(C)/C=C/C=C(C)/C=C/C1=C(C)C(=O)C(O)CC1(C)C)C=CC=C(/C)C=CC2=C(C)C(=O)CCC2(C)C OOUTWVMJGMVRQF-DOYZGLONSA-N 0.000 description 1
- 102000004160 Phosphoric Monoester Hydrolases Human genes 0.000 description 1
- 108090000608 Phosphoric Monoester Hydrolases Proteins 0.000 description 1
- 206010051246 Photodermatosis Diseases 0.000 description 1
- 206010034972 Photosensitivity reaction Diseases 0.000 description 1
- 241000651950 Phyllodium Species 0.000 description 1
- 229920002556 Polyethylene Glycol 300 Polymers 0.000 description 1
- RLNUPSVMIYRZSM-UHFFFAOYSA-N Pristinamycin Natural products CC1OC(=O)C(C=2C=CC=CC=2)NC(=O)C2CC(=O)CCN2C(=O)C(CC=2C=CC(=CC=2)N(C)C)CCN(C)C(=O)C2CCCN2C(=O)C(CC)NC(=O)C1NC(=O)C1=NC=CC=C1O RLNUPSVMIYRZSM-UHFFFAOYSA-N 0.000 description 1
- 108010079780 Pristinamycin Proteins 0.000 description 1
- CWEZAWNPTYBADX-UHFFFAOYSA-N Procyanidin Natural products OC1C(OC2C(O)C(Oc3c2c(O)cc(O)c3C4C(O)C(Oc5cc(O)cc(O)c45)c6ccc(O)c(O)c6)c7ccc(O)c(O)c7)c8c(O)cc(O)cc8OC1c9ccc(O)c(O)c9 CWEZAWNPTYBADX-UHFFFAOYSA-N 0.000 description 1
- MOJZMWJRUKIQGL-FWCKPOPSSA-N Procyanidin C2 Natural products O[C@@H]1[C@@H](c2cc(O)c(O)cc2)Oc2c([C@H]3[C@H](O)[C@@H](c4cc(O)c(O)cc4)Oc4c3c(O)cc(O)c4)c(O)cc(O)c2[C@@H]1c1c(O)cc(O)c2c1O[C@@H]([C@H](O)C2)c1cc(O)c(O)cc1 MOJZMWJRUKIQGL-FWCKPOPSSA-N 0.000 description 1
- 241000241413 Propolis Species 0.000 description 1
- 108050003267 Prostaglandin G/H synthase 2 Proteins 0.000 description 1
- 102000003923 Protein Kinase C Human genes 0.000 description 1
- 108090000315 Protein Kinase C Proteins 0.000 description 1
- 244000226566 Psoralea corylifolia Species 0.000 description 1
- 241000882882 Psychotria capensis Species 0.000 description 1
- 241000410468 Pterostyrax Species 0.000 description 1
- CZPWVGJYEJSRLH-UHFFFAOYSA-N Pyrimidine Chemical compound C1=CN=CN=C1 CZPWVGJYEJSRLH-UHFFFAOYSA-N 0.000 description 1
- ODHCTXKNWHHXJC-GSVOUGTGSA-N Pyroglutamic acid Natural products OC(=O)[C@H]1CCC(=O)N1 ODHCTXKNWHHXJC-GSVOUGTGSA-N 0.000 description 1
- ZVOLCUVKHLEPEV-UHFFFAOYSA-N Quercetagetin Natural products C1=C(O)C(O)=CC=C1C1=C(O)C(=O)C2=C(O)C(O)=C(O)C=C2O1 ZVOLCUVKHLEPEV-UHFFFAOYSA-N 0.000 description 1
- 235000019484 Rapeseed oil Nutrition 0.000 description 1
- QNVSXXGDAPORNA-UHFFFAOYSA-N Resveratrol Natural products OC1=CC=CC(C=CC=2C=C(O)C(O)=CC=2)=C1 QNVSXXGDAPORNA-UHFFFAOYSA-N 0.000 description 1
- 102000034527 Retinoid X Receptors Human genes 0.000 description 1
- 108010038912 Retinoid X Receptors Proteins 0.000 description 1
- HWTZYBCRDDUBJY-UHFFFAOYSA-N Rhynchosin Natural products C1=C(O)C(O)=CC=C1C1=C(O)C(=O)C2=CC(O)=C(O)C=C2O1 HWTZYBCRDDUBJY-UHFFFAOYSA-N 0.000 description 1
- AUNGANRZJHBGPY-SCRDCRAPSA-N Riboflavin Chemical compound OC[C@@H](O)[C@@H](O)[C@@H](O)CN1C=2C=C(C)C(C)=CC=2N=C2C1=NC(=O)NC2=O AUNGANRZJHBGPY-SCRDCRAPSA-N 0.000 description 1
- 241000124033 Salix Species 0.000 description 1
- 241000899950 Salix glauca Species 0.000 description 1
- 241000277331 Salmonidae Species 0.000 description 1
- 235000005794 Salvia japonica Nutrition 0.000 description 1
- 244000295490 Salvia japonica Species 0.000 description 1
- CHQXDFSBBGKYND-UHFFFAOYSA-N Schisanol Natural products C1CC2(C)C3CCC4C(C)(C)C(O)CCC4(C)C3=CCC2(C)C1C(C)C1CC=C(C)C(=O)O1 CHQXDFSBBGKYND-UHFFFAOYSA-N 0.000 description 1
- UFCGDBKFOKKVAC-DSASHONVSA-N Schisantherin A Chemical compound O([C@H]1C=2C=C(C(=C(OC)C=2C2=C(OC)C=3OCOC=3C=C2C[C@H](C)[C@@]1(O)C)OC)OC)C(=O)C1=CC=CC=C1 UFCGDBKFOKKVAC-DSASHONVSA-N 0.000 description 1
- 206010039792 Seborrhoea Diseases 0.000 description 1
- VYPSYNLAJGMNEJ-UHFFFAOYSA-N Silicium dioxide Chemical compound O=[Si]=O VYPSYNLAJGMNEJ-UHFFFAOYSA-N 0.000 description 1
- 206010040943 Skin Ulcer Diseases 0.000 description 1
- 206010067868 Skin mass Diseases 0.000 description 1
- 102100038803 Somatotropin Human genes 0.000 description 1
- 102000007451 Steroid Receptors Human genes 0.000 description 1
- 229940100389 Sulfonylurea Drugs 0.000 description 1
- 206010042496 Sunburn Diseases 0.000 description 1
- 241000032211 Terebra Species 0.000 description 1
- 239000004098 Tetracycline Substances 0.000 description 1
- 229940123464 Thiazolidinedione Drugs 0.000 description 1
- 102000013090 Thioredoxin-Disulfide Reductase Human genes 0.000 description 1
- 108010079911 Thioredoxin-disulfide reductase Proteins 0.000 description 1
- 239000005844 Thymol Substances 0.000 description 1
- LUKBXSAWLPMMSZ-OWOJBTEDSA-N Trans-resveratrol Chemical compound C1=CC(O)=CC=C1\C=C\C1=CC(O)=CC(O)=C1 LUKBXSAWLPMMSZ-OWOJBTEDSA-N 0.000 description 1
- 108090001012 Transforming Growth Factor beta Proteins 0.000 description 1
- 102000004887 Transforming Growth Factor beta Human genes 0.000 description 1
- 108010009583 Transforming Growth Factors Proteins 0.000 description 1
- 102000009618 Transforming Growth Factors Human genes 0.000 description 1
- XEFQLINVKFYRCS-UHFFFAOYSA-N Triclosan Chemical group OC1=CC(Cl)=CC=C1OC1=CC=C(Cl)C=C1Cl XEFQLINVKFYRCS-UHFFFAOYSA-N 0.000 description 1
- 235000001484 Trigonella foenum graecum Nutrition 0.000 description 1
- 244000250129 Trigonella foenum graecum Species 0.000 description 1
- 240000001260 Tropaeolum majus Species 0.000 description 1
- 235000004424 Tropaeolum majus Nutrition 0.000 description 1
- HDOVUKNUBWVHOX-QMMMGPOBSA-N Valacyclovir Chemical compound N1C(N)=NC(=O)C2=C1N(COCCOC(=O)[C@@H](N)C(C)C)C=N2 HDOVUKNUBWVHOX-QMMMGPOBSA-N 0.000 description 1
- 235000009499 Vanilla fragrans Nutrition 0.000 description 1
- 244000263375 Vanilla tahitensis Species 0.000 description 1
- 235000012036 Vanilla tahitensis Nutrition 0.000 description 1
- 244000105017 Vicia sativa Species 0.000 description 1
- 241000700605 Viruses Species 0.000 description 1
- 229930003471 Vitamin B2 Natural products 0.000 description 1
- 235000018936 Vitellaria paradoxa Nutrition 0.000 description 1
- 241001135917 Vitellaria paradoxa Species 0.000 description 1
- 206010047642 Vitiligo Diseases 0.000 description 1
- 206010048222 Xerosis Diseases 0.000 description 1
- 241001280343 Xymalos monospora Species 0.000 description 1
- 235000009932 Zanthoxylum simulans Nutrition 0.000 description 1
- 244000089698 Zanthoxylum simulans Species 0.000 description 1
- 241001148683 Zostera marina Species 0.000 description 1
- HEAHZSUCFKFERC-IWGRKNQJSA-N [(2e)-2-[[4-[(e)-[7,7-dimethyl-3-oxo-4-(sulfomethyl)-2-bicyclo[2.2.1]heptanylidene]methyl]phenyl]methylidene]-7,7-dimethyl-3-oxo-4-bicyclo[2.2.1]heptanyl]methanesulfonic acid Chemical compound CC1(C)C2CCC1(CS(O)(=O)=O)C(=O)\C2=C\C(C=C1)=CC=C1\C=C/1C(=O)C2(CS(O)(=O)=O)CCC\1C2(C)C HEAHZSUCFKFERC-IWGRKNQJSA-N 0.000 description 1
- RWBDAAUJJAQPGB-UHFFFAOYSA-N [Zn].[S].N1C=CC=C1 Chemical compound [Zn].[S].N1C=CC=C1 RWBDAAUJJAQPGB-UHFFFAOYSA-N 0.000 description 1
- 239000001560 acacia catechu Substances 0.000 description 1
- MKUXAQIIEYXACX-UHFFFAOYSA-N aciclovir Chemical group N1C(N)=NC(=O)C2=C1N(COCCO)C=N2 MKUXAQIIEYXACX-UHFFFAOYSA-N 0.000 description 1
- 229960004150 aciclovir Drugs 0.000 description 1
- 229960005339 acitretin Drugs 0.000 description 1
- 230000004913 activation Effects 0.000 description 1
- 230000001154 acute effect Effects 0.000 description 1
- 125000002252 acyl group Chemical group 0.000 description 1
- 229960002916 adapalene Drugs 0.000 description 1
- LZCDAPDGXCYOEH-UHFFFAOYSA-N adapalene Chemical compound C1=C(C(O)=O)C=CC2=CC(C3=CC=C(C(=C3)C34CC5CC(CC(C5)C3)C4)OC)=CC=C21 LZCDAPDGXCYOEH-UHFFFAOYSA-N 0.000 description 1
- 210000001789 adipocyte Anatomy 0.000 description 1
- 210000002171 adipose macrophage Anatomy 0.000 description 1
- 239000002671 adjuvant Substances 0.000 description 1
- QNHQEUFMIKRNTB-UHFFFAOYSA-N aesculetin Natural products C1CC(=O)OC2=C1C=C(O)C(O)=C2 QNHQEUFMIKRNTB-UHFFFAOYSA-N 0.000 description 1
- GUAFOGOEJLSQBT-UHFFFAOYSA-N aesculetin dimethyl ether Natural products C1=CC(=O)OC2=C1C=C(OC)C(OC)=C2 GUAFOGOEJLSQBT-UHFFFAOYSA-N 0.000 description 1
- 230000008484 agonism Effects 0.000 description 1
- 230000001476 alcoholic effect Effects 0.000 description 1
- 150000001298 alcohols Chemical class 0.000 description 1
- 239000002170 aldosterone antagonist Substances 0.000 description 1
- 229940083712 aldosterone antagonist Drugs 0.000 description 1
- 150000001335 aliphatic alkanes Chemical class 0.000 description 1
- 125000001931 aliphatic group Chemical group 0.000 description 1
- IHUNBGSDBOWDMA-AQFIFDHZSA-N all-trans-acitretin Chemical compound COC1=CC(C)=C(\C=C\C(\C)=C\C=C\C(\C)=C\C(O)=O)C(C)=C1C IHUNBGSDBOWDMA-AQFIFDHZSA-N 0.000 description 1
- 235000020224 almond Nutrition 0.000 description 1
- 208000004631 alopecia areata Diseases 0.000 description 1
- 239000003888 alpha glucosidase inhibitor Substances 0.000 description 1
- QMAYBMKBYCGXDH-UHFFFAOYSA-N alpha-amorphene Natural products C1CC(C)=CC2C(C(C)C)CC=C(C)C21 QMAYBMKBYCGXDH-UHFFFAOYSA-N 0.000 description 1
- 230000003698 anagen phase Effects 0.000 description 1
- 208000007502 anemia Diseases 0.000 description 1
- UIERETOOQGIECD-ARJAWSKDSA-N angelic acid Chemical compound C\C=C(\C)C(O)=O UIERETOOQGIECD-ARJAWSKDSA-N 0.000 description 1
- 150000003931 anilides Chemical class 0.000 description 1
- 239000005557 antagonist Substances 0.000 description 1
- 229930014669 anthocyanidin Natural products 0.000 description 1
- 150000001452 anthocyanidin derivatives Chemical class 0.000 description 1
- 235000008758 anthocyanidins Nutrition 0.000 description 1
- 230000000844 anti-bacterial effect Effects 0.000 description 1
- 230000003627 anti-cholesterol Effects 0.000 description 1
- 230000001387 anti-histamine Effects 0.000 description 1
- 229940121363 anti-inflammatory agent Drugs 0.000 description 1
- 239000002260 anti-inflammatory agent Substances 0.000 description 1
- 230000000845 anti-microbial effect Effects 0.000 description 1
- 239000000051 antiandrogen Substances 0.000 description 1
- 239000000739 antihistaminic agent Substances 0.000 description 1
- 239000004599 antimicrobial Substances 0.000 description 1
- 229940124522 antiretrovirals Drugs 0.000 description 1
- 239000003903 antiretrovirus agent Substances 0.000 description 1
- 235000021407 appetite control Nutrition 0.000 description 1
- 235000021016 apples Nutrition 0.000 description 1
- 238000013459 approach Methods 0.000 description 1
- 229940114079 arachidonic acid Drugs 0.000 description 1
- 235000021342 arachidonic acid Nutrition 0.000 description 1
- 229960000271 arbutin Drugs 0.000 description 1
- JXSVIVRDWWRQRT-UYDOISQJSA-N asiatic acid Chemical compound C1[C@@H](O)[C@H](O)[C@@](C)(CO)[C@@H]2CC[C@@]3(C)[C@]4(C)CC[C@@]5(C(O)=O)CC[C@@H](C)[C@H](C)[C@H]5C4=CC[C@@H]3[C@]21C JXSVIVRDWWRQRT-UYDOISQJSA-N 0.000 description 1
- 229940011658 asiatic acid Drugs 0.000 description 1
- LBGFKBYMNRAMFC-PYSQTNCISA-N asiatic acid Natural products C[C@@H]1CC[C@@]2(CC[C@]3(C)C(=CC[C@@H]4[C@@]5(C)C[C@@H](O)[C@H](O)[C@@](C)(CO)[C@@H]5CC[C@@]34C)[C@]2(C)[C@H]1C)C(=O)O LBGFKBYMNRAMFC-PYSQTNCISA-N 0.000 description 1
- 239000000605 aspartame Substances 0.000 description 1
- 235000010357 aspartame Nutrition 0.000 description 1
- IAOZJIPTCAWIRG-QWRGUYRKSA-N aspartame Chemical compound OC(=O)C[C@H](N)C(=O)N[C@H](C(=O)OC)CC1=CC=CC=C1 IAOZJIPTCAWIRG-QWRGUYRKSA-N 0.000 description 1
- 229960003438 aspartame Drugs 0.000 description 1
- 229940050000 astaxanthin 4 mg Drugs 0.000 description 1
- 208000006673 asthma Diseases 0.000 description 1
- LMEKQMALGUDUQG-UHFFFAOYSA-N azathioprine Chemical compound CN1C=NC([N+]([O-])=O)=C1SC1=NC=NC2=C1NC=N2 LMEKQMALGUDUQG-UHFFFAOYSA-N 0.000 description 1
- 229960002170 azathioprine Drugs 0.000 description 1
- 229960002255 azelaic acid Drugs 0.000 description 1
- XVAMCHGMPYWHNL-UHFFFAOYSA-N bemotrizinol Chemical compound OC1=CC(OCC(CC)CCCC)=CC=C1C1=NC(C=2C=CC(OC)=CC=2)=NC(C=2C(=CC(OCC(CC)CCCC)=CC=2)O)=N1 XVAMCHGMPYWHNL-UHFFFAOYSA-N 0.000 description 1
- 229960004101 bemotrizinol Drugs 0.000 description 1
- 235000010233 benzoic acid Nutrition 0.000 description 1
- RWCCWEUUXYIKHB-UHFFFAOYSA-N benzophenone Chemical compound C=1C=CC=CC=1C(=O)C1=CC=CC=C1 RWCCWEUUXYIKHB-UHFFFAOYSA-N 0.000 description 1
- 239000012965 benzophenone Substances 0.000 description 1
- 229940024874 benzophenone Drugs 0.000 description 1
- 229960003328 benzoyl peroxide Drugs 0.000 description 1
- 239000002876 beta blocker Substances 0.000 description 1
- 229940097320 beta blocking agent Drugs 0.000 description 1
- 150000001277 beta hydroxy acids Chemical class 0.000 description 1
- DYLPEFGBWGEFBB-UHFFFAOYSA-N beta-Cedren Natural products C1C23C(C)CCC3C(C)(C)C1C(=C)CC2 DYLPEFGBWGEFBB-UHFFFAOYSA-N 0.000 description 1
- MJVXAPPOFPTTCA-UHFFFAOYSA-N beta-Sistosterol Natural products CCC(CCC(C)C1CCC2C3CC=C4C(C)C(O)CCC4(C)C3CCC12C)C(C)C MJVXAPPOFPTTCA-UHFFFAOYSA-N 0.000 description 1
- LGJMUZUPVCAVPU-UHFFFAOYSA-N beta-Sitostanol Natural products C1CC2CC(O)CCC2(C)C2C1C1CCC(C(C)CCC(CC)C(C)C)C1(C)CC2 LGJMUZUPVCAVPU-UHFFFAOYSA-N 0.000 description 1
- NJKOMDUNNDKEAI-UHFFFAOYSA-N beta-sitosterol Natural products CCC(CCC(C)C1CCC2(C)C3CC=C4CC(O)CCC4C3CCC12C)C(C)C NJKOMDUNNDKEAI-UHFFFAOYSA-N 0.000 description 1
- 125000002619 bicyclic group Chemical group 0.000 description 1
- FQUNFJULCYSSOP-UHFFFAOYSA-N bisoctrizole Chemical compound N1=C2C=CC=CC2=NN1C1=CC(C(C)(C)CC(C)(C)C)=CC(CC=2C(=C(C=C(C=2)C(C)(C)CC(C)(C)C)N2N=C3C=CC=CC3=N2)O)=C1O FQUNFJULCYSSOP-UHFFFAOYSA-N 0.000 description 1
- 210000001124 body fluid Anatomy 0.000 description 1
- 239000010839 body fluid Substances 0.000 description 1
- 230000037396 body weight Effects 0.000 description 1
- 238000009835 boiling Methods 0.000 description 1
- 235000021324 borage oil Nutrition 0.000 description 1
- 235000008429 bread Nutrition 0.000 description 1
- 235000019835 bromelain Nutrition 0.000 description 1
- 210000000621 bronchi Anatomy 0.000 description 1
- 239000001273 butane Substances 0.000 description 1
- CZBZUDVBLSSABA-UHFFFAOYSA-N butylated hydroxyanisole Chemical compound COC1=CC=C(O)C(C(C)(C)C)=C1.COC1=CC=C(O)C=C1C(C)(C)C CZBZUDVBLSSABA-UHFFFAOYSA-N 0.000 description 1
- 229940043253 butylated hydroxyanisole Drugs 0.000 description 1
- 239000006227 byproduct Substances 0.000 description 1
- 229960002882 calcipotriol Drugs 0.000 description 1
- LWQQLNNNIPYSNX-UROSTWAQSA-N calcipotriol Chemical compound C1([C@H](O)/C=C/[C@@H](C)[C@@H]2[C@]3(CCCC(/[C@@H]3CC2)=C\C=C\2C([C@@H](O)C[C@H](O)C/2)=C)C)CC1 LWQQLNNNIPYSNX-UROSTWAQSA-N 0.000 description 1
- 229960005069 calcium Drugs 0.000 description 1
- 229940025250 camphora Drugs 0.000 description 1
- 239000010238 camphora Substances 0.000 description 1
- 239000004204 candelilla wax Substances 0.000 description 1
- 229940073532 candelilla wax Drugs 0.000 description 1
- 235000013868 candelilla wax Nutrition 0.000 description 1
- 235000012682 canthaxanthin Nutrition 0.000 description 1
- 239000001659 canthaxanthin Substances 0.000 description 1
- 229940008033 canthaxanthin Drugs 0.000 description 1
- 235000013736 caramel Nutrition 0.000 description 1
- 239000004202 carbamide Substances 0.000 description 1
- 150000001720 carbohydrates Chemical class 0.000 description 1
- 235000014633 carbohydrates Nutrition 0.000 description 1
- 229910002091 carbon monoxide Inorganic materials 0.000 description 1
- 239000002327 cardiovascular agent Substances 0.000 description 1
- 229940125692 cardiovascular agent Drugs 0.000 description 1
- 229960004203 carnitine Drugs 0.000 description 1
- 229940044199 carnosine Drugs 0.000 description 1
- CQOVPNPJLQNMDC-ZETCQYMHSA-N carnosine Chemical compound [NH3+]CCC(=O)N[C@H](C([O-])=O)CC1=CNC=N1 CQOVPNPJLQNMDC-ZETCQYMHSA-N 0.000 description 1
- 235000021466 carotenoid Nutrition 0.000 description 1
- 150000001747 carotenoids Chemical class 0.000 description 1
- ADRVNXBAWSRFAJ-UHFFFAOYSA-N catechin Natural products OC1Cc2cc(O)cc(O)c2OC1c3ccc(O)c(O)c3 ADRVNXBAWSRFAJ-UHFFFAOYSA-N 0.000 description 1
- 235000005487 catechin Nutrition 0.000 description 1
- 150000001768 cations Chemical class 0.000 description 1
- 239000013592 cell lysate Substances 0.000 description 1
- 230000003833 cell viability Effects 0.000 description 1
- 229940081733 cetearyl alcohol Drugs 0.000 description 1
- 229960002788 cetrimonium chloride Drugs 0.000 description 1
- WOWHHFRSBJGXCM-UHFFFAOYSA-M cetyltrimethylammonium chloride Chemical compound [Cl-].CCCCCCCCCCCCCCCC[N+](C)(C)C WOWHHFRSBJGXCM-UHFFFAOYSA-M 0.000 description 1
- 229940119217 chamomile extract Drugs 0.000 description 1
- 235000020221 chamomile extract Nutrition 0.000 description 1
- 230000008859 change Effects 0.000 description 1
- 235000013351 cheese Nutrition 0.000 description 1
- 239000013522 chelant Substances 0.000 description 1
- 239000002738 chelating agent Substances 0.000 description 1
- 238000006243 chemical reaction Methods 0.000 description 1
- 238000002512 chemotherapy Methods 0.000 description 1
- 229940112822 chewing gum Drugs 0.000 description 1
- 235000015218 chewing gum Nutrition 0.000 description 1
- 229960003260 chlorhexidine Drugs 0.000 description 1
- 229940059329 chondroitin sulfate Drugs 0.000 description 1
- 208000019902 chronic diarrheal disease Diseases 0.000 description 1
- 229950001002 cianidanol Drugs 0.000 description 1
- 210000000589 cicatrix Anatomy 0.000 description 1
- 229960003749 ciclopirox Drugs 0.000 description 1
- SCKYRAXSEDYPSA-UHFFFAOYSA-N ciclopirox Chemical compound ON1C(=O)C=C(C)C=C1C1CCCCC1 SCKYRAXSEDYPSA-UHFFFAOYSA-N 0.000 description 1
- 229960001265 ciclosporin Drugs 0.000 description 1
- SECPZKHBENQXJG-UHFFFAOYSA-N cis-palmitoleic acid Natural products CCCCCCC=CCCCCCCCC(O)=O SECPZKHBENQXJG-UHFFFAOYSA-N 0.000 description 1
- 239000004927 clay Substances 0.000 description 1
- 229960003344 climbazole Drugs 0.000 description 1
- 229960002227 clindamycin Drugs 0.000 description 1
- KDLRVYVGXIQJDK-AWPVFWJPSA-N clindamycin Chemical compound CN1C[C@H](CCC)C[C@H]1C(=O)N[C@H]([C@H](C)Cl)[C@@H]1[C@H](O)[C@H](O)[C@@H](O)[C@@H](SC)O1 KDLRVYVGXIQJDK-AWPVFWJPSA-N 0.000 description 1
- 235000019864 coconut oil Nutrition 0.000 description 1
- 239000003240 coconut oil Substances 0.000 description 1
- 239000003086 colorant Substances 0.000 description 1
- 238000002485 combustion reaction Methods 0.000 description 1
- 230000000052 comparative effect Effects 0.000 description 1
- 230000000295 complement effect Effects 0.000 description 1
- 229920002770 condensed tannin Polymers 0.000 description 1
- 208000034557 congenital alopecia Diseases 0.000 description 1
- 208000010247 contact dermatitis Diseases 0.000 description 1
- 238000010411 cooking Methods 0.000 description 1
- 229920001577 copolymer Polymers 0.000 description 1
- 235000005687 corn oil Nutrition 0.000 description 1
- 239000002285 corn oil Substances 0.000 description 1
- 108091008723 corticosteroid receptors Proteins 0.000 description 1
- 229930182912 cyclosporin Natural products 0.000 description 1
- 229960003067 cystine Drugs 0.000 description 1
- KWGRBVOPPLSCSI-UHFFFAOYSA-N d-ephedrine Natural products CNC(C)C(O)C1=CC=CC=C1 KWGRBVOPPLSCSI-UHFFFAOYSA-N 0.000 description 1
- 229960000860 dapsone Drugs 0.000 description 1
- GHVNFZFCNZKVNT-UHFFFAOYSA-M decanoate Chemical compound CCCCCCCCCC([O-])=O GHVNFZFCNZKVNT-UHFFFAOYSA-M 0.000 description 1
- 238000005034 decoration Methods 0.000 description 1
- 239000013530 defoamer Substances 0.000 description 1
- 230000018044 dehydration Effects 0.000 description 1
- 238000006297 dehydration reaction Methods 0.000 description 1
- 238000006356 dehydrogenation reaction Methods 0.000 description 1
- 238000000326 densiometry Methods 0.000 description 1
- 238000004332 deodorization Methods 0.000 description 1
- 230000035614 depigmentation Effects 0.000 description 1
- 230000037304 dermatophytes Effects 0.000 description 1
- WBGKWQHBNHJJPZ-LECWWXJVSA-N desonide Chemical compound C1CC2=CC(=O)C=C[C@]2(C)[C@@H]2[C@@H]1[C@@H]1C[C@H]3OC(C)(C)O[C@@]3(C(=O)CO)[C@@]1(C)C[C@@H]2O WBGKWQHBNHJJPZ-LECWWXJVSA-N 0.000 description 1
- 229960003662 desonide Drugs 0.000 description 1
- 229960003949 dexpanthenol Drugs 0.000 description 1
- 235000019425 dextrin Nutrition 0.000 description 1
- 206010012601 diabetes mellitus Diseases 0.000 description 1
- 150000001982 diacylglycerols Chemical class 0.000 description 1
- 235000005911 diet Nutrition 0.000 description 1
- 235000007882 dietary composition Nutrition 0.000 description 1
- 230000000378 dietary effect Effects 0.000 description 1
- MTHSVFCYNBDYFN-UHFFFAOYSA-N diethylene glycol Chemical compound OCCOCCO MTHSVFCYNBDYFN-UHFFFAOYSA-N 0.000 description 1
- 238000009792 diffusion process Methods 0.000 description 1
- 229940120503 dihydroxyacetone Drugs 0.000 description 1
- PKPOVTYZGGYDIJ-UHFFFAOYSA-N dioctyl carbonate Chemical compound CCCCCCCCOC(=O)OCCCCCCCC PKPOVTYZGGYDIJ-UHFFFAOYSA-N 0.000 description 1
- 229960000520 diphenhydramine Drugs 0.000 description 1
- 208000016097 disease of metabolism Diseases 0.000 description 1
- 235000021186 dishes Nutrition 0.000 description 1
- 235000019301 disodium ethylene diamine tetraacetate Nutrition 0.000 description 1
- 229930004069 diterpene Natural products 0.000 description 1
- 150000004141 diterpene derivatives Chemical class 0.000 description 1
- 239000002934 diuretic Substances 0.000 description 1
- 230000001882 diuretic effect Effects 0.000 description 1
- LQZZUXJYWNFBMV-UHFFFAOYSA-N dodecan-1-ol Chemical compound CCCCCCCCCCCCO LQZZUXJYWNFBMV-UHFFFAOYSA-N 0.000 description 1
- DLAHAXOYRFRPFQ-UHFFFAOYSA-N dodecyl benzoate Chemical compound CCCCCCCCCCCCOC(=O)C1=CC=CC=C1 DLAHAXOYRFRPFQ-UHFFFAOYSA-N 0.000 description 1
- 231100000673 dose–response relationship Toxicity 0.000 description 1
- 230000037336 dry skin Effects 0.000 description 1
- JWJOTENAMICLJG-QWBYCMEYSA-N dutasteride Chemical compound O=C([C@H]1CC[C@H]2[C@H]3[C@@H]([C@]4(C=CC(=O)N[C@@H]4CC3)C)CC[C@@]21C)NC1=CC(C(F)(F)F)=CC=C1C(F)(F)F JWJOTENAMICLJG-QWBYCMEYSA-N 0.000 description 1
- 229960004199 dutasteride Drugs 0.000 description 1
- 235000014134 echinacea Nutrition 0.000 description 1
- 229960003913 econazole Drugs 0.000 description 1
- 235000013601 eggs Nutrition 0.000 description 1
- 230000008030 elimination Effects 0.000 description 1
- 238000003379 elimination reaction Methods 0.000 description 1
- 229960002852 ellagic acid Drugs 0.000 description 1
- 235000004132 ellagic acid Nutrition 0.000 description 1
- HTCXJNNIWILFQQ-UHFFFAOYSA-M emmi Chemical compound ClC1=C(Cl)C2(Cl)C3C(=O)N([Hg]CC)C(=O)C3C1(Cl)C2(Cl)Cl HTCXJNNIWILFQQ-UHFFFAOYSA-M 0.000 description 1
- 230000008451 emotion Effects 0.000 description 1
- 238000005538 encapsulation Methods 0.000 description 1
- 210000003038 endothelium Anatomy 0.000 description 1
- 229960004697 enzacamene Drugs 0.000 description 1
- 229960002179 ephedrine Drugs 0.000 description 1
- 229960003276 erythromycin Drugs 0.000 description 1
- CLXOLTFMHAXJST-UHFFFAOYSA-N esculentic acid Natural products C12CC=C3C4CC(C)(C(O)=O)CCC4(C(O)=O)CCC3(C)C1(C)CCC1C2(C)CCC(O)C1(CO)C CLXOLTFMHAXJST-UHFFFAOYSA-N 0.000 description 1
- ILEDWLMCKZNDJK-UHFFFAOYSA-N esculetin Chemical compound C1=CC(=O)OC2=C1C=C(O)C(O)=C2 ILEDWLMCKZNDJK-UHFFFAOYSA-N 0.000 description 1
- 230000032050 esterification Effects 0.000 description 1
- 238000005886 esterification reaction Methods 0.000 description 1
- 238000002481 ethanol extraction Methods 0.000 description 1
- SFNALCNOMXIBKG-UHFFFAOYSA-N ethylene glycol monododecyl ether Chemical compound CCCCCCCCCCCCOCCO SFNALCNOMXIBKG-UHFFFAOYSA-N 0.000 description 1
- 241001233957 eudicotyledons Species 0.000 description 1
- 230000008020 evaporation Effects 0.000 description 1
- 238000004299 exfoliation Methods 0.000 description 1
- 238000013213 extrapolation Methods 0.000 description 1
- 208000011318 facial edema Diseases 0.000 description 1
- 230000001815 facial effect Effects 0.000 description 1
- 238000000855 fermentation Methods 0.000 description 1
- 230000004151 fermentation Effects 0.000 description 1
- 239000000706 filtrate Substances 0.000 description 1
- 229960004039 finasteride Drugs 0.000 description 1
- DBEPLOCGEIEOCV-WSBQPABSSA-N finasteride Chemical compound N([C@@H]1CC2)C(=O)C=C[C@]1(C)[C@@H]1[C@@H]2[C@@H]2CC[C@H](C(=O)NC(C)(C)C)[C@@]2(C)CC1 DBEPLOCGEIEOCV-WSBQPABSSA-N 0.000 description 1
- 210000004905 finger nail Anatomy 0.000 description 1
- QOLIPNRNLBQTAU-UHFFFAOYSA-N flavan Chemical group C1CC2=CC=CC=C2OC1C1=CC=CC=C1 QOLIPNRNLBQTAU-UHFFFAOYSA-N 0.000 description 1
- 235000019634 flavors Nutrition 0.000 description 1
- 229960001347 fluocinolone acetonide Drugs 0.000 description 1
- FEBLZLNTKCEFIT-VSXGLTOVSA-N fluocinolone acetonide Chemical compound C1([C@@H](F)C2)=CC(=O)C=C[C@]1(C)[C@]1(F)[C@@H]2[C@@H]2C[C@H]3OC(C)(C)O[C@@]3(C(=O)CO)[C@@]2(C)C[C@@H]1O FEBLZLNTKCEFIT-VSXGLTOVSA-N 0.000 description 1
- 229960000289 fluticasone propionate Drugs 0.000 description 1
- WMWTYOKRWGGJOA-CENSZEJFSA-N fluticasone propionate Chemical compound C1([C@@H](F)C2)=CC(=O)C=C[C@]1(C)[C@]1(F)[C@@H]2[C@@H]2C[C@@H](C)[C@@](C(=O)SCF)(OC(=O)CC)[C@@]2(C)C[C@@H]1O WMWTYOKRWGGJOA-CENSZEJFSA-N 0.000 description 1
- 239000006260 foam Substances 0.000 description 1
- 229960000304 folic acid Drugs 0.000 description 1
- 235000019152 folic acid Nutrition 0.000 description 1
- 239000011724 folic acid Substances 0.000 description 1
- 238000013467 fragmentation Methods 0.000 description 1
- 238000006062 fragmentation reaction Methods 0.000 description 1
- 239000003205 fragrance Substances 0.000 description 1
- SJWWTRQNNRNTPU-ABBNZJFMSA-N fucoxanthin Chemical compound C[C@@]1(O)C[C@@H](OC(=O)C)CC(C)(C)C1=C=C\C(C)=C\C=C\C(\C)=C\C=C\C=C(/C)\C=C\C=C(/C)C(=O)C[C@]1(C(C[C@H](O)C2)(C)C)[C@]2(C)O1 SJWWTRQNNRNTPU-ABBNZJFMSA-N 0.000 description 1
- AQLRNQCFQNNMJA-UHFFFAOYSA-N fucoxanthin Natural products CC(=O)OC1CC(C)(C)C(=C=CC(=CC=CC(=CC=CC=C(/C)C=CC=C(/C)C(=O)CC23OC2(C)CC(O)CC3(C)C)C)CO)C(C)(O)C1 AQLRNQCFQNNMJA-UHFFFAOYSA-N 0.000 description 1
- IECPWNUMDGFDKC-MZJAQBGESA-N fusidic acid Chemical group O[C@@H]([C@@H]12)C[C@H]3\C(=C(/CCC=C(C)C)C(O)=O)[C@@H](OC(C)=O)C[C@]3(C)[C@@]2(C)CC[C@@H]2[C@]1(C)CC[C@@H](O)[C@H]2C IECPWNUMDGFDKC-MZJAQBGESA-N 0.000 description 1
- 229960004675 fusidic acid Drugs 0.000 description 1
- 229940074391 gallic acid Drugs 0.000 description 1
- 235000004515 gallic acid Nutrition 0.000 description 1
- JBHJOURGKXURIW-UHFFFAOYSA-N gamma-cadinene Natural products CC(C)C1CCC(=C2CCC(=C)CC12)C JBHJOURGKXURIW-UHFFFAOYSA-N 0.000 description 1
- 235000021189 garnishes Nutrition 0.000 description 1
- 239000000499 gel Substances 0.000 description 1
- 230000002068 genetic effect Effects 0.000 description 1
- 208000007565 gingivitis Diseases 0.000 description 1
- 239000003862 glucocorticoid Substances 0.000 description 1
- 150000002337 glycosamines Chemical class 0.000 description 1
- 230000002710 gonadal effect Effects 0.000 description 1
- 230000005484 gravity Effects 0.000 description 1
- 229940094952 green tea extract Drugs 0.000 description 1
- 235000020688 green tea extract Nutrition 0.000 description 1
- 229940053688 green tea extract 200 mg Drugs 0.000 description 1
- 239000003102 growth factor Substances 0.000 description 1
- 239000000122 growth hormone Substances 0.000 description 1
- 239000001963 growth medium Substances 0.000 description 1
- 238000010438 heat treatment Methods 0.000 description 1
- KWLMIXQRALPRBC-UHFFFAOYSA-L hectorite Chemical compound [Li+].[OH-].[OH-].[Na+].[Mg+2].O1[Si]2([O-])O[Si]1([O-])O[Si]([O-])(O1)O[Si]1([O-])O2 KWLMIXQRALPRBC-UHFFFAOYSA-L 0.000 description 1
- 229910000271 hectorite Inorganic materials 0.000 description 1
- IUJAMGNYPWYUPM-UHFFFAOYSA-N hentriacontane Chemical compound CCCCCCCCCCCCCCCCCCCCCCCCCCCCCCC IUJAMGNYPWYUPM-UHFFFAOYSA-N 0.000 description 1
- 241000411851 herbal medicine Species 0.000 description 1
- 229940076640 hesperidin methylchalcone Drugs 0.000 description 1
- UBHWBODXJBSFLH-UHFFFAOYSA-N hexadecan-1-ol;octadecan-1-ol Chemical compound CCCCCCCCCCCCCCCCO.CCCCCCCCCCCCCCCCCCO UBHWBODXJBSFLH-UHFFFAOYSA-N 0.000 description 1
- IPCSVZSSVZVIGE-UHFFFAOYSA-M hexadecanoate Chemical compound CCCCCCCCCCCCCCCC([O-])=O IPCSVZSSVZVIGE-UHFFFAOYSA-M 0.000 description 1
- ACCCMOQWYVYDOT-UHFFFAOYSA-N hexane-1,1-diol Chemical compound CCCCCC(O)O ACCCMOQWYVYDOT-UHFFFAOYSA-N 0.000 description 1
- 230000002061 histotrophic effect Effects 0.000 description 1
- 235000010181 horse chestnut Nutrition 0.000 description 1
- 235000012171 hot beverage Nutrition 0.000 description 1
- 229960000890 hydrocortisone Drugs 0.000 description 1
- 229920001461 hydrolysable tannin Polymers 0.000 description 1
- 229940089491 hydroxycitric acid Drugs 0.000 description 1
- ZQDWXGKKHFNSQK-UHFFFAOYSA-N hydroxyzine Chemical compound C1CN(CCOCCO)CCN1C(C=1C=CC(Cl)=CC=1)C1=CC=CC=C1 ZQDWXGKKHFNSQK-UHFFFAOYSA-N 0.000 description 1
- 229960000930 hydroxyzine Drugs 0.000 description 1
- 206010020718 hyperplasia Diseases 0.000 description 1
- 235000015243 ice cream Nutrition 0.000 description 1
- 208000026278 immune system disease Diseases 0.000 description 1
- 230000007813 immunodeficiency Effects 0.000 description 1
- 229960003444 immunosuppressant agent Drugs 0.000 description 1
- 230000001861 immunosuppressant effect Effects 0.000 description 1
- 239000003018 immunosuppressive agent Substances 0.000 description 1
- 238000011534 incubation Methods 0.000 description 1
- 230000006698 induction Effects 0.000 description 1
- 208000027866 inflammatory disease Diseases 0.000 description 1
- 230000000977 initiatory effect Effects 0.000 description 1
- 238000002347 injection Methods 0.000 description 1
- 239000007924 injection Substances 0.000 description 1
- 229940125396 insulin Drugs 0.000 description 1
- 239000003089 intermedin derivative Substances 0.000 description 1
- 230000009545 invasion Effects 0.000 description 1
- 208000001875 irritant dermatitis Diseases 0.000 description 1
- 230000007794 irritation Effects 0.000 description 1
- 125000000959 isobutyl group Chemical group [H]C([H])([H])C([H])(C([H])([H])[H])C([H])([H])* 0.000 description 1
- LDHQCZJRKDOVOX-IHWYPQMZSA-N isocrotonic acid Chemical compound C\C=C/C(O)=O LDHQCZJRKDOVOX-IHWYPQMZSA-N 0.000 description 1
- 229960005280 isotretinoin Drugs 0.000 description 1
- 239000008633 juniper tar Substances 0.000 description 1
- MWDZOUNAPSSOEL-UHFFFAOYSA-N kaempferol Natural products OC1=C(C(=O)c2cc(O)cc(O)c2O1)c3ccc(O)cc3 MWDZOUNAPSSOEL-UHFFFAOYSA-N 0.000 description 1
- 230000003780 keratinization Effects 0.000 description 1
- 229960004125 ketoconazole Drugs 0.000 description 1
- BEJNERDRQOWKJM-UHFFFAOYSA-N kojic acid Chemical compound OCC1=CC(=O)C(O)=CO1 BEJNERDRQOWKJM-UHFFFAOYSA-N 0.000 description 1
- 229960004705 kojic acid Drugs 0.000 description 1
- WZNJWVWKTVETCG-UHFFFAOYSA-N kojic acid Natural products OC(=O)C(N)CN1C=CC(=O)C(O)=C1 WZNJWVWKTVETCG-UHFFFAOYSA-N 0.000 description 1
- 229940061515 laureth-4 Drugs 0.000 description 1
- 229930187586 licochalcone Natural products 0.000 description 1
- 229940040145 liniment Drugs 0.000 description 1
- 239000000865 liniment Substances 0.000 description 1
- 102000004311 liver X receptors Human genes 0.000 description 1
- 108090000865 liver X receptors Proteins 0.000 description 1
- 210000003712 lysosome Anatomy 0.000 description 1
- 230000001868 lysosomic effect Effects 0.000 description 1
- 239000010469 macadamia oil Substances 0.000 description 1
- PRAUVHZJPXOEIF-AOLYGAPISA-N madecassic acid Chemical compound C1[C@@H](O)[C@H](O)[C@@](C)(CO)[C@@H]2[C@H](O)C[C@@]3(C)[C@]4(C)CC[C@@]5(C(O)=O)CC[C@@H](C)[C@H](C)[C@H]5C4=CC[C@@H]3[C@]21C PRAUVHZJPXOEIF-AOLYGAPISA-N 0.000 description 1
- 229940011656 madecassic acid Drugs 0.000 description 1
- BUWCHLVSSFQLPN-UHFFFAOYSA-N madecassic acid Natural products CC1CCC2(CCC3(C)C(=CCC4C5(C)CC(O)C(O)C(C)(C5CCC34C)C(=O)O)C2C1C)C(=O)OC6OC(COC7OC(CO)C(OC8OC(C)C(O)C(O)C8O)C(O)C7O)C(O)C(O)C6O BUWCHLVSSFQLPN-UHFFFAOYSA-N 0.000 description 1
- 230000001071 malnutrition Effects 0.000 description 1
- 235000000824 malnutrition Nutrition 0.000 description 1
- 229910052748 manganese Inorganic materials 0.000 description 1
- 239000011572 manganese Substances 0.000 description 1
- WPBNNNQJVZRUHP-UHFFFAOYSA-L manganese(2+);methyl n-[[2-(methoxycarbonylcarbamothioylamino)phenyl]carbamothioyl]carbamate;n-[2-(sulfidocarbothioylamino)ethyl]carbamodithioate Chemical compound [Mn+2].[S-]C(=S)NCCNC([S-])=S.COC(=O)NC(=S)NC1=CC=CC=C1NC(=S)NC(=O)OC WPBNNNQJVZRUHP-UHFFFAOYSA-L 0.000 description 1
- 235000013310 margarine Nutrition 0.000 description 1
- 239000003264 margarine Substances 0.000 description 1
- 235000010746 mayonnaise Nutrition 0.000 description 1
- 239000008268 mayonnaise Substances 0.000 description 1
- 235000012054 meals Nutrition 0.000 description 1
- 210000002752 melanocyte Anatomy 0.000 description 1
- 208000030159 metabolic disease Diseases 0.000 description 1
- 230000002503 metabolic effect Effects 0.000 description 1
- XZWYZXLIPXDOLR-UHFFFAOYSA-N metformin Chemical compound CN(C)C(=N)NC(N)=N XZWYZXLIPXDOLR-UHFFFAOYSA-N 0.000 description 1
- 229960003105 metformin Drugs 0.000 description 1
- 229930182817 methionine Natural products 0.000 description 1
- 229960000485 methotrexate Drugs 0.000 description 1
- 229960004469 methoxsalen Drugs 0.000 description 1
- SQBBOVROCFXYBN-UHFFFAOYSA-N methoxypsoralen Natural products C1=C2OC(=O)C(OC)=CC2=CC2=C1OC=C2 SQBBOVROCFXYBN-UHFFFAOYSA-N 0.000 description 1
- FAARLWTXUUQFSN-UHFFFAOYSA-N methylellagic acid Natural products O1C(=O)C2=CC(O)=C(O)C3=C2C2=C1C(OC)=C(O)C=C2C(=O)O3 FAARLWTXUUQFSN-UHFFFAOYSA-N 0.000 description 1
- 229940100573 methylpropanediol Drugs 0.000 description 1
- 230000000813 microbial effect Effects 0.000 description 1
- 244000005700 microbiome Species 0.000 description 1
- 229960004023 minocycline Drugs 0.000 description 1
- 230000004048 modification Effects 0.000 description 1
- 238000012986 modification Methods 0.000 description 1
- RZRNAYUHWVFMIP-UHFFFAOYSA-N monoelaidin Natural products CCCCCCCCC=CCCCCCCCC(=O)OCC(O)CO RZRNAYUHWVFMIP-UHFFFAOYSA-N 0.000 description 1
- 238000004264 monolayer culture Methods 0.000 description 1
- 150000002772 monosaccharides Chemical class 0.000 description 1
- 150000002773 monoterpene derivatives Chemical class 0.000 description 1
- 210000004877 mucosa Anatomy 0.000 description 1
- 229960003128 mupirocin Drugs 0.000 description 1
- 229930187697 mupirocin Natural products 0.000 description 1
- DDHVILIIHBIMQU-YJGQQKNPSA-L mupirocin calcium hydrate Chemical compound O.O.[Ca+2].C[C@H](O)[C@H](C)[C@@H]1O[C@H]1C[C@@H]1[C@@H](O)[C@@H](O)[C@H](C\C(C)=C\C(=O)OCCCCCCCCC([O-])=O)OC1.C[C@H](O)[C@H](C)[C@@H]1O[C@H]1C[C@@H]1[C@@H](O)[C@@H](O)[C@H](C\C(C)=C\C(=O)OCCCCCCCCC([O-])=O)OC1 DDHVILIIHBIMQU-YJGQQKNPSA-L 0.000 description 1
- OHDXDNUPVVYWOV-UHFFFAOYSA-N n-methyl-1-(2-naphthalen-1-ylsulfanylphenyl)methanamine Chemical compound CNCC1=CC=CC=C1SC1=CC=CC2=CC=CC=C12 OHDXDNUPVVYWOV-UHFFFAOYSA-N 0.000 description 1
- OFBQJSOFQDEBGM-UHFFFAOYSA-N n-pentane Natural products CCCCC OFBQJSOFQDEBGM-UHFFFAOYSA-N 0.000 description 1
- DQCKKXVULJGBQN-XFWGSAIBSA-N naltrexone Chemical compound N1([C@@H]2CC3=CC=C(C=4O[C@@H]5[C@](C3=4)([C@]2(CCC5=O)O)CC1)O)CC1CC1 DQCKKXVULJGBQN-XFWGSAIBSA-N 0.000 description 1
- 229960003086 naltrexone Drugs 0.000 description 1
- 206010029410 night sweats Diseases 0.000 description 1
- 230000036565 night sweats Effects 0.000 description 1
- 229910017604 nitric acid Inorganic materials 0.000 description 1
- 229910052757 nitrogen Inorganic materials 0.000 description 1
- 235000019520 non-alcoholic beverage Nutrition 0.000 description 1
- 210000001331 nose Anatomy 0.000 description 1
- 235000019488 nut oil Nutrition 0.000 description 1
- 239000010466 nut oil Substances 0.000 description 1
- 208000015380 nutritional deficiency disease Diseases 0.000 description 1
- WWZKQHOCKIZLMA-UHFFFAOYSA-M octanoate Chemical compound CCCCCCCC([O-])=O WWZKQHOCKIZLMA-UHFFFAOYSA-M 0.000 description 1
- WWZKQHOCKIZLMA-UHFFFAOYSA-N octanoic acid Chemical compound CCCCCCCC(O)=O WWZKQHOCKIZLMA-UHFFFAOYSA-N 0.000 description 1
- 229960001679 octinoxate Drugs 0.000 description 1
- 239000002674 ointment Substances 0.000 description 1
- 229940055577 oleyl alcohol Drugs 0.000 description 1
- XMLQWXUVTXCDDL-UHFFFAOYSA-N oleyl alcohol Natural products CCCCCCC=CCCCCCCCCCCO XMLQWXUVTXCDDL-UHFFFAOYSA-N 0.000 description 1
- 230000003287 optical effect Effects 0.000 description 1
- 150000007524 organic acids Chemical class 0.000 description 1
- 239000003960 organic solvent Substances 0.000 description 1
- 210000004681 ovum Anatomy 0.000 description 1
- 230000003647 oxidation Effects 0.000 description 1
- 238000007254 oxidation reaction Methods 0.000 description 1
- 230000036542 oxidative stress Effects 0.000 description 1
- 229960001528 oxymetazoline Drugs 0.000 description 1
- 229930195143 oxyphenol Natural products 0.000 description 1
- BJRNKVDFDLYUGJ-UHFFFAOYSA-N p-hydroxyphenyl beta-D-alloside Natural products OC1C(O)C(O)C(CO)OC1OC1=CC=C(O)C=C1 BJRNKVDFDLYUGJ-UHFFFAOYSA-N 0.000 description 1
- 238000012856 packing Methods 0.000 description 1
- 229940023569 palmate Drugs 0.000 description 1
- 229940055729 papain Drugs 0.000 description 1
- 235000019834 papain Nutrition 0.000 description 1
- 239000012188 paraffin wax Substances 0.000 description 1
- 230000003071 parasitic effect Effects 0.000 description 1
- 230000032696 parturition Effects 0.000 description 1
- 230000001575 pathological effect Effects 0.000 description 1
- 229940049954 penicillin Drugs 0.000 description 1
- 150000002969 pentanoic acid esters Chemical class 0.000 description 1
- 230000010412 perfusion Effects 0.000 description 1
- 208000028169 periodontal disease Diseases 0.000 description 1
- 230000003239 periodontal effect Effects 0.000 description 1
- 102000013415 peroxidase activity proteins Human genes 0.000 description 1
- 108040007629 peroxidase activity proteins Proteins 0.000 description 1
- 108091008725 peroxisome proliferator-activated receptors alpha Proteins 0.000 description 1
- 238000001050 pharmacotherapy Methods 0.000 description 1
- 150000007965 phenolic acids Chemical class 0.000 description 1
- 229940044115 phlorhizin Drugs 0.000 description 1
- IOUVKUPGCMBWBT-UHFFFAOYSA-N phloridzosid Natural products OC1C(O)C(O)C(CO)OC1OC1=CC(O)=CC(O)=C1C(=O)CCC1=CC=C(O)C=C1 IOUVKUPGCMBWBT-UHFFFAOYSA-N 0.000 description 1
- IOUVKUPGCMBWBT-QNDFHXLGSA-N phlorizin Chemical compound O[C@@H]1[C@@H](O)[C@H](O)[C@@H](CO)O[C@H]1OC1=CC(O)=CC(O)=C1C(=O)CCC1=CC=C(O)C=C1 IOUVKUPGCMBWBT-QNDFHXLGSA-N 0.000 description 1
- 235000019139 phlorizin Nutrition 0.000 description 1
- QGVLYPPODPLXMB-QXYKVGAMSA-N phorbol Natural products C[C@@H]1[C@@H](O)[C@]2(O)[C@H]([C@H]3C=C(CO)C[C@@]4(O)[C@H](C=C(C)C4=O)[C@@]13O)C2(C)C QGVLYPPODPLXMB-QXYKVGAMSA-N 0.000 description 1
- 239000010452 phosphate Substances 0.000 description 1
- 229940067631 phospholipid Drugs 0.000 description 1
- 150000003904 phospholipids Chemical class 0.000 description 1
- 230000008845 photoaging Effects 0.000 description 1
- 230000036211 photosensitivity Effects 0.000 description 1
- 239000006187 pill Substances 0.000 description 1
- 229940116406 poloxamer 184 Drugs 0.000 description 1
- 229920000642 polymer Polymers 0.000 description 1
- 238000006116 polymerization reaction Methods 0.000 description 1
- 229920001296 polysiloxane Polymers 0.000 description 1
- 238000003825 pressing Methods 0.000 description 1
- 229960003961 pristinamycin Drugs 0.000 description 1
- DAIKHDNSXMZDCU-OUDXUNEISA-N pristinamycin-IIA Natural products CC(C)[C@H]1OC(=O)C2=CCCN2C(=O)c3coc(CC(=O)C[C@H](O)C=C(C)C=CCNC(=O)C=C[C@@H]1C)n3 DAIKHDNSXMZDCU-OUDXUNEISA-N 0.000 description 1
- JOOMGSFOCRDAHL-XKCHLWDXSA-N pristinamycin-IIB Natural products CC(C)[C@@H]1OC(=O)[C@H]2CCCN2C(=O)c3coc(CC(=O)C[C@@H](O)C=C(C)C=CCNC(=O)C=C[C@H]1C)n3 JOOMGSFOCRDAHL-XKCHLWDXSA-N 0.000 description 1
- 102000004196 processed proteins & peptides Human genes 0.000 description 1
- HGVVOUNEGQIPMS-UHFFFAOYSA-N procyanidin Chemical compound O1C2=CC(O)=CC(O)=C2C(O)C(O)C1(C=1C=C(O)C(O)=CC=1)OC1CC2=C(O)C=C(O)C=C2OC1C1=CC=C(O)C(O)=C1 HGVVOUNEGQIPMS-UHFFFAOYSA-N 0.000 description 1
- 229920002414 procyanidin Polymers 0.000 description 1
- 229940069949 propolis Drugs 0.000 description 1
- 150000003180 prostaglandins Chemical class 0.000 description 1
- 235000019419 proteases Nutrition 0.000 description 1
- 230000004224 protection Effects 0.000 description 1
- ZCCUUQDIBDJBTK-UHFFFAOYSA-N psoralen Chemical class C1=C2OC(=O)C=CC2=CC2=C1OC=C2 ZCCUUQDIBDJBTK-UHFFFAOYSA-N 0.000 description 1
- 238000004080 punching Methods 0.000 description 1
- 238000000746 purification Methods 0.000 description 1
- 229940073745 quaternium-82 Drugs 0.000 description 1
- 235000005875 quercetin Nutrition 0.000 description 1
- 229960001285 quercetin Drugs 0.000 description 1
- 239000002516 radical scavenger Substances 0.000 description 1
- 238000001959 radiotherapy Methods 0.000 description 1
- 230000009257 reactivity Effects 0.000 description 1
- 238000011084 recovery Methods 0.000 description 1
- 210000000664 rectum Anatomy 0.000 description 1
- 230000009467 reduction Effects 0.000 description 1
- 235000021067 refined food Nutrition 0.000 description 1
- 229940108461 rennet Drugs 0.000 description 1
- 108010058314 rennet Proteins 0.000 description 1
- 230000000284 resting effect Effects 0.000 description 1
- 235000021283 resveratrol Nutrition 0.000 description 1
- 229940016667 resveratrol Drugs 0.000 description 1
- 235000020945 retinal Nutrition 0.000 description 1
- 239000011604 retinal Substances 0.000 description 1
- NCYCYZXNIZJOKI-OVSJKPMPSA-N retinal group Chemical group C\C(=C/C=O)\C=C\C=C(\C=C\C1=C(CCCC1(C)C)C)/C NCYCYZXNIZJOKI-OVSJKPMPSA-N 0.000 description 1
- 229960002477 riboflavin Drugs 0.000 description 1
- 229960001860 salicylate Drugs 0.000 description 1
- YGSDEFSMJLZEOE-UHFFFAOYSA-M salicylate Chemical compound OC1=CC=CC=C1C([O-])=O YGSDEFSMJLZEOE-UHFFFAOYSA-M 0.000 description 1
- 229930192961 schisandrol Natural products 0.000 description 1
- 238000009991 scouring Methods 0.000 description 1
- DCKVNWZUADLDEH-UHFFFAOYSA-N sec-butyl acetate Chemical compound CCC(C)OC(C)=O DCKVNWZUADLDEH-UHFFFAOYSA-N 0.000 description 1
- VIDTVPHHDGRGAF-UHFFFAOYSA-N selenium sulfide Chemical compound [Se]=S VIDTVPHHDGRGAF-UHFFFAOYSA-N 0.000 description 1
- 229960005265 selenium sulfide Drugs 0.000 description 1
- 229940091258 selenium supplement Drugs 0.000 description 1
- 230000035807 sensation Effects 0.000 description 1
- 235000019615 sensations Nutrition 0.000 description 1
- 230000037307 sensitive skin Effects 0.000 description 1
- 238000000926 separation method Methods 0.000 description 1
- 229930004725 sesquiterpene Natural products 0.000 description 1
- 229940057910 shea butter Drugs 0.000 description 1
- UNAANXDKBXWMLN-UHFFFAOYSA-N sibutramine Chemical compound C=1C=C(Cl)C=CC=1C1(C(N(C)C)CC(C)C)CCC1 UNAANXDKBXWMLN-UHFFFAOYSA-N 0.000 description 1
- 229960004425 sibutramine Drugs 0.000 description 1
- USDOQCCMRDNVAH-UHFFFAOYSA-N sigma-cadinene Natural products C1C=C(C)CC2C(C(C)C)CC=C(C)C21 USDOQCCMRDNVAH-UHFFFAOYSA-N 0.000 description 1
- KZJWDPNRJALLNS-VJSFXXLFSA-N sitosterol Chemical compound C1C=C2C[C@@H](O)CC[C@]2(C)[C@@H]2[C@@H]1[C@@H]1CC[C@H]([C@H](C)CC[C@@H](CC)C(C)C)[C@@]1(C)CC2 KZJWDPNRJALLNS-VJSFXXLFSA-N 0.000 description 1
- 235000015500 sitosterol Nutrition 0.000 description 1
- 229950005143 sitosterol Drugs 0.000 description 1
- NLQLSVXGSXCXFE-UHFFFAOYSA-N sitosterol Natural products CC=C(/CCC(C)C1CC2C3=CCC4C(C)C(O)CCC4(C)C3CCC2(C)C1)C(C)C NLQLSVXGSXCXFE-UHFFFAOYSA-N 0.000 description 1
- 230000036555 skin type Effects 0.000 description 1
- 231100000019 skin ulcer Toxicity 0.000 description 1
- 239000000344 soap Substances 0.000 description 1
- 229910052708 sodium Inorganic materials 0.000 description 1
- 235000011121 sodium hydroxide Nutrition 0.000 description 1
- DMRMZQATXPQOTP-GWTDSMLYSA-M sodium;(4ar,6r,7r,7as)-6-(6-amino-8-bromopurin-9-yl)-2-oxido-2-oxo-4a,6,7,7a-tetrahydro-4h-furo[3,2-d][1,3,2]dioxaphosphinin-7-ol Chemical compound [Na+].C([C@H]1O2)OP([O-])(=O)O[C@H]1[C@@H](O)[C@@H]2N1C(N=CN=C2N)=C2N=C1Br DMRMZQATXPQOTP-GWTDSMLYSA-M 0.000 description 1
- 235000014214 soft drink Nutrition 0.000 description 1
- 239000007787 solid Substances 0.000 description 1
- 239000000243 solution Substances 0.000 description 1
- 238000000935 solvent evaporation Methods 0.000 description 1
- 235000014347 soups Nutrition 0.000 description 1
- 235000020712 soy bean extract Nutrition 0.000 description 1
- 235000012424 soybean oil Nutrition 0.000 description 1
- 239000003549 soybean oil Substances 0.000 description 1
- 238000002798 spectrophotometry method Methods 0.000 description 1
- ZGHOATLFXGBJGZ-KBPBESRZSA-N sphenanlignan Natural products O(C)c1c(OC)cc(C[C@@H]([C@H](Cc2cc3OCOc3cc2)C)C)cc1O ZGHOATLFXGBJGZ-KBPBESRZSA-N 0.000 description 1
- 229960002256 spironolactone Drugs 0.000 description 1
- LXMSZDCAJNLERA-ZHYRCANASA-N spironolactone Chemical compound C([C@@H]1[C@]2(C)CC[C@@H]3[C@@]4(C)CCC(=O)C=C4C[C@H]([C@@H]13)SC(=O)C)C[C@@]21CCC(=O)O1 LXMSZDCAJNLERA-ZHYRCANASA-N 0.000 description 1
- 230000001954 sterilising effect Effects 0.000 description 1
- 238000004659 sterilization and disinfection Methods 0.000 description 1
- 230000003637 steroidlike Effects 0.000 description 1
- 230000004936 stimulating effect Effects 0.000 description 1
- 230000008093 supporting effect Effects 0.000 description 1
- 239000000725 suspension Substances 0.000 description 1
- 229920002994 synthetic fiber Polymers 0.000 description 1
- 235000013616 tea Nutrition 0.000 description 1
- 229960002180 tetracycline Drugs 0.000 description 1
- 229930101283 tetracycline Natural products 0.000 description 1
- 235000019364 tetracycline Nutrition 0.000 description 1
- 150000003522 tetracyclines Chemical class 0.000 description 1
- TUNFSRHWOTWDNC-HKGQFRNVSA-N tetradecanoic acid Chemical compound CCCCCCCCCCCCC[14C](O)=O TUNFSRHWOTWDNC-HKGQFRNVSA-N 0.000 description 1
- ZRKFYGHZFMAOKI-QMGMOQQFSA-N tgfbeta Chemical compound C([C@H](NC(=O)[C@H](C(C)C)NC(=O)CNC(=O)[C@H](CCC(O)=O)NC(=O)[C@H](CCCNC(N)=N)NC(=O)[C@H](CC(N)=O)NC(=O)[C@H](CC(C)C)NC(=O)[C@H]([C@@H](C)O)NC(=O)[C@H](CCC(O)=O)NC(=O)[C@H]([C@@H](C)O)NC(=O)[C@H](CC(C)C)NC(=O)CNC(=O)[C@H](C)NC(=O)[C@H](CO)NC(=O)[C@H](CCC(N)=O)NC(=O)[C@@H](NC(=O)[C@H](C)NC(=O)[C@H](C)NC(=O)[C@@H](NC(=O)[C@H](CC(C)C)NC(=O)[C@@H](N)CCSC)C(C)C)[C@@H](C)CC)C(=O)N[C@@H]([C@@H](C)O)C(=O)N[C@@H](C(C)C)C(=O)N[C@@H](CC=1C=CC=CC=1)C(=O)N[C@@H](C)C(=O)N1[C@@H](CCC1)C(=O)N[C@@H]([C@@H](C)O)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](C)C(=O)N[C@@H](CC=1C=CC=CC=1)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](C)C(=O)N[C@@H](CC(C)C)C(=O)N1[C@@H](CCC1)C(=O)N1[C@@H](CCC1)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CO)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CC(C)C)C(O)=O)C1=CC=C(O)C=C1 ZRKFYGHZFMAOKI-QMGMOQQFSA-N 0.000 description 1
- 229960004559 theobromine Drugs 0.000 description 1
- 150000001467 thiazolidinediones Chemical class 0.000 description 1
- 239000002562 thickening agent Substances 0.000 description 1
- 238000007436 thin-layer chromatography-densitometry Methods 0.000 description 1
- 229960000790 thymol Drugs 0.000 description 1
- 210000001541 thymus gland Anatomy 0.000 description 1
- OGIDPMRJRNCKJF-UHFFFAOYSA-N titanium oxide Inorganic materials [Ti]=O OGIDPMRJRNCKJF-UHFFFAOYSA-N 0.000 description 1
- 229930003802 tocotrienol Natural products 0.000 description 1
- 235000019148 tocotrienols Nutrition 0.000 description 1
- 235000021404 traditional food Nutrition 0.000 description 1
- 238000012546 transfer Methods 0.000 description 1
- 230000032258 transport Effects 0.000 description 1
- 229960003500 triclosan Drugs 0.000 description 1
- 230000001960 triggered effect Effects 0.000 description 1
- 235000001019 trigonella foenum-graecum Nutrition 0.000 description 1
- VLPFTAMPNXLGLX-UHFFFAOYSA-N trioctanoin Chemical compound CCCCCCCC(=O)OCC(OC(=O)CCCCCCC)COC(=O)CCCCCCC VLPFTAMPNXLGLX-UHFFFAOYSA-N 0.000 description 1
- 230000001228 trophic effect Effects 0.000 description 1
- 150000003667 tyrosine derivatives Chemical class 0.000 description 1
- VBEQCZHXXJYVRD-GACYYNSASA-N uroanthelone Chemical compound C([C@@H](C(=O)N[C@H](C(=O)N[C@@H](CS)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H](CS)C(=O)N[C@H](C(=O)N[C@@H]([C@@H](C)CC)C(=O)NCC(=O)N[C@@H](CC=1C=CC(O)=CC=1)C(=O)N[C@@H](CO)C(=O)NCC(=O)N[C@@H](CC(O)=O)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CS)C(=O)N[C@@H](CCC(N)=O)C(=O)N[C@@H]([C@@H](C)O)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CC(O)=O)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CC=1C2=CC=CC=C2NC=1)C(=O)N[C@@H](CC=1C2=CC=CC=C2NC=1)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCCNC(N)=N)C(O)=O)C(C)C)[C@@H](C)O)NC(=O)[C@H](CO)NC(=O)[C@H](CC(O)=O)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CO)NC(=O)[C@H](CCC(O)=O)NC(=O)[C@@H](NC(=O)[C@H](CC=1NC=NC=1)NC(=O)[C@H](CCSC)NC(=O)[C@H](CS)NC(=O)[C@@H](NC(=O)CNC(=O)CNC(=O)[C@H](CC(N)=O)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CS)NC(=O)[C@H](CC=1C=CC(O)=CC=1)NC(=O)CNC(=O)[C@H](CC(O)=O)NC(=O)[C@H](CC=1C=CC(O)=CC=1)NC(=O)[C@H](CO)NC(=O)[C@H](CO)NC(=O)[C@H]1N(CCC1)C(=O)[C@H](CS)NC(=O)CNC(=O)[C@H]1N(CCC1)C(=O)[C@H](CC=1C=CC(O)=CC=1)NC(=O)[C@H](CO)NC(=O)[C@@H](N)CC(N)=O)C(C)C)[C@@H](C)CC)C1=CC=C(O)C=C1 VBEQCZHXXJYVRD-GACYYNSASA-N 0.000 description 1
- 210000001215 vagina Anatomy 0.000 description 1
- 229940093257 valacyclovir Drugs 0.000 description 1
- 229910052720 vanadium Inorganic materials 0.000 description 1
- GPPXJZIENCGNKB-UHFFFAOYSA-N vanadium Chemical compound [V]#[V] GPPXJZIENCGNKB-UHFFFAOYSA-N 0.000 description 1
- 230000002792 vascular Effects 0.000 description 1
- 108010080213 vascular factor Proteins 0.000 description 1
- 239000005526 vasoconstrictor agent Substances 0.000 description 1
- 230000000304 vasodilatating effect Effects 0.000 description 1
- 230000024883 vasodilation Effects 0.000 description 1
- 230000001457 vasomotor Effects 0.000 description 1
- 229940088594 vitamin Drugs 0.000 description 1
- 229930003231 vitamin Natural products 0.000 description 1
- 235000013343 vitamin Nutrition 0.000 description 1
- 239000011782 vitamin Substances 0.000 description 1
- NCYCYZXNIZJOKI-UHFFFAOYSA-N vitamin A aldehyde Natural products O=CC=C(C)C=CC=C(C)C=CC1=C(C)CCCC1(C)C NCYCYZXNIZJOKI-UHFFFAOYSA-N 0.000 description 1
- 235000019164 vitamin B2 Nutrition 0.000 description 1
- 239000011716 vitamin B2 Substances 0.000 description 1
- 102000009310 vitamin D receptors Human genes 0.000 description 1
- 108050000156 vitamin D receptors Proteins 0.000 description 1
- 239000007762 w/o emulsion Substances 0.000 description 1
- 238000009736 wetting Methods 0.000 description 1
- 239000000080 wetting agent Substances 0.000 description 1
- 235000013618 yogurt Nutrition 0.000 description 1
- 101150076297 ywhaz gene Proteins 0.000 description 1
- NWONKYPBYAMBJT-UHFFFAOYSA-L zinc sulfate Chemical compound [Zn+2].[O-]S([O-])(=O)=O NWONKYPBYAMBJT-UHFFFAOYSA-L 0.000 description 1
- 229960001763 zinc sulfate Drugs 0.000 description 1
- 229910000368 zinc sulfate Inorganic materials 0.000 description 1
- SFVVQRJOGUKCEG-OPQSFPLASA-N β-MSH Chemical class C1C[C@@H](O)[C@H]2C(COC(=O)[C@@](O)([C@@H](C)O)C(C)C)=CCN21 SFVVQRJOGUKCEG-OPQSFPLASA-N 0.000 description 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
- A61K36/79—Schisandraceae (Schisandra family)
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61Q—SPECIFIC USE OF COSMETICS OR SIMILAR TOILETRY PREPARATIONS
- A61Q19/00—Preparations for care of the skin
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23L—FOODS, FOODSTUFFS, OR NON-ALCOHOLIC BEVERAGES, NOT COVERED BY SUBCLASSES A21D OR A23B-A23J; THEIR PREPARATION OR TREATMENT, e.g. COOKING, MODIFICATION OF NUTRITIVE QUALITIES, PHYSICAL TREATMENT; PRESERVATION OF FOODS OR FOODSTUFFS, IN GENERAL
- A23L33/00—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K8/00—Cosmetics or similar toiletry preparations
- A61K8/18—Cosmetics or similar toiletry preparations characterised by the composition
- A61K8/96—Cosmetics or similar toiletry preparations characterised by the composition containing materials, or derivatives thereof of undetermined constitution
- A61K8/97—Cosmetics or similar toiletry preparations characterised by the composition containing materials, or derivatives thereof of undetermined constitution from algae, fungi, lichens or plants; from derivatives thereof
- A61K8/9783—Angiosperms [Magnoliophyta]
- A61K8/9789—Magnoliopsida [dicotyledons]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/08—Antiallergic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61Q—SPECIFIC USE OF COSMETICS OR SIMILAR TOILETRY PREPARATIONS
- A61Q17/00—Barrier preparations; Preparations brought into direct contact with the skin for affording protection against external influences, e.g. sunlight, X-rays or other harmful rays, corrosive materials, bacteria or insect stings
- A61Q17/005—Antimicrobial preparations
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61Q—SPECIFIC USE OF COSMETICS OR SIMILAR TOILETRY PREPARATIONS
- A61Q17/00—Barrier preparations; Preparations brought into direct contact with the skin for affording protection against external influences, e.g. sunlight, X-rays or other harmful rays, corrosive materials, bacteria or insect stings
- A61Q17/04—Topical preparations for affording protection against sunlight or other radiation; Topical sun tanning preparations
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61Q—SPECIFIC USE OF COSMETICS OR SIMILAR TOILETRY PREPARATIONS
- A61Q19/00—Preparations for care of the skin
- A61Q19/02—Preparations for care of the skin for chemically bleaching or whitening the skin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61Q—SPECIFIC USE OF COSMETICS OR SIMILAR TOILETRY PREPARATIONS
- A61Q19/00—Preparations for care of the skin
- A61Q19/06—Preparations for care of the skin for countering cellulitis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61Q—SPECIFIC USE OF COSMETICS OR SIMILAR TOILETRY PREPARATIONS
- A61Q19/00—Preparations for care of the skin
- A61Q19/08—Anti-ageing preparations
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61Q—SPECIFIC USE OF COSMETICS OR SIMILAR TOILETRY PREPARATIONS
- A61Q19/00—Preparations for care of the skin
- A61Q19/10—Washing or bathing preparations
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61Q—SPECIFIC USE OF COSMETICS OR SIMILAR TOILETRY PREPARATIONS
- A61Q5/00—Preparations for care of the hair
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61Q—SPECIFIC USE OF COSMETICS OR SIMILAR TOILETRY PREPARATIONS
- A61Q5/00—Preparations for care of the hair
- A61Q5/006—Antidandruff preparations
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61Q—SPECIFIC USE OF COSMETICS OR SIMILAR TOILETRY PREPARATIONS
- A61Q5/00—Preparations for care of the hair
- A61Q5/02—Preparations for cleaning the hair
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61Q—SPECIFIC USE OF COSMETICS OR SIMILAR TOILETRY PREPARATIONS
- A61Q7/00—Preparations for affecting hair growth
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Engineering & Computer Science (AREA)
- Chemical & Material Sciences (AREA)
- Mycology (AREA)
- Medicinal Chemistry (AREA)
- Natural Medicines & Medicinal Plants (AREA)
- Pharmacology & Pharmacy (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Epidemiology (AREA)
- Organic Chemistry (AREA)
- Dermatology (AREA)
- Biotechnology (AREA)
- Botany (AREA)
- Microbiology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Birds (AREA)
- Rheumatology (AREA)
- Alternative & Traditional Medicine (AREA)
- Immunology (AREA)
- Nutrition Science (AREA)
- Food Science & Technology (AREA)
- Polymers & Plastics (AREA)
- Pulmonology (AREA)
- Pain & Pain Management (AREA)
- Medical Informatics (AREA)
- Medicines Containing Plant Substances (AREA)
- Cosmetics (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Coloring Foods And Improving Nutritive Qualities (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Abstract
本发明涉及一种包含华中五味子果实提取物的化妆品、皮肤病学或营养药组合物。所述华中五味子果实提取物选自肽与糖提取物、粗制油、精制油、精制油浓缩物或所述浓缩物的不可皂化成分。本发明也涉及用于制备华中五味子果实的肽与糖提取物、精制油和浓缩物以及油的不可皂化成分的方法。最后,本发明涉及所述提取物的皮肤病学、化妆品和营养药用途。
Description
简介
本发明涉及一种化妆品、皮肤病学或营养药组合物,其包含合适的赋形剂和华中五味子(Schisandra sphenanthera)提取物。
华中五味子植物
具有植物学名称五味子,这种植物属于木兰纲(Magnoliopsida)和木兰目(Magnoliales)。植物学的科是五味子科(Schisandraceae)。完整拉丁语名称是华中五味子(Schisandra sphenanthera Rehd.et Wils.)。该植物的俗名:橙色花五味子(schisandre àfleurs orangées)(在法国)、南方五味子与柠檬木(在英格兰)以及华中五味子(hua zhong wu wei zi)与南五味子(nan wu wie zi)(在中国)。
这些灌木源自中国北部及俄罗斯和韩国的毗连地区。世界上存在约25个属于五味子属的物种。这些物种中大约16个是中国的。在中国,将两个物种正式认可作为药物:五味子(S.chinensis)和华中五味子(S.sphenanthera)(He等人,1997)。在传统中药中使用它们的浆果来治疗咳嗽、哮喘、盗汗、遗精和慢性腹泻。也使用它们作为强壮药和治疗慢性疲劳。
单独使用的术语“五味子(Schisandra)”可以指两种不同的植物:五味子(Schisandra chinensis)和华中五味子(Schisandra sphenanthera)。长久以来已经将这两个物种视为等效:它们可能根据其起源命名:五味子为“北五味子”和华中五味子为“南五味子”。
五味子是雌雄异体的植物(具有迥异的雄花和雌花)。所述果实为悬挂成簇的形式,其与醋栗灌丛的果实多少相似。所述果实在其上部(大致5-10cm)具有裸露的花梗,所述花梗在其下部被比醋栗略大、更紧凑和坚实的鲜红色浆果覆盖。球状种子在尺寸上是数毫米。
所述果实特征
虽然五味子(S.chinensis)的果实已经成为大量文献的主题(传统用途、化学组成、药理学作用和皮肤病学作用:尤其,见WO 2005/044289),但是对华中五味子(S.sphenanthera)的研究工作少得多。
-根据中国传统就其用途而言名声较差,
-在西方几乎不使用,
-与五味子(S.chinensis)相比总新木脂体的比例较低。
然而,商业上,认为华中五味子的果实在成本上低于五味子的果实。
华中五味子果实以其高的去氧五味子素含量为特征。相反,与五味子种子相比,华中五味子果实的五味子素和γ-五味子素含量极低(Zhu等人,2007)。近来,Huyke等人(2007)的文章报道了五味子和华中五味子提取物对细胞增殖的作用的对比研究。
五味子的干燥果实包含大约20%精油,其包含7%至30%不可皂化物(unsaponifiable)(Huyke等人,2007)。所述油的不可皂化成分中含有木脂体。其他活性组分包括植物甾醇以及维生素C和E。
精油(单萜和倍半萜烯)
所述精油富含倍半萜烯衍生物(Song等人,2007):
δ-杜松烯:25.6%,
γ-杜松烯,
β-雪松烯,
檀香醇。
五味子果实的精油比华中五味子果实的精油含有更多的单萜烃(monoterpene hydrocarbon)(Huyke等人,2007)。
甾类
谷甾醇(Huyke等人,2007)(在果实中<0.1%)
三萜醇
五味子醇(I)(Schisanol(I))(Yue等人,1994)
木脂体(Lignans)
A.定性数据
将木脂体视为该果实中用于皮肤病学、化妆品或药物应用的活性物质。已经在五味子果实中发现多于40种二苯并[a,c]环辛二烯骨架新木脂体(dibenzo[a,c]cyclooctadiene-skeleton neolignans),或多或少被有机酸(乙酸、苯甲酸、当归酸或巴豆酸)酯化。这些新木脂体是新颖组分。木脂体的一般结构如下:
去氧五味子素:R1,3,5=H;R2,4,6-11=CH3
表I中提供在华中五味子果实中鉴定到的新木脂体的名单。对于其结构,见Hancke等人,1999;He等人,1997;和Huyke等人,2007的出版物。
表I
(1):Liu等人,1978;(2):Huyke等人,2007;(3)Zhu等人,2007;(4):Yue等人,1994;(5)Ikeya等人,1991;(6):Ikeya等人,1990。
已经在五味子果实的种子内鉴定到一种二芳基丁烷木脂体,称作华中五脂素(sphenanlignan)(I)(Jiang等人,2005),并且其具有以下结构:
B.定量数据
通过薄层色谱(TLC)-光密度测定法(TLC-densitometry)对10个五味子物种实施的分析解释了各物种之间色谱图形方面的差异(Wang等人,1991)。存在来自高效液相色谱(HPLC)分析华中五味子新木脂体的几个数据集,例如:Zhou等人,2005。
根据以英语发表的文章,下表II提供华中五味子果实中的主要新木脂体含量。
表II
(*):通过乙醇提取物外推所得的结果
(**):命名不完整;五味子酯A的异构结构。
华中五味子果实以其高的去氧五味子素含量为特征。相反,与五味子种子相比,其五味子素和γ-五味子素含量极低(Zhu等人,2007)。
果实提取物:使用的形式
除了在中国以脱水状态下的传统用途之外,华中五味子果实也以提取物的形式使用,其中通过能够夹带该果实的新木脂体的提取溶剂获得所述提取物。文献中提到的溶剂是乙醇、与共溶剂联合或不联合的超临界CO2(SC-CO2)、和己烷。
几项发表的研究曾试图比较SC-CO2、氯仿和50%甲醇与乙醇相对于果实新木脂体的提取能力。
根据最近公开,通过CO2或CO2+5%乙醇或通过己烷提取华中五味子果实产生了就新木脂体而言十分相似的提取物组合物。相反,乙醇的使用导致两种新木脂体(脱氢五味子素和戈米辛O)的较劣提取,以及γ-五味子素的明显较好提取(Huyke等人,2007)。
已经在Yang(2001)的文章中提出华中五味子果实新木脂体(去氧五味子素,γ-五味子素等)的最佳SC-CO2提取条件:21Mpa、37℃和CO2流速5升/分钟。
赤-红血丝(erythro-couperose)和酒渣鼻(rosacea)的生理病理学
酒渣鼻是主要侵袭面部的常见皮肤病,并且可见面红外观(血管舒缩性潮红(vasomotor flashes))、永久红斑、丘疹、小疱和毛细血管扩张。次要标准经常可以显现为烧灼或螫刺感觉、红斑块、皮肤干燥、面部水肿及皮肤肿块和眼部表现。
这种皮肤病可以由许多因素触发和加重,如:热饮料、含酒精的饮料、温度变化、辛辣食物、锻炼、应激和强烈情绪、阳光等。
长久以来将酒渣鼻的生理病理定位为不甚了解和多因素性(遗传因素、炎性因素和血管因素)。
最近,发现并且证明多种机制参与酒渣鼻的引发(Yamasaki K.和Gallo RL.,2009):
1)先天免疫改变:抗菌肽(cathelicidin)(LL37)的变体以高于正常的量存在;另外,这些变体具有炎性特征并且诱导IL-8分泌;
2)血管病症:新血管发生导致毛细血管扩张(可见的小血管);反复的血管舒缩反应造成淋巴系统的损害,所述的损害是持续炎症的原因;
3)微生物作用;
4)氧化应激和阳光。
这些多样机制相互关联。尤其,抗菌肽(cathelicidin)也可以触发血管病症。
现有技术
文献中未发现关于华中五味子工业用途的信息。似乎该物种的果实未曾被开发用于新木脂体的分离,即便在美国(US 5,484,595)的一份专利中也是如此。
医药用途:
凡诺华公司(Phynova)的申请WO 2007/020382描述了包含四种植物(包括五味子或华中五味子)的提取物的组合物,所述组合物用于治疗肝病、代谢病和/或免疫病,并且更具体地意图治疗丙型肝炎。
广州中一药业(Guang Zhou Zhongyi Pharmaceutical)的申请WO2006/122485和WO 2006/1222454描述了意图治疗糖尿病的组合物,所述组合物包含几种植物(包括华中五味子)的混合物。
Zhao先生的申请US 2003/0026854描述了用于治疗肝病的基于五味子素的药物;特别地所述五味子素是从五味子或华中五味子中提取。
申请WO 2007/005760描述了治疗抗化疗癌细胞的组合物,所述组合物包含五味子素家族的化合物、戈米辛和源于五味子果实提取物及华中五味子果实提取物的其他化合物。
在欧洲,主管机关批准的药物均不含有华中五味子提取物。通常认为,华中五味子在药用上劣于五味子并且它仅用作活性木脂体的备选资源。
皮肤病学和化妆品用途:
Huyke等人(2007)的文章描述并且比较了华中五味子提取物和五味子提取物对于培养下的细胞的作用:人永生化表皮细胞(HaCaT)和A431表皮细胞的增殖以剂量依赖性方式受到这些提取物抑制,而非极性提取物比极性提取物更有效。华中五味子的SC-CO2提取物证明最有活性,IC50为20μg/ml。在采用游离细胞的酶抑制试验中,所述SC-CO2提取物强烈地抑制环氧化酶2(重组COX-2)产生前列腺素(与吲哚美辛的1μg/ml相比,IC50=0.2μg/ml)。它也减少由紫外线B诱导的PGE2产生(IC50=4μg/ml)和HaCaT角质形成细胞中的COX-2表达。该项研究的作者得出结论:华中五味子的SC-CO2提取物可以用于预防和治疗皮肤的炎性或过度增生性疾病。
已经在专利申请KR 2001931中描述了五味子提取物在预防痤疮方面的用途,在组合物中还包含选自如木瓜蛋白酶和菠萝蛋白酶的植物蛋白酶的剥脱剂或者源于微生物的剥脱剂。
已经在CN 11040971中描述了传统中药的抗痤疮组合物:它包含10份称作“石菖蒲(shi chang pu)”的菖蒲(Acorus calamus)、8份五味子果实和3份其他植物。
发明描述
本发明人已经发现,华中五味子果实提取物具有此前从未描述过的美容性质和皮肤病学性质。尤其,华中五味子提取物第一次因其特殊性质而使用并且不作为五味子(Schisandra chinensis)的替代物使用。
本发明的目的是一种化妆品、皮肤病学或营养药组合物,其包含任选地与合适赋形剂组合的华中五味子果实提取物。
可以获得并且单独或组合地使用几种华中五味子果实提取物。
所述华中五味子果实提取物选自至少:
-一种肽与糖提取物;
-一种具有下表3中所示分析结果的粗制油:
表3:粗制华中五味子油的分析结果
油成分 | % |
C14 | 0 |
C16 | 7.7 |
C16′ | 0.4 |
C18 | 2.4 |
C18′ | 13.3 |
C18″ | 75.0 |
C18″′ | 0.5 |
C20 | 0.5 |
C20′ | 0.2 |
C22 | 0 |
C22′ | 0 |
C24 | 0 |
生育酚含量(g/100g) | 0.01 |
甾醇含量(g/100g) | 0.54 |
木脂体含量(g/100g) | 6.2 |
萜烯含量(g/100g) | 21.4 |
-一种精制油,其具有表4中所显示的特征并且尤其没有或具有极少(不显著量的)的萜烯:
表4:精制华中五味子油的分析结果
油成分 | % |
C14 | 0 |
C16 | 7.5 |
C16′ | 0.1 |
C18 | 2.4 |
C18′ | 13.3 |
C18″ | 75.5 |
C18″′ | 0.5 |
C20 | 0.5 |
C20′ | 0.2 |
C22 | 0 |
C22′ | 0 |
C24 | 0 |
生育酚含量(g/100g) | 0.01 |
甾醇含量(g/100g) | 0.74 |
木脂体含量(g/100g) | 7.8 |
-所述精制油的一种浓缩物,或者
-源于所述精制油浓缩物的一种不可皂化物。
根据本发明的第一变例,所述华中五味子果实提取物是肽与糖提取物不包含木脂体。
术语“肽提取物”指主要由肽组成的提取物。
术语“糖提取物”指主要由单糖组成的提取物。
本发明的肽提取物有利地具有以下规格:
肽含量(%) | 5-90 |
总糖含量(%) | 5-90 |
根据本发明的优选方面,所述肽与糖提取物包括以重量计10%至50%的肽和以重量计10%至60%的糖,其中所述百分数相对于所述提取物的总重量计算。
根据本发明的第二变例,所述华中五味子果实提取物是脂质提取物,该脂质提取物选自粗制油、精制油、所述精制油的浓缩物或源于所述浓缩物的不可皂化物。
所述脂质提取物(粗制油、精制油)可以通过几种方法获得:
-物理提取法,如在机械压力机(mechanical press)上冷榨、在双螺杆挤出机上压榨等;
-使用有机溶剂(脂肪族烷、醇类、氯代溶剂、氟代溶剂等)的化学提取法;
-使用单独和/或随同共溶剂一起的二氧化碳,在超临界介质中提取。
对于华中五味子油的提取,将优选使用在超临界介质如二氧化碳中的溶剂。
根据分子蒸馏方法精制粗制华中五味子油以消除萜烯成分。精制的油因而是“无萜烯的粗制油”。
术语“浓缩物”指已经经历过分子蒸馏步骤的精制油。
术语“不可皂化物”指精制油浓缩物的不可皂化成分,所述的不可皂化成分在皂化步骤和使用合适溶剂提取不可皂化物的步骤后获得。
本发明也涉及用于从本发明的粗制油中制备精制华中五味子油的方法,所述方法包括分子蒸馏所述粗制油的步骤。
所述分子蒸馏步骤优选地使用选自离心分子蒸馏器和刮膜式分子装置(wiped-film molecular device)的装置实施。
离心分子蒸馏器是本领域技术人员已知的。例如,申请EP 493 144描述了这个类型的分子蒸馏器。通常,待蒸馏的产物以薄层铺摊在高速转动的锥形转子的受热表面(热表面)上。所述蒸馏室置于真空下。在这些条件下,所述油的组分(如萜烯)从热表面蒸发而不沸腾,其优点在于所述油及其组分,特别是不可皂化物(认为这些产物脆弱)在此操作过程中不降解。
本领域技术人员也已知的刮膜式分子蒸馏器包含配备有转动刮片(wiperblade)的蒸馏室,所述的刮片能够将待蒸馏的产物在蒸发表面(热表面)上连续展开。通过置于蒸馏室中央的冷指(cold finger)冷凝产物的蒸气。外周供给系统和真空系统与离心蒸馏器极相似(供给泵、回转叶片式真空泵、油扩散泵等)。通过重力流回收残余物和馏出物。
本发明还涉及用于制备在其不可皂化成分中浓缩的精制华中五味子果实油浓缩物的方法。该方法包括分子蒸馏精制油的步骤。尤其,所述分子蒸馏步骤使用选自上文所述的离心分子蒸馏器和刮膜式分子装置的装置实施。
本发明还涉及用于制备华中五味子果实不可皂化物的方法,其包括以下步骤:皂化本发明的精制华中五味子果实油浓缩物,并且随后使用合适的溶剂提取所述不可皂化物。随后洗涤所述提取物直至彻底消除皂类,并且随后将溶剂蒸发。最后,不可皂化物经历蒸汽除臭,随后经历氮汽提以消除痕量的溶剂和水。
本发明还以用于制备华中五味子果实的肽与糖提取物的方法作为目的。这种用于制备华中五味子果实的肽与糖提取物的方法包括以下相继步骤:
a)从五味子果实开始,提取粗制油和油饼并且回收分散于水中的所述油饼;
b)用纤维素酶、蛋白酶和α-淀粉酶的酶混合物酶处理所述油饼;随后
c)热处理以抑制所述酶;
d)离心、超滤并且在具有15kDa截止值的膜上透滤以消除残余蛋白质;
e)纳米过滤以消除例如矿物盐或游离氨基酸;
f)可以将肽提取物在活性炭存在下漂白并且将它在过滤后回收。
有利地,可以将所述肽与糖提取物冻干。
根据本发明的一个方面,化妆品、皮肤病学或营养药组合物包含至少两种华中五味子果实提取物。尤其,所述组合物包含肽与糖提取物和粗制油,或肽与糖提取物和精制油,或肽与糖提取物和精制油浓缩物,或肽与糖提取物和不可皂化物。
根据本发明的另一个方面,所述化妆品、皮肤病学或营养药组合物可以进一步包含除所述华中五味子果实提取物之外的至少一种其他活性化合物。
所述的其他化合物可以选自下文提到的全部化合物及其功能性等同物。
所述的其他化合物尤其可以选自通常在皮肤病学中使用的活性剂如润肤剂、润湿性活性剂、角蛋白合成激活物、角质层调节剂、角质层分离剂、重构皮肤屏障的物质(皮肤脂质合成的激活物)、过氧化物酶体增殖物激活的受体(peroxisome proliferator-activated receptor,PPAR)激动药、RXR或LXR激动物、维生素D或皮质类固醇受体激动物、角质形成细胞分化活化物(类视黄醇、(开奥希多)、钙)、皮脂调节剂、抗刺激剂、安抚剂(soothingagent)、抗炎药、抗氧化剂和抗老化剂。
所述的其他化合物也可以选自具有互补性治疗作用的活性剂,如抗生素、益生元(prebiotics)和益生菌(probiotics)、抗菌药、抗真菌化合物、抗病毒药、防腐剂、免疫调制剂(他克莫司或吡美莫司)、唑啉、生长因子、结瘢剂或促营养分子、色素沉着或色素消褪剂、脂肪分解剂或脂肪生成抑制剂或抗蜂窝组织(anti-cellulite agent)剂或缩减剂(reducing agent)、(色素性或超细)无机或有机滤光物和遮光物、传统或功能性食物:升血糖或降血糖、抗脂肪或抗蜂窝组织营养物、抗胆固醇、抗氧化、供能、重构、影响更年期继发体征的食物。
所述的其他化合物也可以选自天然的植物提取物(来自可以在水相或油相中提取的植物:多酚、类黄酮(flavonoids)、其他肽和糖等)、含有植物油不可皂化物的复合物(compound)、甾醇不可皂化物或含有它们的产物(植物油不可皂化物,特别是豆油不可皂化物、植物脂不可皂化物或油性物质(butyraceousmatter)及其混合物、天然蜡不可皂化物、油提取物不可皂化物、油脂工业副产品的不可皂化物、动物脂肪提取物不可皂化物、海洋动物油不可皂化物、乳脂提取物不可皂化物、从单细胞生物提取的脂质不可皂化物、从藻类和海洋生物提取的脂质不可皂化物)、甾醇、甾烷醇、植物甾醇、植物甾烷醇、生育酚、向日葵和/或油菜籽和/或棕榈油浓缩物、微量元素、维生素、ω-3或-6或-9脂肪酸、降血糖性或升血糖性或增甜植物。
最常使用的润湿/润肤活性剂是甘油或其衍生物、脲、吡咯烷酮羧酸及其衍生物、任何分子量的透明质酸、葡萄糖胺聚糖和海洋源、植物源或生物技术源的任何其他多糖,例如黄原胶、岩藻聚糖某些脂肪酸如月桂酸、肉豆蔻酸、多不饱和以及单不饱和ω-3、-6、-7和-9脂肪酸,如亚油酸和棕榈油酸、向日葵油精华素(oleodistillate)、鳄梨肽、古朴阿苏果油(cupuacubutter)。
可以组合使用的角蛋白合成活化物有利地是类视黄醇、羽扇豆肽、角质层或颗粒层关键蛋白(角蛋白)和角化粒、鳄梨糖、昆诺阿藜(quinoa)肽提取物。
抗炎性/抗刺激剂和安抚剂限制了由细胞因子或花生四烯酸代谢介质造成的炎症反应,并且具有安抚和抗刺激性质。最常规的是甘草次酸(甘草衍生物)和其盐及酯、硫辛酸、β-胡萝卜素、维生素B3(烟酰胺(niacinamide)、尼克酰胺(nicotinamide))、维生素E、维生素C、维生素B12、类黄酮(绿茶、槲皮素等)、番茄红素或叶黄素、鳄梨糖、鳄梨油精华素(oleodistillate)、阿拉伯半乳聚糖、羽扇豆肽、羽扇豆总提取物、昆诺阿藜肽提取物、循环神经酰胺(唑啉衍生物)、异黄酮,例如染料木黄酮/染料木苷、黄豆苷原/黄豆苷、泉水或温泉水(雅漾(eau d’Avène)、理肤泉(eau de la RochePosay)、圣泉薇(eau de Saint Gervais)、依泉(eau d’Uriage)、珂玛德(eau deGamarde))、枸杞(Lycium barbarum)提取物、植物氨基酸肽或复合物、局部用氨苯砜、或甾体抗炎药(SAID)如皮质类固醇类或非甾体抗炎药(NSAID)。
常使用的角质层调节剂/角质层分离剂包括:最常使用的角质层调节剂/角质层分离剂包括:果实的α-羟酸(AHAS)(柠檬酸、羟乙酸、苹果酸、乳酸等)、AHA酯、AHAS与其他分子的组合如苹果酸和杏仁蛋白的组合((克瑞托莱特))、羟乙酸或乳酸与精氨酸的组合或羟酸与脂质分子如(脂-羟酸)的组合、两性羟酸复合物(AHCare)、柳树皮(白柳树皮提取物)、壬二酸和其盐及酯、水杨酸及其衍生物如辛酰基水杨酸或与其他分子的组合如水杨酸和多糖(β-羟酸或BHA)的组合、他扎罗汀、阿达帕林、以及维甲酸家族的分子如类视黄醇、视黄醛、异维甲酸和视黄醇。
可以组合使用的皮脂调节剂有利地选自包括5-α-还原酶抑制剂(例如活性物质5-α(阿沃库塔))的组。锌(和其葡萄糖酸盐、水杨酸盐和焦谷氨酸)也具有皮脂抑制活性。也可以提到在12周应用后显著降低皮脂分泌速率的螺内酯,一种抗雄激素和醛固酮拮抗剂。其他分子(例如从西葫芦(Cucurbitapepo),从南瓜籽、南瓜种子油以及扇叶菜棕(palm cabbage)提取)通过抑制5-α-还原酶转录和活性限制皮脂产生。影响皮脂性质的其他脂源皮脂调节剂如亚油酸是有意义的。
可以组合使用的生长因子有利地是贝卡普勒明(becaplermin)和转化生长因子β(TGF-β)、表皮生长因子(EGF)、神经生长因子(NGF)和血管内皮生长因子(VEGF)。
术语“抗氧化剂”指减少或防止其他化学物质氧化的分子。可以组合使用的抗氧化有利地选自由以下物质组成的组:硫醇和酚、甘草衍生物如甘草次酸和其盐及酯、α-没药醇、银杏提取物、金盏花(Calendula)提取物、环神经酰胺(唑啉衍生物)、鳄梨肽、微量元素如铜、锌和硒、硫辛酸、维生素B12、维生素B3(烟酰胺、烟酰胺)、维生素C、维生素E、辅酶Q10、磷虾、谷胱甘肽、丁羟甲苯(BHT)、丁羟茴醚(BHA)、番茄红素或叶黄素、β-胡萝卜素、多酚的巨大家族如单宁、酚酸、花青素、类黄酮,例如绿茶、红浆果、可可、葡萄、粉色西番莲(Passiflora incarnata)或柑橘(Citrus)的提取物,或异黄酮,例如染料木黄酮/染料木苷和黄豆苷原/黄豆苷。抗氧化剂类群还包括抗糖化剂如肌肽或某些肽、N-乙酰半胱氨酸以及抗氧化或游离基清除酶,如超氧化物歧化酶(SOD)、过氧化氢酶、谷胱甘肽过氧化物酶、硫氧还蛋白还原酶及其拮抗剂。
可以组合使用的结瘢/修复屏障功能并且刺激表皮的关键脂质合成的物质有利地是维生素A、泛醇(维生素B5)、鳄梨糖、羽扇醇、玛卡肽提取物、藜麦肽提取物、阿拉伯半乳聚糖、氧化锌、镁、硅、羟基积雪草酸或积雪草酸、硫酸葡聚糖、辅酶Q10、葡糖胺及其衍生物、硫酸软骨素和总体糖胺聚糖(GAGs)、硫酸葡聚糖、神经酰胺、胆固醇、角鲨烷、磷脂、发酵或未发酵过的大豆肽、植物肽、海洋多糖、植物多糖或生物技术多糖,如藻类提取物或蕨类提取物、微量元素、富含单宁的植物的提取物如从没食子酸衍生的单宁,其称作没食性单宁或可水解单宁,最初在栎树瘿中找到,和从黄烷单元聚合产生的儿茶素单宁,其模型由儿茶(Acacia catechu)提供。
可以使用的微量元素有利地选自由铜、镁、锰、铬、硒、硅、锌及其混合物组成的组。也可以使用向日葵浓缩物,更有利地是亚油酸性向日葵浓缩物,如由法国科延公司(Laboratoires Expanscience)出售活性物质(索林)、植物油不可皂化物如鳄梨呋喃PPAR激动物(罗格列酮、吡格列酮)、RXR和LXR。
可以组合使用的抗真菌化合物有利地是益康唑和酮康唑。
可以组合使用的杀菌防腐剂例如是三氯生、氯己定和季铵。
可以组合使用的抗生素有利地是夫西地酸、青霉素、四环素、普那霉素红霉素、克林霉素、莫匹罗星、米诺环素和多西环素。可以组合使用的抗病毒药有利地是阿昔洛韦和伐昔洛韦。
可以组合使用的防腐剂例如是在化妆品或营养药中通常使用的那些防腐剂,具有抗细菌活性的分子(假防腐剂)如辛酸衍生物(例如辛酰甘氨酸辛酸甘油酯等),如己二醇和乙酰丙酸钠、锌和铜衍生物(葡糖酸盐和PCA)、植物鞘氨醇及其衍生物、过氧苯甲酰、吡罗克酮乙醇胺、巯氧吡啶锌、二硫化硒。
可以组合使用的防晒活性物质包括UVB和/或UVA滤光或遮光物,或本领域技术人员已知的任何无机和/或有机遮光或滤光剂,所述技术人员将根据所寻求的保护程度调整它们的选择和其浓度。
作为防晒活性物质的实例,可以具体提到二氧化钛、氧化锌、亚甲基双-苯并三唑基四甲基丁基酚(品牌名称:Tinosorb M(天来施M))和双-乙基己氧苯酚甲氧苯基三嗪(品牌名称:Tinosorb S(天来施S))、辛-水杨酸、丁基甲氧基二苯甲酰基甲烷、对苯二亚甲基二樟脑磺酸、4-甲基亚苄基樟脑、二苯酮、甲氧基肉桂酸乙基己酯、二甲基对氨基苯甲酸(PABA)乙基己酯和二乙基己基丁酰胺基三嗪酮。
可以组合使用的还原剂有利地是咖啡因、海草(wrack)、植物提取物(例如:常春藤、可可、瓜拉那(guarana)、花竹柏(假叶树属(Ruscus))、绿茶、maté、四川胡椒(Sichuan pepper)和欧洲七叶树提取物)、积雪草(Centellaasiatica)、肉碱、海罂粟碱、七叶素、异黄酮类例如染料木黄酮和银杏(Ginkgobiloba)、福司柯林、视黄醇和其他维甲酸类、根皮苷和海茴香(sea fennel)。
预防脱发和/或强化头发和指甲的物质有利地是植物甾醇、异黄酮类例如,大豆异黄酮、视黄醇、锌及其衍生物、neoruscine、维生素E、维生素B2、维生素B3、维生素B6、维生素PP、维生素B5(泛醇,bepanthen)、维生素B8(维生素H或生物素)、维生素B9(叶酸)、α羟酸、奎宁和某些氨基酸如半胱氨酸、胱氨酸和甲硫氨酸。可以使用的其他化合物包括5-α-还原酶抑制剂例如,非那雄胺、度他雄胺、锯叶棕(Serenoa serrulata或Serenoa repens)、西葫芦提取物或某些植物甾醇。也可以提到角蛋白、微量元素、矿物盐、某些植物蛋白质或脂质提取物例如,苋科(Pfaffia)、鼠尾草、柠檬、人参、金鸡纳树、霍霍巴(jojoba)、七叶树、蜂蜜、小麦、荨麻、紫锥菊(echinea)或椰子提取物。
抗头皮屑物质(用于头皮)有利地选自豆瓣菜属(Nasturtium)提取物、维生素F、麝香草酚、粘土、巯氧吡啶锌、锌PCA、葡萄糖酸锌、硫酸锌、樟脑、桃金娘提取物、水杨酸、维生素B5、氯咪巴唑、鱼石脂、硒及其衍生物、南瓜籽提取物、红花属(Carthamus)提取物、白千层(Melaleuca)油提取物、琉璃苣和含羞草(Mimosa tenuiflora)油、蜂胶、科泰奥(kertyol)、羟乙酸、克鲁埃米德(keluamid)、环匹罗司乙醇胺、吡罗克酮乙醇胺、辛酰甘氨酸和5-αAvocuta。
可以组合使用的药物或化妆品物质有利地是适于预防和/或治疗以下病症的药物:
-特异反应性:皮质类固醇如氢化可的松、地奈德、氟轻松、丙酸氟替卡松、抑制钙神经的局部用免疫调制剂如他克莫司和吡美莫司、环孢菌素、硫唑嘌呤、甲氨蝶呤、维生素B12、抗微生物分子、抗组胺药如羟嗪和苯海拉明、抗生素、益生菌、纳曲酮、PPAR-α激动物如向日葵油精华素、含有神经酰胺或其他关键性表皮脂质的润肤剂,
-座疮:抗生素、过氧苯甲酰、维甲酸、壬二酸、维生素PP、维生素B3、锌、细胞周期蛋白。
-湿疹:免疫调制剂、润肤剂、鲑鱼油、琉璃苣油、益生菌,
-酒渣鼻:珀摩丝奥(permethol)、染料木黄酮、七叶苷、硫酸葡聚糖、橙皮苷甲基查尔酮、维甲酸、甘草查耳酮、羟甲唑啉、激动素、甘草提取物、多酚、类黄酮、原花青素(绿茶)、类维生素P、花竹柏提取物、国槐(Sophorajaponica)、金缕梅(Hamamelis)提取物和抗生素如多西环素,
-银屑病:皮质类固醇、卡泊三醇、骨化三醇、他扎罗汀、杜松油、阿维A酸和PUVA疗法。
可以组合使用的药物或食物有利地是升血脂和/或降血脂药物或食物。尤其可以提到基于磺酰脲和基于格列奈的药物、基于α-葡糖苷酶抑制剂的药物、基于双胍的药物(二甲双胍)、胰岛素敏感性活化物或含有作为PARR激动剂的噻唑烷二酮类(TZD、吡格列酮、罗格列酮)的药物、他汀家族或贝特家族(PPAR-α激动剂)降血脂药物、奥利司他(赛尼可)和西布曲明(瑞都克提尔(Reductyl)或辛布垂(Sibutral))。
可以组合使用的抗脂肪营养物有利地选自由组成的组阻断脂肪吸收的营养物如壳聚糖、能够增加生热的营养物(脂肪燃烧者)如麻黄碱(中药“麻黄”)、咖啡因、茶碱和可可碱和酸橙、能够控制食欲的营养物(饥饿抑制剂)如L-苯丙氨酸和L-酪氨酸、能够控制血糖症的营养物如矿物质,例如铬或钒或镁,或印度草药武靴藤(Gymnema sylvestre)、脂肪生成抑制剂如藤黄果提取物(Garcinia cambogia)羟基柠檬酸提取物和能够运输脂肪的营养物如L-肉碱。
使血糖再平衡的升血糖性食物或疗法的实例包括抗逆转录病毒药、糖皮质素、免疫抑制剂、IFN-α、性甾体类、THS、口服避孕丸、生长激素、拟效感神经药、心血管药物、利尿药、β-阻滞剂、钙制剂和拟效感神经药物。
可以组合使用的降血糖性植物有利地选自由组成的组胡芦巴(Trigonellafoenum-graecum)、科罗索酸(大花紫薇(Lagerstroemia speciosa)树的叶的活性化合物)、武靴藤(Gymnema sylvestre)、苦瓜(Momordica charantia)果汁、桉树(蓝桉(Eucalyptus globulus))、人参(Panax ginseng)和欧洲越桔(黑果越桔(Vaccinium myrtillus))叶。
可以组合使用的免疫调制剂有利地是他克莫司、吡美莫司和唑啉。可以组合使用的唑啉有利地是选自由2-十一基-4-羟甲基-4-甲基-1,3-唑啉、2-十一基-4,4-甲基-1,3-唑啉、(E)-4,4-甲基-2-十七碳-8-烯-1,3-唑啉、4-羟甲基-4-甲基-2-十七基-1,3-唑啉、(E)-4-羟甲基-4-甲基-2-十七碳-8-烯-1,3-唑啉和2-十一基-4-乙基-4-羟甲基-1,3-唑啉组成的组中的唑啉。甚至更有利地,所述唑啉是称作OX-100或环神经酰胺的2-十一基-4,4-甲基-1,3-唑啉。
可以组合使用的色素消褪剂或除色素剂包括氢醌及其衍生物、熊果苷、维A酸、视黄醇、视黄醛、维甲酸、氢醌、皮质类固醇类、曲酸、壬二酸、鞣花酸、丙酮酸、羟乙酸、维生素B3(烟酰胺)或PP、维生素C、环神经酰胺间苯二酚衍生物、白藜芦醇甘草或桑白皮提取物、α-硫辛酸、亚油酸、吲哚美辛、阳离子螯合剂如乙二胺四乙酸(EDTA)和大豆提取物如染料木黄酮。也可以提到由Seppic出售的(N-碳烯酰基-L-苯丙氨酸),它是美容用除色素剂。
可以组合使用的色素沉着剂例如是使皮肤染色的物质如二羟丙酮和黑色素类;刺激天然色素沉着过程的物质如在皮肤病学中具有治疗性质的补骨脂素类(8-甲氧基补骨脂素、5-甲氧基补骨脂素、4,5′,8-三甲基补骨脂素或补骨脂(Psoralea corylifolia)和大阿米芹(Ammi majus)的植物提取物)、类胡萝卜素类(番茄红素、斑蝥黄)、刺激环AMP途径的物质如(1.cAMP类似物,如8-溴-cAMP或双丁酰cAMP,2.福司柯林,3.异丁基-甲基-黄嘌呤或茶碱)、蛋白激酶C活化物(二酰甘油,尤其,油酰基-乙酰基-甘油)、脂族或环状二醇(1,2-丙二醇、5-降莰烷-2,2-二甲醇、降莰烷-2,2-二甲醇)、双环单萜二醇、酪氨酸衍生物(L-酪氨酸、L-DOPA)、二甲基亚砜、亲溶酶体物质、胸腺嘧啶二核苷酸、DNA片段、黑素细胞刺激激素类似物、3-异丁基-1-甲基黄嘌呤、硝酸供体(Brown,光化学和光生物学杂志B:生物学(Journal of photochemistryand photobiology B:biology)63(2001)148-161);或植物提取物如稻肽,和显示促黑色素生成活性的藻类:掌状海带(Laminaria digitata)(来自Codif的)。
特别有利的本发明组合是一种组合物,该组合物包含华中五味子果实肽与糖提取物和植物及动物不可皂化物,例如,鳄梨和大豆不可皂化物和不可皂化的植物油或动物油浓缩物,例如,向日葵油或棕榈油浓缩物,或含有不可皂化物的植物油,例如,大豆油和菜籽油,以及不可皂化物的衍生物如鳄梨呋喃、甾醇酯和维生素衍生物。“甾醇”不可皂化物是这样的不可皂化物,其甾醇(甲基甾醇和三萜醇)的含量相对于该不可皂化物的总重量是以重量计20%至95%,优选地以重量计45%至65%。
特别有利的本发明组合是一种组合物,该组合物包含华中五味子果实提取物和鳄梨糖(如申请WO 2005/115421中所述)。所述组合物特别适于治疗皮肤屏障修复和炎症。
特别有利的本发明组合是一种组合物,该组合物包含华中五味子果实提取物和鳄梨肽(如国际申请WO 2005/105123中所述)。所述组合物特别适于治疗刺激和炎症。
另一个特别有利的本发明组合是一种组合物,该组合物包含华中五味子果实提取物和鳄梨油(如国际申请WO 2004/012496、WO 2004/012752、WO2004/016106、WO 2007/057439中所述)。
另一个特别有利的本发明组合是是一种组合物,该组合物包含华中五味子果实提取物和鳄梨呋喃(鳄梨呋喃,其可以通过国际申请WO 01/21605中所述的方法获得)。所述组合物特别适于治疗炎症、促进瘢痕形成和适于其抗老化性质。
另一个特别有利的本发明组合是一种组合物,该组合物包含华中五味子果实提取物和和5-α(鳄梨油酸丁酯)。所述组合物特别适于抑制5-α-还原酶(见WO 01/52837和WO 02/06205)和适于调节痤疮和头皮屑中存在的皮脂溢出分泌物增加。
另一个特别有利的本发明组合是一种组合物,该组合物包含华中五味子果实提取物和鳄梨及大豆不可皂化物。可以组合使用的鳄梨及大豆不可皂化物有利地分别是处于大约1∶3-2∶3比例的鳄梨呋喃性不可皂化物和大豆不可皂化物的混合物。鳄梨及大豆不可皂化物甚至更有利地是由Laboratoires Expanscience出售的产品
另一个特别有利的本发明组合是一种组合物,该组合物包含华中五味子果实提取物和向日葵油精华素,甚至更有利地是具有亚油酸性向日葵浓缩物的向日葵油精华素(oleodistillate),如由Laboratoires Expanscience出售的活性物质(见国际申请WO 01/21150)。所述组合物特别适于治疗炎症和皮肤屏障修复。
另一个特别有利的本发明组合是是一种组合物,该组合物包含华中五味子果实提取物和大豆不可皂化物,如根据国际申请WO 01/51596中所述的方法获得的大豆不可皂化物。
另一个特别有利的本发明组合是一种组合物,该组合物包含华中五味子果实提取物和羽扇醇(FR 2,822,821,FR 2,857,596)。所述组合物特别适于支持瘢痕形成。
另一个特别有利的本发明组合是是一种组合物,该组合物包含华中五味子果实提取物和羽扇豆肽,如根据申请WO 2005/102259中所述的方法获得的羽扇豆肽。所述组合物特别适于治疗炎症,并且因其抗老化性质而使用。
另一个特别有利的本发明组合是一种组合物,该组合物包含华中五味子果实提取物和总羽扇豆提取物(见国际申请WO 2005/102259)。所述组合物特别适于治疗刺激。
另一个特别有利的本发明组合是是一种组合物,该组合物包含华中五味子果实提取物和羽扇豆油,有利地是甜味白色羽扇豆油,如国际申请WO 98/47479中所述的甜味白色羽扇豆油。
另一个特别有利的本发明组合是一种组合物,该组合物包含华中五味子果实提取物和玛卡肽提取物(见国际申请WO 2004/112742)。所述组合物因其结瘢性质和抗老化性质而特别受赏识。
特别有利的本发明组合是一种组合物,该组合物包含华中五味子果实肽与糖提取物和稻肽(见国际申请2008/009709)。所述组合物因其与刺激黑素形成和与黑色素转移相关的性质而特别受赏识。
另一个特别有利的本发明组合是一种组合物,该组合物包含华中五味子果实提取物和环神经酰胺(唑啉衍生物),如国际申请WO 2004/050052、WO 2004/050079和WO 2004/112741中所述。所述组合物特别适于治疗炎症反应。
另一个特别有利的本发明组合是一种组合物,该组合物包含华中五味子果实提取物和藜麦提取物,尤其肽提取物(见国际申请WO 2008/112742)。所述组合物特别适于治疗炎性疾病和皮肤屏障修复。
另一个特别有利的本发明组合是一种组合物,该组合物包含华中五味子果实提取物和古朴阿苏果油。所述组合物因其润湿性质而特别受赏识。
另一个特别有利的本发明组合是一种组合物,该组合物包含华中五味子果实提取物和油菜籽浓缩物。
另一个有利的本发明组合是一种组合物,该组合物包含华中五味子果实提取物和玉米浓缩物。
除华中五味子果实提取物之外,全部这些组合包含至少一种其他活性化合物,并且可以包含如上所述的两种、三种、四种或更多种活性化合物。
本发明的组合物可以以适于局部施加或适于口服、直肠、阴道、鼻部、耳部、支气管或肠胃外给药的多种制剂形式制备。
根据第一变例,多种制剂适于局部施加,并且包括乳膏剂、乳剂、乳、香膏剂、洗剂、油剂、水溶液剂或氢化-醇或乙醇酸溶液剂、粉剂、贴剂、喷雾剂或用于外部施加的任何其他产品。
根据第二变例,多种制剂适于口服给药,其中可以在膳食组合物或膳食补充剂中包含所述五味子果实提取物。在本发明背景下,可以以原样华中五味子果实提取物(例如精制油)的形式或者以硬质或软质明胶或植物胶囊剂的形式提供膳食补充剂。所述膳食补充剂因而可以含有以重量计10%至100%的华中五味子果实提取物。
根据本发明的这个第二变例,在不限制的情况下,也可以在包括以下制品的食物、饮料和营养药中并入本发明的华中五味子果实提取物:
1)乳制品如乳酪、黄油、乳和其他乳状饮料、含有乳产品、冰淇淋和酸乳的混合物和糊状食品;
2)基于脂肪的制品如人造黄油、糊状食品、蛋黄酱、烹调用脂肪、油炸用油和维纳格雷酸辣沙司(vinaigrette);
3)由谷物组成的基于谷物的制品,如面包和面食制品,无论这些食品是否经过烹煮、焙烘或加工;
4)糖果如巧克力、糖食、口香糖、甜品、顶端配料(topping)、清凉果汁饮料(sorbet)、蛋糕糖衣(icing)和其他饰菜(garnishe);
5)酒精或无酒精饮料,包括苏打水和其他软饮料、果汁、膳食补充物、饮料形式的正餐代用品如在品牌名称BoostTM和EnsureTM下销售的那些正餐代用品,和;
6)多种制品如蛋类、加工食品如汤、即用型面食制品调味汁、准备好的菜肴和相同类型的其他制品。
可以借助技术如混合、灌注、注射、掺混、吸附、揉捏和喷洒在食物中、营养药中、膳食产品,尤其高蛋白产品中,或饮料中直接并且在无其他修饰下并入本发明的组合物。
可以根据建立适于患者或适于动物的药物疗法、尤其皮肤学疗法或兽医疗法时通常所考虑的标准例如,该患者或动物的年龄或体重、该患者或动物整体状态的严重性、对所述疗法的耐受性、明显的副作用和皮肤类型,确定本发明化合物和组合物的给药模式及、投予方案和最佳植物制剂形式。根据想要的给药法的类型,本发明的有效组合物和/或化合物可以进一步包含至少一种可药用的赋形剂,尤其皮肤病学可接受的赋形剂。根据第一变例,使用适于体外局部施加的赋形剂。本发明的组合物还可以包含本领域技术人员已知的至少一种药用佐剂,其选自增稠剂、防腐剂、香料、色料、化学或无机滤料(filter)、润湿剂、温泉水等。
包含了具有所示规范的华中五味子果实提取物的组合物特别意图用于化妆品、皮肤病学或营养药用途。
在美容或皮肤病学用途的背景下,将会有利地以适于局部施加的制剂形式配制所述组合物。包含肽与糖提取物的组合物特别意图用于化妆品或皮肤病学用途。
在营养药用途的背景下,针对营养或美容目的(美容食物),将会有利地以适于口服给药的制剂形式配制所述组合物。该组合物将不包含赋形剂并且将整体地被包含于精制华中五味子油中。
本发明也以使用选自华中五味子果实肽与糖提取物或华中五味子果实脂质提取物的华中五味子果实提取物用于制造化妆品或皮肤病学或食物组合物作为目的,其中所述的华中五味子果实脂质提取物选自由粗制油、精制油、浓缩物或不可皂化物组成的组。
在第一方面,本发明以选自如上文定义的肽与糖提取物或粗制油或精制油或浓缩物或不可皂化物中的华中五味子果实提取物在化妆品组合物中的用途作为目的,用于预防和治疗过敏性、炎性或刺激性反应或病变,或者皮肤和/或粘膜屏障或稳态的和/或不成熟、正常或成熟/老化的上皮附属物的病症。
在第二方面,本发明以选自如上文定义的肽与糖提取物或粗制油或精制油或浓缩物或不可皂化物中的华中五味子果实提取物在食物组合物(如功能性食物)中的用途作为目的,用于预防和治疗过敏性、炎性或刺激性反应或病变,或者皮肤和/或粘膜屏障或稳态的和/或不成熟、正常或成熟/老化的上皮附属物的病症。
功能性食物是常规食物或可视作常规食物,所述常规食物是正常膳食的一部分并且以提供超过该食物常见营养功能的有利生理益处或降低慢性病风险作为特征。
尤其,所述功能性食物意图预防和治疗过敏性、炎性或刺激性反应或病变,或者以下对象的屏障或稳态病症:
-皮肤,如痤疮、酒渣鼻(赤-红血丝)、皮肤发红、银屑病、血管病、尿布疹、特应性皮炎、湿疹、接触性皮炎、刺激性皮炎、过敏性皮炎、脂溢性皮炎(乳痂)、银屑病、敏感皮肤、反应性皮肤、干性皮肤(干燥病)、皮肤脱水、发红的皮肤、皮肤红斑、老化和光老化的皮肤、光敏感性皮肤、色素沉着的皮肤(黑斑病、炎症后色素沉着等)、失色素的皮肤(白癫风)、患有蜂窝织炎的皮肤、松弛皮肤、具有牵拉痕的皮肤、粗皮病、皲裂、虫咬、裂痕,尤其,乳房裂痕、晒伤、因全部类型射线所致的炎症、由化学病原因素、物理病原因素(抗张力:孕妇)、细菌学病原因素、真菌或病毒病原因素、寄生性病原因素(虱、螨、癣、蜱螨、皮肤真菌)或放射学因素或由先天性免疫缺损(抗微生物肽)或获得性性免疫缺损(细胞、体液、细胞因子)所致的刺激,和/或
-粘膜,如患有牙龈炎的齿龈和牙周组织(新生儿中敏感齿龈、因使用烟草所致的卫生问题等)、牙周病或伴有男性或女性生殖器区域内部或外部刺激的生殖器粘膜,和/或
-上皮附属物如不成熟、正常或成熟/老化的甲(易碎、脆弱甲等)和毛发(秃发、头皮屑、多毛症、脂溢性皮炎、毛囊炎),尤其显示头皮病症如雄性、急性、局限性、瘢痕性或先天性秃发、新生儿中枕部秃发、斑秃、因化疗法/放疗法所致的秃发或休止期期脱发、再生期脱发、毛发营养不良、拔毛症、癣或者油性或干性头皮屑。
本发明也涉及食物或营养药组合物,其包含选自华中五味子果实肽与糖提取物或华中五味子果实脂质提取物的华中五味子果实提取物,其中所述的脂质提取物本身选自由粗制油、精制油、浓缩物或不可皂化物组成的组。
在第三方面,本发明以选自如上文定义的肽与糖提取物或粗制油或精制油或浓缩物或不可皂化物中的华中五味子果实提取物的治疗用途作为目的,用于预防和治疗过敏性、炎性或刺激性反应或病变,或者皮肤和/或粘膜屏障或稳态的和/或不成熟、正常或成熟/老化的上皮附属物的病症。
根据优选的方面,本发明以华中五味子果实肽与糖提取物在化妆品组合物中用于治疗和预防皮肤发红、赤-红血丝和酒渣鼻的用途作为目的。
根据另一个优选的方面,本发明以华中五味子果实肽与糖提取物在食物组合物中用于治疗和预防皮肤发红、赤-红血丝和酒渣鼻的用途作为目的。
根据第三优选的方面,本发明以华中五味子果实肽与糖提取物用于治疗和预防皮肤发红、赤-红血丝和/或酒渣鼻的治疗用途作为目的。
实施例
实施例1:用于局部施加的组合物
本发明人在下文提供几种用于局部施加的组合物。可以将所述油、木脂体中浓缩的精制油、不可皂化成分和华中五味子肽与糖提取物并入多种化妆产品中,如洁肤水(cleansing water)、水包油乳液、油包水乳液、油、乳、洗液、洗发剂、泡沫产品和喷雾剂,下文提出它们的组成。
润湿性洁肤水
原料/品牌名称 | % |
纯水 | 补足余量至(QSP)100% |
生物糖胶(Biosaccharide gum) | 1%-5% |
丁二醇 | 1%-5% |
透明质酸 | 0%-5% |
五味子肽与糖提取物 | 0.01%-5% |
防腐剂 | 0%-1% |
柠檬酸一水合物 | 0%-1% |
氨丁三醇 | 0%-1% |
用于敏感皮肤的洁肤水
原料/品牌名称 | % |
辛酰甘氨酸 | 0%-1% |
苏打碱液(Soda lye) | 0%-1% |
多价螯合剂 | 0%-1% |
丁二醇 | 1%-5% |
β-萝卜素 | 0%-2% |
五味子浓缩物 | 0.01%-5% |
防腐剂 | 0%-1% |
PEG-32 | 1%-5% |
PEG-7棕榈椰油酸酯(palmcocoate) | 1%-5% |
葡萄糖酸锌 | 0%-1% |
柠檬酸 | 0%-1% |
纯水 | QSP 100% |
香料(Fragrance) | 0%-1% |
泊洛沙姆184 | 1%-5% |
抗老化乳剂
原料/品牌名称 | % |
液体异链烷烃 | 5%-20% |
异鲸蜡醇硬脂酸酯 | 5%-20% |
Al-Mg羟硬脂酸盐 | 5%-20% |
Abil WE 09 | 1%-5% |
甘油 | 1%-5% |
凡士林油 | 1%-5% |
微粉化氧化锌 | 1%-5% |
丁二醇 | 1%-5% |
视黄醇 | 0%-1% |
维生素C | 0%-5% |
五味子不可皂化成分 | 0.01%-5% |
异壬酸异壬酯 | 1%-5% |
蜂蜡 | 1%-5% |
酒石酸钠 | 1%-5% |
氯化钠 | 0%-5% |
甘氨酸 | 1%-5% |
防腐剂 | 0%-1% |
胆固醇 | 0%-1% |
植物鞘氨醇 | 0%-1% |
酒石酸 | 0%-1% |
纯水 | QSP 100% |
重构用乳剂
还原油(Reducing oil)
原料/品牌名称 | % |
增溶剂 | 0%-1% |
甜杏仁油 | 5%-20% |
椰油辛酸/癸酸酯(Copra caprylate/caprate) | QSP 100% |
精制澳洲坚果油(macadamia oil) | 5%-20% |
甘油辛酰癸酸酯(Glycerol caprylocaprate) | 5%-20% |
天然α-没药醇 | 0%-1% |
α-生育酚 | 0%-1% |
常春藤提取物 | 0%-5% |
精制五味子油 | 0.01%-5% |
防腐剂 | 0%-1% |
酯 | 0%-1% |
用于干性、特异反应性皮肤的乳
原料/品牌名称 | % |
甜杏仁油 | 1%-5% |
玉米油 | 1%-5% |
硬脂酸 | 1%-5% |
C16-C18鲸蜡酸 | 0%-1% |
消泡剂70414 | 0%-1% |
月桂醇11OE | 1%-5% |
PEG 300单月桂酸酯 | 0%-1% |
单油酸甘油酯 | 0%-1% |
单硬脂酸甘油酯 | 1%-5% |
维生素B12 | 0%-5% |
五味子浓缩物 | 0.1%-5% |
防腐剂 | 0%-1% |
柠檬酸 | 0%-1% |
柠檬酸三钠 | 0%-1% |
纯水 | QSP 100% |
香料 | 0%-1% |
花生油 | 1%-5% |
氢化棕榈油 | 1%-5% |
泡沫
原料/品牌名称 | % |
纯水 | QSP 100% |
月桂酰两性基乙酸盐 | 5%-20% |
椰油基葡糖苷 | 5%-20% |
表面活性剂1 | 5%-20% |
表面活性剂2 | 5%-20% |
PEG 6000二硬脂酸酯 | 1%-5% |
防腐剂 | 1%-5% |
五味子油 | 0.1%-5% |
洋甘菊提取物(Chamomile extract) | 1%-5% |
柠檬酸一水合物 | 0%-1% |
多价螯合剂 | 0%-1% |
香料 | 0%-1% |
苏打碱液 | 0%-1% |
顺滑喷雾剂(Soothing spray)
原料/品牌名称 | % |
纯水 | QSP 100% |
三(月桂醇聚醚-4)磷酸酯 | 1%-5% |
碳酸二辛酯 | 1%-5% |
丁二醇 | 1%-5% |
赤藓醇酯(Erythrityl ester) | 1%-5% |
液体凡士林油 | 1%-5% |
雪亚脂(Shea butter) | 0%-1% |
植物油 | 0%-1% |
防腐剂 | 0%-1% |
番茄红素 | 0%-5% |
五味子不可皂化成分 | 0.01%-5% |
苏打碱液 | 0%-1% |
香料 | 0%-1% |
黄原胶 | 0%-1% |
卡波姆 | 0%-1% |
多价螯合剂 | 0%-1% |
柠檬酸 | 0%-1% |
纯化清洁霜
原料/品牌名称 | % |
纯水 | QSP 100% |
阿拉同恩(Arlatone) | 10%-30% |
椰油基葡糖苷 | 5%-20% |
羟丙基瓜尔胶(Hydroxypropyl guar) | 1%-5% |
辛酰甘氨酸 | 0%-2% |
防腐剂 | 0%-2% |
香料 | 0%-1% |
柠檬酸 | 0%-1% |
锌吡咯烷酮羧酸(PCA) | 0%-1% |
五味子肽与糖提取物 | 0.01%-5% |
抗痤疮乳剂
原料/品牌名称 | % |
PEG40硬脂酸酯 | 1%-5% |
PEG5硬脂酸甘油酯 | 1%-5% |
地蜡 | 1%-5% |
单硬脂酸甘油酯 | 1%-5% |
失水山梨醇硬脂酸酯 | 0%-2% |
鲸蜡醇 | 0%-2% |
苹果酸氢酯醇 | 5%-20% |
维生素E | 0%-1% |
维生素B3 | 0%-5% |
亚油酸 | 0%-1% |
五味子肽与糖提取物 | 0.01%-5% |
丁二醇 | 1%-5% |
吡罗克酮乙醇胺(Piroctolamine) | 0%-1% |
防腐剂 | 0%-1% |
甘油 | 1%-10% |
黄原胶 | 0%-1% |
锌PCA | 0%-2% |
米淀粉 | 1%-5% |
尼龙6 | 0%-2% |
聚丙烯酰胺凝胶 | 1%-5% |
维生素B6 | 0%-1% |
香料 | 0%-1% |
纯水 | QSP 100% |
抗发红乳剂
原料/品牌名称 | % |
PEG40硬脂酸酯 | 1%-5% |
PEG5硬脂酸甘油酯 | 1%-5% |
地蜡 | 1%-5% |
单硬脂酸甘油酯 | 1%-5% |
失水山梨醇硬脂酸酯 | 0%-2% |
鲸蜡醇 | 0%-2% |
苹果酸氢酯醇(Dimalate alcohol) | 5%-20% |
七叶苷(Esculoside) | 0%-2% |
国槐(Sophora japonica) | 0%-5% |
维生素E | 0%-1% |
五味子油 | 0.01%-5% |
丁二醇 | 1%-5% |
吡罗克酮乙醇胺(Piroctolamine) | 0%-1% |
防腐剂 | 0%-1% |
甘油 | 1%-10% |
黄原胶 | 0%-1% |
锌PCA | 0%-2% |
米淀粉 | 1%-5% |
尼龙6 | 0%-2% |
聚丙烯酰胺凝胶 | 1%-5% |
维生素B6 | 0%-1% |
香料 | 0%-1% |
纯水 | QSP 100% |
修复护理
原料/品牌名称 | % |
PEG40硬脂酸酯 | 1%-5% |
PEG5硬脂酸甘油酯 | 1%-5% |
地蜡 | 1%-5% |
单硬脂酸甘油酯 | 1%-5% |
失水山梨醇硬脂酸酯 | 0%-2% |
鲸蜡醇 | 0%-2% |
苹果酸氢酯醇 | 5%-20% |
维生素E | 0%-1% |
辅酶Q10 | 0%-2% |
神经酰胺 | 0%-5% |
精制五味子油 | 0.01%-5% |
丁二醇 | 1%-5% |
吡罗克酮乙醇胺 | 0%-1% |
防腐剂 | 0%-1% |
甘油 | 1%-10% |
黄原胶 | 0%-1% |
锌PCA | 0%-2% |
米淀粉 | 1%-5% |
尼龙6 | 0%-2% |
聚丙烯酰胺凝胶 | 1%-5% |
维生素B6 | 0%-1% |
香料 | 0%-1% |
纯水 | QSP 100% |
除色素乳剂
原料/品牌名称 | % |
异壬酸异壬酯 | 1%-10% |
异鲸蜡醇硬脂酸酯 | 1%-10% |
PEG40硬脂酸酯 | 1%-5% |
PEG5硬脂酸甘油酯 | 1%-5% |
防腐剂 | 0%-1% |
C16-C18鲸蜡醇 | 0%-2% |
PPG/SMDI聚合物 | 0%-1% |
水杨酸 | 0%-2% |
角鲨烷凝胶 | 0%-2% |
二辛醚 | 1%-10% |
苹果酸氢酯醇 | 1%-10% |
向日葵提取物 | 1%-10% |
氨丁三醇 | 1%-5% |
丁二醇 | 1%-10% |
柠檬酸三钠 | 0%-1% |
小核菌胶 | 0%-1% |
米淀粉 | 1%-10% |
聚丙烯酰胺凝胶 | 0%-1% |
维生素C | 0%-2% |
甘氨酸 | 0%-2% |
香料 | 0%-1% |
维生素E | 0%-2% |
柠檬酸 | 0%-1% |
Sepiwhite(酰苯胺) | 0%-2% |
五味子浓缩物 | 0.01%-5% |
纯水 | QSP 100% |
抗细菌滚搽棒(stick roll-on)
原料/品牌名称 | % |
纯水 | QSP 100% |
丁二醇 | 1%-5% |
过氧化苯甲酰 | 0%-2% |
辛酰甘氨酸 | 0%-5% |
锌PCA | 0%-5% |
五味子油 | 0.1%-5% |
卡波姆(Carbomer) | 0%-2% |
防腐剂 | 0%-1% |
柠檬酸 | 0%-1% |
氨丁三醇 | 0%-1% |
擦剂(scrub)
原料/品牌名称 | % |
Arlatone duo(阿拉同恩多) | 5%-20% |
表皮剥脱剂 | 1%-10% |
小核菌胶 | 1%-10% |
防腐剂 | 0%-1% |
辛酰甘氨酸 | 0%-1% |
苏打 | 0%-1% |
五味子肽与糖提取物 | 0.01%-5% |
多价螯合剂 | 0%-1% |
柠檬酸 | 0%-1% |
纯水 | QSP 100% |
香料 | 0%-1% |
角化液
原料/品牌名称 | % |
鲸蜡醇 | 1%-5% |
硅氧烷345(silicone 345) | 1%-5% |
抗氧化剂 | 0%-1% |
纯水 | QSP 100% |
西曲氯铵 | 0%-5% |
奎宁 | 0%-5% |
维生素B5 | 0%-5% |
五味子油 | 0.01%-5% |
水解小麦蛋白 | 0%-1% |
防腐剂 | 0%-2% |
香料 | 0%-1% |
pH调节剂 | 0%-1% |
抗头皮屑洗发剂
原料/品牌名称 | % |
纯水 | QSP 100% |
月桂酰两性基乙酸盐 | 5%-20% |
椰油基葡糖苷 | 5%-20% |
PEG6000二硬脂酸酯 | 1%-5% |
防腐剂 | 0%-2% |
维生素F | 0%-5% |
吡罗克酮乙醇胺(Piroctone olamine) | 0%-2% |
五味子浓缩物 | 0.01%-5% |
吡硫锌 | 0%-1% |
pH调节剂 | 0%-1% |
多价螯合剂 | 0%-1% |
香料 | 0%-1% |
调理剂
原料/品牌名称 | % |
鲸蜡硬脂醇/鲸蜡硬脂醇聚醚-33 | 1%-5% |
季铵盐-82(Quaternium-82) | 0%-2% |
纯水 | QSP 100% |
水解小麦蛋白 | 0%-5% |
防腐剂 | 0%-2% |
pH调节剂 | 0%-1% |
香料 | 0%-1% |
半胱氨酸 | 0%-5% |
精制五味子油 | 0.01%-5% |
毛细血管强化洗液
原料/品牌名称 | % |
纯水 | QSP 100% |
甲基丙二醇 | 5%-20% |
防腐剂 | 0%-2% |
pH调节剂 | 0%-1% |
香料 | 0%-1% |
生物素 | 0%-5% |
维生素B9 | 0%-5% |
五味子浓缩物 | 0.01%-5% |
β-谷固醇 | 0%-1% |
椰油酸乙基己酯 | 0%-5% |
PEG-40蓖麻油 | 0%-5% |
光防护棒(Photoprotecting stick)
原料/品牌名称 | % |
蓖麻油 | QSP100% |
油醇 | 10%-20% |
棕榈油 | 10%-20% |
聚甘油-3-蜂蜡 | 10%-20% |
小烛树蜡 | 10%-20% |
锂蒙脱石 | 10%-20% |
二氧化钛 | 0%-5% |
五味子不可皂化成分 | 0.01%-5% |
雪亚脂 | 0%-5% |
维生素E | 0%-1% |
防晒系数(SPF)50+防晒霜
原料/品牌名称 | % |
B4纯水 | QSP 100% |
钛氧化物 | 10%-20% |
环五硅氧烷 | 5%-15% |
棕榈酸辛酯 | 5%-15% |
C12-C15烷基苯甲酸酯 | 5%-10% |
戊酸癸酯 | 5%-10% |
锌氧化物 | 5%-10% |
甘油 | 1%-5% |
PEG-45/十二烷甘醇共聚物 | 1%-5% |
五味子肽与糖提取物 | 0.01%-5% |
氯化钠 | 1%-5% |
糊精棕榈酸酯 | 1%-2% |
维生素E | 0%-2% |
防腐剂 | 0%-2% |
羟丙基瓜尔胶(Hydroxypropyl guar) | 0%-1% |
芦荟(Aloe vera) | 0%-1% |
苏打碱液 | 0%-1% |
乙二胺四乙酸二钠盐(EDTA 2-Na) | 0%-1% |
葡萄糖酸锌 | 0%-1% |
SPF50+防晒喷雾剂
抗发红乳剂
原料/品牌名称 | % |
PEG40硬脂酸酯 | 1%-5% |
PEG5硬脂酸甘油酯 | 1%-5% |
地蜡 | 1%-5% |
单硬脂酸甘油酯 | 1%-5% |
失水山梨醇硬脂酸酯 | 0%-2% |
鲸蜡醇 | 0%-2% |
苹果酸氢酯醇 | 5%-20% |
国槐(Sophora japonica) | 0%-5% |
维生素E | 0%-1% |
五味子肽与糖提取物 | 0.01%-5% |
丁二醇 | 1%-5% |
吡罗克酮乙醇胺(Piroctolamine) | 0%-1% |
防腐剂 | 0%-1% |
甘油 | 1%-10% |
黄原胶 | 0%-1% |
锌PCA | 0%-2% |
米淀粉 | 1%-5% |
尼龙6 | 0%-2% |
聚丙烯酰胺凝胶 | 1%-5% |
维生素B6 | 0%-1% |
香料 | 0%-1% |
纯水 | QSP 100% |
抗老化抗发红乳剂
原料/品牌名称 | % |
液体异链烷烃 | 5%-20% |
异鲸蜡醇硬脂酸酯 | 5%-20% |
Al-Mg羟硬脂酸盐 | 5%-20% |
Abil WE 09 | 1%-5% |
甘油 | 1%-5% |
凡士林油 | 1%-5% |
微粉化锌氧化物 | 1%-5% |
丁二醇 | 1%-5% |
视黄醇 | 0%-1% |
维生素C | 0%-5% |
五味子肽与糖提取物 | 0.01%-5% |
异壬酸异壬酯 | 1%-5% |
蜂蜡 | 1%-5% |
酒石酸钠 | 1%-5% |
氯化钠 | 0%-5% |
甘氨酸 | 1%-5% |
防腐剂 | 0%-1% |
胆固醇 | 0%-1% |
植物鞘氨醇 | 0%-1% |
酒石酸 | 0%-1% |
纯水 | QSP 100% |
实施例2:用于口服给药的组合物
将所述五味子油、浓缩物和肽以能够每日给药50mg至200mg五味子提取物的组成集成入口服组合物中。
2.1软胶囊剂形式的抗牵拉痕组合物
A-组合物1
-五味子肽与糖提取物 30mg
-星果棕油(Awara oil) 60mg
-不可皂化物丰富的油菜籽油 300mg
-B族维生素(B1、B2、B3、B5、B6、B9、B12)QSP 100%RDA
-生育三烯酚 QSP 50%RDA
-维生素E
-蜂蜡
-大豆卵磷脂
-滋养性明胶
-丙三醇 QSP 1软胶囊剂
所述组合物作为每日4至6粒500mg胶囊剂给药。
B-组合物2
-五味子油 30mg
-富含神经酰胺和极性脂质的谷物油 300mg
-羽扇豆油 50mg
-维生素E QSP 100%RDA
-维生素C QSP 50%RDA
-蜂蜡
-大豆卵磷脂
-滋养性明胶
-丙三醇 QSP 1软胶囊剂
所述组合物作为每日4至6粒500mg胶囊剂给药。
2.2抗脱发片剂
-五味子浓缩物 25mg
-含硫氨基酸丰富的谷物提取物(玉米、荞麦、谷子、斯佩尔特小麦) 200mg
-维生素C QSP 50%RDA
-鱼软骨葡萄糖胺聚糖 200mg
-糖酸(Glucidex)IT 19(压缩剂(compression agent))
QSP一个800mg片剂
所述组合物作为每日5至8个片剂给药。
-五味子不可皂化成分 200mg
-含硫氨基酸丰富的谷物提取物(玉米、荞麦、谷子、斯佩尔特小麦) 200mg
-螯合物形式的Zn QSP 100%RDA
-维生素C QSP 50%RDA
-鱼软骨葡萄糖胺聚糖 200mg
-果味料(柑橘果实、红浆果)、丁磺氨钾、糖酸(Glucidex)IT19(压缩剂) QSP一个2,000mg片剂
所述组合物每日给药一次。
2.3还原性粉棒(reducing powder stick)的实例
-五味子肽与糖提取物 100mg
-富含多酚的茶提取物 100mg
-富含低聚原花青素(OPC)的葡萄提取物 50mg
-植物β-葡聚糖 100mg
-黄原胶 1mg
-抗坏血酸钠 0.3mg
-麦芽糊精 QSP5g
所述组合物每日施用给药二两次。
-五味子不可皂化成分 100mg
-积雪草(Centella asiatica)提取物 100mg
-镁、硒、锰 QSP 100%RDA
-黄原胶 1mg
-抗坏血酸钠 0.3mg
-麦芽糊精 QSP5g
所述组合物每日施用给药二两次。
2.4巧克力味压缩饼干的实例
-精制五味子油 200mg
-番茄红素 6mg
-虾青素 4mg
-岩藻黄质(Fucoxanthin) 4mg
-微胶囊化形式的叶黄素 4mg
-微胶囊化的生育三烯酚 QSP 100%RDA 以维生素E计
-黑巧克力、低聚果糖、糖、果糖糖浆、减脂可可(fat-reduced cocoa)、松脆谷物(crunchy cereal)、脱脂乳粉、杏仁、甘油、山梨糖醇、植物油、葡萄糖浆、调味料、甜炼乳、大豆卵磷脂、脂肪酸甘油一酯和甘油二酯、焦糖化糖浆、麦芽糊精、盐、山梨酸钾、α-生育酚
QSP一个50g的条
所述组合物每日给药一次。
2.5香草味压缩饼干(cereal bar)的实例
-五味子油 200mg
-含硫氨基酸丰富的谷物提取物(玉米、荞麦、谷子、斯佩尔特小麦) 200mg
-鱼软骨葡萄糖胺聚糖 200mg
-富含多酚的绿茶提取物 200mg
-低聚果糖、糖、果糖糖浆、松脆谷物(crunchy cereal)、脱脂乳粉、杏仁、甘油、山梨糖醇、植物油、葡萄糖浆、调味料、甜炼乳、大豆卵磷脂、脂肪酸甘油一酯和甘油二酯、焦糖化糖浆、麦芽糊精、盐、山梨酸钾、α-生育酚
QSP一个50g的条
所述组合物每日给药一次。
2.6果仁糖味乳状饮料的实例
-五味子浓缩物 200mg
-富含多酚的绿茶提取物 100mg
-B族维生素(B 1、B2、B3、B5、B6、B9、B 12)
QSP 100%RDA
-Zn、Mg、Se QSP 100%RDA
-脱脂奶粉、调味料、果糖、蛋清、榛子果仁、糖、焦糖、β-胡萝卜素、黄原胶、阿斯巴甜、丁磺氨钾、大豆卵磷脂、麦芽糊精
QSP一个30g包装
所述组合物每日给药一次。
实施例3:华中五味子肽与糖提取物在酒渣鼻的炎性阶段中的活性
在实施例3至5中,“五味子肽”的表述指含有某个百分数的肽的华中五味子肽与糖提取物。
为了评价五味子肽在酒渣鼻炎性阶段的潜在活性,我们研究了这种活性物质复合物对角质形成细胞中受维生素D类似物(骨化三醇(calcitriol))诱导的激肽释放酶5(KLK5)和抗菌肽(cathelicidin)(LL37)基因表达的影响。
材料与方法
正常的人表皮角质形成细胞(NHEK)在补充有Ca++的培养基中培养以使所述细胞进入分化状态。
在10-7M骨化三醇(维生素D类似物)存在或不存在下,用0.05%(w/v)五味子肽处理角质形成细胞24小时。
在所述处理结束时,排除培养上清液,并且使用提取试剂盒(RNeasyMini试剂盒,凯杰(Qiagen))提取总RNA。随后,将总RNA在芯片中使用ExperionTM系统和Experion RNA StdSens试剂盒(伯乐(Bio-Rad))分析并且随后使用iScript cDNA合成试剂盒(Bio-Rad)逆转录成cDNA。
使用SybrGreen技术(iQ SybrGreen试剂盒,Bio-Rad),在iQ5系统(Bio-Rad)上通过实时PCR选择性扩增新合成的与目的基因(KLK5和LL37)或与参考基因相关的cDNA。
实时RT-PCR方法能够相对于参考基因的表达水平,将对应于给定处理的目的基因表达水平相对定量。
结果的定量分析基于阈循环的收集。
阈循环(Ct)是荧光发射信号统计地和显著高于背景时的时点。阈循环与靶DNA的初始拷贝数直接相关。
对于每份样品,目的基因的表达水平由最稳定的参考基因的表达水平归一化。使用GeNorm macro,确定最稳定的参考基因;在这个情况下,它是GAPDH基因。
ΔCt因而计算如下:
ΔCt=Ct靶基因-Ct参考基因
在第二步骤中,确定作为处理和目的基因拷贝数的函数的变异。ΔΔCt因而计算如下:
ΔΔCt=ΔCt对照-ΔCt处理
最后,计算相对量(RQ):RQ=(1+E)ΔΔCt。
将E(效率)视为等于1,并且因而:
RQ=2ΔΔCt
通过单因素方差分析,随后通过Tukey检验(GraphPad Prism 5.02版软件,GraphPad Software,圣地亚哥,加利福尼亚州,美国)对ΔCt值验证结果的显著性。
结果
KLK5基因表达:
骨化三醇(维生素D类似物)强烈并且显著地刺激角质形成细胞的激肽释放酶5基因表达(+149%,p<0.01)。
五味子肽显著地抑制由骨化三醇诱导的KLK5表达(54%抑制,p<0.01)。
$$:p<0.01相对于对照细胞
**:p<0.01相对于受刺激的对照
LL37基因表达
骨化三醇强烈并且显著地刺激角质形成细胞的LL37基因表达(+795%,p<0.01)。
五味子肽显著地抑制由骨化三醇诱导的LL37表达(58%抑制,p<0.01)。
$$$:p<0.001相对于对照细胞
**:p<0.01相对于受刺激的对照
结论
在这些实验条件下,五味子肽调节酒渣鼻中增加的一种标记抗菌肽(cathelicidin)(LL37)的表达,以及负责该标记成熟的酶(激肽释放酶5)的表达。
因而,五味子肽可以辅助调节酒渣鼻中炎症反应的诱导。
实施例4:华中五味子肽与糖提取物对于炎症其他参数的活性
材料与方法
正常的人角质形成细胞与浓度0.005%和0.05%的五味子肽或10-7M地塞米松(抗炎参考分子)预孵育24小时。
随后在五味子肽或地塞米松始终存在下,通过用10μg/ml PMA(佛波醇12-十四酸酯13-乙酸酯,Sigma)处理24小时诱导炎症。
在孵育结束时,通过酶联免疫吸附测定(ELISA)测量培养上清液中存在的白细胞介素-1β(IL-1β)、白细胞介素-8(IL-8)和白细胞介素-6(IL-6)的量。
平行地,通过中性红试验确定生物活跃细胞的数目。通过除以在中性红试验结束时获得的OD540值,将对于每种条件所分析的细胞因子的量还原成活细胞的数目。
通过单因素方差分析,随后通过Tukey检验(GraphPad Prism 5.02版软件,GraphPad Software,圣地亚哥,加利福尼亚州,美国)验证结果的显著性。
结果
IL-1β分泌:
用PMA处理明确地刺激IL-1β由角质形成细胞释放,并且地塞米松明确地抑制这种释放(-65%);这些结果验证了该试验。
在所测试的两个浓度上,五味子肽显著地抑制角质形成细胞中由PMA诱导的IL-1β分泌:在0.005%,64%抑制(p<0.001);和在0.05%,56%抑制(p<0.001)。
$$$:p<0.001相对于对照细胞
***:p<0.001相对于受刺激的对照
IL-8分泌:
用PMA处理明确地刺激IL-8由角质形成细胞释放,并且地塞米松明确地抑制这种释放(-53%);这些结果验证了该试验。
在所测试的两个浓度上,五味子肽显著地抑制由PMA诱导的IL-8释放:在0.005%,58%抑制(p<0.001);和在0.05%,37%抑制(p<0.001)。
$$$:p<0.001相对于对照细胞
***:p<0.001相对于受刺激的对照
IL-6分泌:
用PMA处理显著地诱导IL-6由角质形成细胞分泌,并且地塞米松抑制这种释放;这些结果验证了该试验。
在所测试的两个浓度上,五味子肽强烈并且显著地抑制由PMA诱导的IL-6释放:在0.005%,-70%(p<0.001);和在0.05%,-74%(p<0.001)。
$$:p<0.01相对于对照细胞
***:p<0.001相对于受刺激的对照
结论
在这些实验条件下,五味子肽对初级细胞因子(IL-1β)和两种次级细胞因子(IL-8和IL-6)显示炎症调节作用。
实施例5:华中五味子肽与糖提取物对于血管参数的活性
5.1.限制内皮细胞增殖
材料与方法
将正常人真皮微血管内皮细胞在浓度0.05%和0.1%的五味子肽不存在(对照)或存在下和在10ng/ml血管内皮生长因子(VEGF)(参考活化物)不存在和存在下孵育24或48小时。
在孵育结束时,通过胞内磷酸酶活性的分光光度分析评价细胞活力。
通过单因素方差分析,随后通过Holm-Sidak检验评价统计显著性。
结果
在VEGF不存在下的内皮细胞增殖:
在基线条件(无VEGF)下,在用所测试的两个浓度上的五味子肽处理24小时后,内皮细胞生长显著地减少:
在VEGF存在下的内皮细胞增殖:
相对于对照细胞,VEGF显著地刺激内皮细胞生长:在24小时孵育后+41.4%(p<0.01)和在48小时孵育后+96.3%(p<0.01)。这个结果验证所述试验。
在所测试的两个浓度上,五味子肽显著地抑制由VEGF诱导的内皮细胞增殖:
结论
通过限制内皮细胞增殖,五味子肽可以限制血管发生的早期阶段。
5.2.对角质形成细胞中血管发生标记表达的影响
为了理解五味子肽的抗血管发生作用,研究了角质形成细胞中的参与血管发生的某些基因或蛋白质标记的表达,尤其,促血管发生性生长因子VEGF和纤维生长因子-2(FGF-2)以及抗血管发生性标记血小板反应蛋白-1(THBS-1)的表达。
A.促血管发生性标记(VEGF,FGF-2)基因的表达
材料与方法
将正常的人表皮角质形成细胞(NHEK)在0.05%和0.1%(w/v)五味子肽存在下孵育48小时。
在所述处理结束时,排除培养上清液,并且使用提取试剂盒(RNeasyMini试剂盒,Qiagen)提取总RNA。随后,将总RNA在芯片中使用ExperionTM系统和Experion RNA StdSens试剂盒(Bio-Rad)分析并且随后使用iScript cDNA合成试剂盒(Bio-Rad)逆转录成cDNA。
使用SybrGreen技术(iQ SybrGreen试剂盒,Bio-Rad),在iQ5系统(Bio-Rad)上通过实时PCR选择性扩增新合成的与目的基因(VEGF、FGF-2、HIF-1α、THBS-1)或与参考基因相关的cDNA。
实时RT-PCR方法能够相对于参考基因的表达水平,将对应于给定处理的目的基因表达水平相对定量。
结果的定量分析基于阈循环的收集。
阈循环(Ct)是荧光发射信号统计地和显著高于背景时的时点。阈循环与靶DNA的初始拷贝数直接相关。
对于每份样品,目的基因的表达水平由最稳定的参考基因的表达水平归一化。使用GeNorm macro,确定最稳定的参考基因;在这个情况下,它是YWHAZ基因。
ΔCt因而计算如下:
ΔCt=Ct靶基因-Ct参考基因
在第二步骤中,确定作为处理和目的基因拷贝数的函数的变异。ΔΔCt因而计算如下:
ΔΔCt=ΔCt对照-ΔCt处理
最后,计算相对量(RQ):RQ=(1+E)ΔΔCt。
将E(效率)视为等于1,并且因而:
RQ=2ΔΔCt
通过单因素方差分析,随后通过Dunnett检验(GraphPad Prism 5.02版软件,GraphPad Software,圣地亚哥,加利福尼亚州,美国)对ΔCt值验证结果的显著性。
结果
血管内皮生长因子(VEGF)基因表达:
在所测试的两个浓度上,五味子肽极强烈并且显著地抑制角质形成细胞的VEGF基因表达:在0.05%,89%抑制(p<0.001);和在0.1%,93%抑制(p<0.001)。
***:p<0.001相对于对照细胞
碱性成纤维细胞生长因子(FGF-2)基因表达:
在所测试的两个浓度上,五味子肽极强烈并且显著地抑制角质形成细胞的FGF-2表达:在0.05%,93%抑制(p<0.001);和在0.1%,95%抑制(p<0.001)。
***:p<0.001相对于对照细胞
血小板反应蛋白-1(Thrombospondin-1)基因表达:
在所测试的两个浓度上,五味子肽显著地刺激角质形成细胞的血小板反应蛋白-1(一种抗血管发生因子)表达:在0.05%,+118%(p<0.01);和在0.1%,+60%(p<0.05)。
*:p<0.05相对于对照细胞
**:p<0.01相对于对照细胞
B.血管发生标记蛋白(VEGF)的表达
材料与方法
正常的人角质形成细胞与浓度0.005%、0.05%和0.1%的五味子肽或10-7M地塞米松(抗炎参考分子)预孵育24小时。
随后在五味子肽或地塞米松始终存在下,通过用10μg/ml PMA处理24小时诱导炎症。
在孵育结束时,通过ELISA测量培养上清液中存在的VEGF的量。
平行地,通过中性红试验确定生物活跃细胞的数目。通过除以在中性红试验结束时获得的OD540值,将对于每种条件所分析的细胞因子的量还原成活细胞的数目。
通过单因素方差分析,随后通过Tukey检验(GraphPad Prism 5.02版软件,GraphPad Software,圣地亚哥,加利福尼亚州,美国)验证结果的显著性。
结果
用PMA处理显著地诱导VEGF由角质形成细胞分泌,并且地塞米松抑制这种释放(-46%);这些结果验证了该试验。
在所测试的三个浓度上,五味子肽强烈并且显著地抑制由PMA诱导的VEGF释放:分别是63%、72%和69%抑制(p<0.001)。
$:p<0.05相对于对照细胞
***:p<0.001相对于受刺激的对照
C.结论
在上文描述的实验条件下,我们展示了五味子肽调节了角质形成细胞中参与诱导血管发生的因子的表达,并且因而具有抗血管发生作用。
实际上,五味子肽减少促血管发生性标记(FGF-2,VEGF)的表达并且增加抗血管发生性标记(THBS-1)的表达。
因而通过抑制血管发生(新血管形成的早期现象),五味子肽可以限制内皮细胞的活化和新血管的生成。
5.3.对血管舒张的影响:内皮素-1的表达
内皮素是一种具有强力血管收缩活性的神经肽。它由内皮和表皮细胞(角质形成细胞)、成纤维细胞、脂肪细胞和巨噬细胞分泌。研究了五味子肽对内皮细胞产生内皮素的影响。
材料与方法
将单层培养的正常成人真皮微血管内皮细胞在0.05%和0.1%的五味子肽或16.7nM胰岛素(参考活化物)不存在(对照)或存在下孵育6小时。
在孵育时间结束时,通过ELISA定量分泌的内皮素。平行地,细胞裂解物中含有的蛋白质由Bradford方法定量。
测定的内皮素的量因而用总蛋白的量归一化,并且结果随后表述为内皮素(ng)对细胞层中总蛋白(μg)的比率。
通过单因素方差分析,随后通过Holm-Sidak检验评价所述结果的统计显著性。
结果
在所测试的两个浓度上,五味子肽显著地增加内皮细胞的内皮素产生:在0.05%,+67%(p<0.05);和在0.1%,+78%(p<0.05)。
*:p<0.05相对于对照细胞
结论
通过影响内皮素激活,五味子肽可以影响血管舒张并且因而减少皮肤发红。
Claims (15)
1.化妆品、皮肤病学或营养药组合物,其包含选自以下的至少一种华中五味子(Schisandra sphenanthera)果实提取物:
-一种肽与糖提取物,
-一种具有以下分析结果的粗制油:
-一种具有以下分析结果的精制油:
-所述精制油的一种浓缩物,或者
-源于所述精制油浓缩物的一种不可皂化物。
2.根据权利要求1所述的组合物,其特征在于,所述肽与糖提取物包括以重量计10%至50%的肽和以重量计10%至60%的糖,其中所述百分数相对于所述肽提取物的总重量计算。
3.根据权利要求1或权利要求2所述的化妆品、皮肤病学或营养药组合物,除了所述华中五味子果实提取物之外,所述组合物还包含至少一种其他的活性化合物。
4.根据权利要求1至3中任一项所述的化妆品、皮肤病学或营养药组合物,其包含至少两种华中五味子果实提取物。
5.用于制备华中五味子果实的肽与糖提取物的方法,其包括以下相继步骤:
-从五味子果实开始,通过超临界CO2提取粗制油并且回收脱脂油饼;
-水相分散所述油饼;
-用纤维素酶、蛋白酶和α-淀粉酶的酶混合物酶处理所述油饼;随后
-离心、超滤、纳米过滤并且回收所述肽提取物。
6.用于从如权利要求1中所定义的粗制油中制备精制华中五味子油的方法,其包括分子蒸馏所述粗制油的步骤。
7.根据权利要求6所述的方法,其特征在于,使用选自离心分子蒸馏器和刮膜式分子装置的装置实施所述分子蒸馏步骤。
8.用于从如权利要求1中所定义的精制油中制备精制华中五味子油浓缩物的方法,其包括分子蒸馏所述精制油的步骤。
9.用于制备华中五味子果实不可皂化物的方法,其包括以下步骤:皂化根据权利要求8所述的方法获得的精制华中五味子果实油浓缩物,并且随后使用合适的溶剂提取所述的不可皂化物。
10.选自如权利要求1中定义的肽与糖提取物或粗制油或精制油或浓缩物或不可皂化物中的华中五味子果实提取物在化妆品组合物中的用途,用于预防和治疗过敏性、炎性或刺激性反应或病变,或者皮肤和/或粘膜屏障或稳态的和/或不成熟、正常或成熟/老化的上皮附属物的病症。
11.选自如权利要求1中定义的肽与糖提取物或粗制油或精制油或浓缩物或不可皂化物中的华中五味子果实提取物在食物组合物中的用途,用于预防和治疗过敏性、炎性或刺激性反应或病变,或者皮肤和/或粘膜屏障或稳态的和/或不成熟、正常或成熟/老化的上皮附属物的病症。
12.选自如权利要求1中定义的肽与糖提取物或粗制油或精制油或浓缩物或不可皂化物中的华中五味子果实提取物的治疗用途,用于预防和治疗过敏性、炎性或刺激性反应或病变,或者皮肤和/或粘膜屏障或稳态的和/或不成熟、正常或成熟/老化的上皮附属物的病症。
13.华中五味子果实肽与糖提取物在化妆品组合物中用于治疗和预防皮肤发红、赤-红血丝和酒渣鼻的用途。
14.华中五味子果实肽与糖提取物在食物组合物中用于治疗和预防皮肤发红、赤-红血丝和酒渣鼻的用途。
15.华中五味子果实肽与糖提取物用于治疗和预防皮肤发红、赤-红血丝和/或酒渣鼻的治疗用途。
Applications Claiming Priority (3)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
FR0955344 | 2009-07-30 | ||
FR0955344A FR2948566B1 (fr) | 2009-07-30 | 2009-07-30 | Extrait du fruit de schizandra sphenanthera et compositions cosmetiques, dermatologiques et nutraceutiques le comprenant |
PCT/EP2010/060873 WO2011012612A2 (fr) | 2009-07-30 | 2010-07-27 | Extrait du fruit de schizandra sphenanthera et compositions cosmetiques, dermatologiques et nutraceutiques le comprenant |
Publications (2)
Publication Number | Publication Date |
---|---|
CN102781421A true CN102781421A (zh) | 2012-11-14 |
CN102781421B CN102781421B (zh) | 2015-07-01 |
Family
ID=42062629
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
CN201080033939.8A Active CN102781421B (zh) | 2009-07-30 | 2010-07-27 | 华中五味子果实提取物和包含它的化妆品、皮肤病学和营养药组合物 |
Country Status (7)
Country | Link |
---|---|
US (1) | US8586107B2 (zh) |
EP (1) | EP2459166B1 (zh) |
JP (1) | JP2013500308A (zh) |
KR (1) | KR101760959B1 (zh) |
CN (1) | CN102781421B (zh) |
FR (1) | FR2948566B1 (zh) |
WO (1) | WO2011012612A2 (zh) |
Cited By (4)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN107427453A (zh) * | 2014-11-26 | 2017-12-01 | 科学发展实验室 | 五味子果实的肽和糖苷提取物及其对皮肤神经系统反应的改善作用 |
CN108714112A (zh) * | 2018-06-12 | 2018-10-30 | 无限极(中国)有限公司 | 组合物及含有该组合物的保湿和/或抗氧化的化妆品 |
CN111132685A (zh) * | 2017-04-25 | 2020-05-08 | 瑞阳公司 | 五味子提取物的组合物和其方法 |
CN113855620A (zh) * | 2021-11-24 | 2021-12-31 | 安赛搏(重庆)生物技术有限公司 | 含有天山雪莲细胞培养物的组合物及其制备方法与应用 |
Families Citing this family (19)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
FR2949044B1 (fr) | 2009-08-12 | 2021-05-07 | Expanscience Lab | Composition comprenant une fraction d'insaponifiable |
KR20120068148A (ko) * | 2010-12-17 | 2012-06-27 | 계명대학교 산학협력단 | 회화나무 추출물을 유효성분으로 포함하는 백반증 또는 백모 개선용 조성물 |
FR2975004B1 (fr) | 2011-05-13 | 2013-06-28 | Expanscience Lab | Nouvel actif anti-rougeurs et compositions cosmetiques le comprenant |
CN104066424A (zh) * | 2011-09-02 | 2014-09-24 | 伯特氏农场有限责任公司 | 包含小果南瓜或大果南瓜提取物的个人护理组合物 |
GB201120772D0 (en) * | 2011-12-02 | 2012-01-11 | Ip Science Ltd | Cocoa-based food products |
US20150202187A1 (en) * | 2012-06-26 | 2015-07-23 | Sarah Bacus | Compositions and methods for treatment of vitiligo |
KR101425023B1 (ko) * | 2013-08-16 | 2014-08-01 | 김윤 | 오미자 오일을 함유하는 계면활성제 조성물 및 이를 함유하는 세정 조성물 |
US9149457B2 (en) | 2013-09-27 | 2015-10-06 | Justin SHER | Nutraceutical composition for PDE4 inhibition, enhanced dopamine metabolism and long term potentiation |
AU2015241297B2 (en) * | 2014-03-31 | 2019-03-28 | Iotech International, Inc. | Stable compositions of uncomplexed iodine and methods of use |
US9662367B2 (en) | 2014-08-01 | 2017-05-30 | Rubikon Ltd. | Adaptogenic compositions and method for production thereof |
EP3463263B1 (en) * | 2016-05-27 | 2020-10-21 | Unilever N.V. | An antimicrobial cleansing composition |
KR102677588B1 (ko) * | 2016-08-31 | 2024-06-24 | 주식회사 파이안에스테틱스 | 식물 꽃부위 유래 유전자 혼합물 제조 방법 및 이를 함유하는 비수계 조성물 |
KR102634258B1 (ko) * | 2016-10-27 | 2024-02-06 | 주식회사 엘지생활건강 | 시잔드린 a를 포함하는 구강질환 예방 또는 치료용 조성물 |
US20180325155A1 (en) * | 2017-05-15 | 2018-11-15 | Hunan Nuoz Biological Technology Co., Ltd. | Method for Eliminating Harmful Substances from Plant Extracts |
FR3068045B1 (fr) | 2017-06-22 | 2021-06-04 | Expanscience Lab | Modeles de peau sensible reconstituee |
KR102152292B1 (ko) * | 2017-10-13 | 2020-09-04 | 한양대학교 산학협력단 | 온천수 및 과일 추출물을 포함하는 미생물 사멸을 위한 조성물 |
FR3098405B1 (fr) | 2019-07-12 | 2021-06-25 | Expanscience Lab | Composition comprenant des polyphénols de graines de passiflore, des peptides d’avocat et un extrait d’hamamélis et utilisation pour traiter et/ou prévenir les vergetures |
KR20230093679A (ko) | 2021-12-20 | 2023-06-27 | 안동대학교 산학협력단 | 남오미자 추출물을 유효성분으로 포함하는 항비만용 조성물 |
CN114917285B (zh) * | 2022-04-06 | 2023-06-23 | 军事科学院军事医学研究院军事兽医研究所 | 一种多糖化合物在预防和治疗呼吸道病毒感染药物中的应用 |
Citations (5)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO2005044289A2 (en) * | 2003-11-07 | 2005-05-19 | Cognis France, S.A.S. | An extract of the fruit of schisandra chinensis and its pharmaceutical and cosmetic use |
CN1968708A (zh) * | 2004-04-30 | 2007-05-23 | 科学发展实验室 | 用于治疗和预防与免疫系统缺陷有关的疾病的含鳄梨肽提取物的药物 |
WO2008025847A2 (fr) * | 2006-08-31 | 2008-03-06 | Laboratoires Expanscience | Utilisation de sucres en c7 dans la prévention et le traitement des mycoses |
CN101200749A (zh) * | 2007-12-19 | 2008-06-18 | 大连工业大学 | 五味子活性成分多糖的制备方法 |
CN101272799A (zh) * | 2005-08-12 | 2008-09-24 | 凡诺华(英国)有限公司 | 用于治疗肝病的基于植物的药物 |
Family Cites Families (35)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
JPH0248592A (ja) | 1988-08-09 | 1990-02-19 | Tsumura & Co | ジベンゾシクロオクタジエン型リグナンの製造法 |
JP2886611B2 (ja) * | 1990-04-18 | 1999-04-26 | 協和メデックス株式会社 | 発毛剤 |
FR2669239B1 (fr) | 1990-11-21 | 1993-06-18 | Electricite De France | Appareil de distillation moleculaire a chauffage par induction. |
JPH06329545A (ja) * | 1993-05-24 | 1994-11-29 | Suntory Ltd | 生薬抽出物を有効成分とするヒアルロニダーゼ阻害剤 |
JP3260918B2 (ja) * | 1993-07-12 | 2002-02-25 | 協和醗酵工業株式会社 | トリテルペン酸誘導体 |
JPH0840924A (ja) * | 1994-07-28 | 1996-02-13 | Kyowa Yakuhin Kk | 抗菌性薬剤の増強剤 |
CN1076181C (zh) * | 1994-10-11 | 2001-12-19 | 孔四新 | 五味可乐及其制备方法 |
JP3781794B2 (ja) * | 1995-01-12 | 2006-05-31 | 協和醗酵工業株式会社 | トリテルペン酸誘導体 |
FR2762512B1 (fr) | 1997-04-24 | 2000-10-13 | Pharmascience Lab | Compositions a base d'huile de lupin, notamment a base d'huile de lupin et d'huile de germe de ble et leur utilisation en cosmetologie, en pharmacie et en tant que complement alimentaire |
FR2798591B1 (fr) | 1999-09-22 | 2001-10-26 | Pharmascience Lab | Utilisation d'un produit d'huile vegetale pour augmenter la synthese des lipides cutanes en cosmetique, pharmacie ou dermatologie et en tant qu'additif alimentaire |
FR2798667B1 (fr) | 1999-09-22 | 2001-12-21 | Pharmascience Lab | Procede d'extraction des composes furaniques et alcools gras polyhydroxyles de l'avocat, composition a base de et utilisation de ces composes en therapeutique, cosmetique et alimentaire |
FR2803598B1 (fr) | 2000-01-12 | 2002-04-26 | Pharmascience Lab | Procede d'extraction des insaponifiables des huiles vegetales au moyen de chloro-1-butane, composition comprenant ces insaponifiables |
FR2803749B1 (fr) | 2000-01-18 | 2006-09-22 | Pharmascience Lab | Utilisation d'au moins un ester gras pour la preparation d'une composition destinee a inhiber l'activite de la 5 alpha-reductase, en pharmacie notamment en dermatologie, en cosmetique et en tant qu'additif alimentaire |
KR20020001931A (ko) | 2000-06-20 | 2002-01-09 | 임병철 | 황백 추출물 및/또는 오미자 추출물을 함유하는 여드름억제 화장료 |
FR2811984B1 (fr) | 2000-07-19 | 2004-02-06 | Pharmascience Lab | Procede de preparation d'un ester de corps gras et son utilisation dans les domaines pharmaceutique, cosmetique ou alimentaire |
FR2822821B1 (fr) | 2001-04-03 | 2004-05-07 | Pharmascience Lab | Extrait de coques de graines de lupin contenant du lupeol, en particulier extrait riche en lupeol et son procede de preparation |
US6605305B2 (en) * | 2001-04-04 | 2003-08-12 | Xinxian Zhao | Plant drug for treatment of liver disease |
WO2004016106A1 (fr) | 2002-07-29 | 2004-02-26 | Laboratoires Expanscience | Procede d'obtention d'un insaponifiable d'avocat riche en lipides furaniques |
CA2493981C (fr) | 2002-07-30 | 2012-06-26 | Laboratoires Expanscience | Procede d'obtention d'un extrait de feuilles d'avocatier riche en lipides furaniques |
FR2847473B1 (fr) | 2002-11-25 | 2007-06-29 | Expanscience Lab | Composition comprenant au moins une oxazolidinone, son utilisation cosmetique et comme medicament |
FR2847471B1 (fr) | 2002-11-25 | 2006-12-29 | Expanscience Lab | Composition comprenant au moins un derive d'acide carbamique ,son utilisation cosmetique et comme medicament |
JP2004244327A (ja) * | 2003-02-12 | 2004-09-02 | Ichimaru Pharcos Co Ltd | 美白剤及び美白化粧料 |
FR2856294B1 (fr) | 2003-06-18 | 2005-08-05 | Expanscience Lab | Utilisation cosmetique d'une composition comprenant au moins une oxazoline, a titre de principe actif, comme amincissant et/ou pour prevenir et/ou traiter la cellulite |
FR2856298B1 (fr) | 2003-06-19 | 2007-08-17 | Expanscience Lab | Extrait de maca et composition cosmetique comprenant un tel extrait |
FR2857596B1 (fr) | 2003-07-18 | 2006-02-03 | Expanscience Lab | Utilisation d'une composition cosmetique ou pharmaceutique comprenant un extrait riche en lupeol, a titre de principe actif, pour stimuler la synthese des proteines de stress |
US20050282910A1 (en) | 2003-11-28 | 2005-12-22 | Xun Hu | Methods of application of chemical compounds having therapeutic activities in treating cancers |
FR2868703B1 (fr) | 2004-04-08 | 2008-06-13 | Expanscience Sa Lab | Extrait total de lupin constitue d'un extrait de sucres de lupin et d'un extrait peptidique de lupin, procede d'obtention et utilisation |
FR2869541B1 (fr) | 2004-04-30 | 2007-12-28 | Expanscience Sa Lab | Utilisation d'une composition comprenant du d-mannoheptulose et/ou du perseitol dans le traitement et la prevention des maladies liees a une modification de l'immunite innee |
WO2006122454A1 (fr) | 2005-05-18 | 2006-11-23 | Guangzhou Zhongyi Pharmaceutical Company Limited | Composition pharmaceutique pour le traitement du diabete et son procede de preparation |
CN100355442C (zh) | 2005-05-18 | 2007-12-19 | 广州中一药业有限公司 | 一种治疗糖尿病的药物组合物及其制备方法 |
FR2893628B1 (fr) | 2005-11-18 | 2008-05-16 | Expanscience Laboratoires Sa | Procede d'obtention d'une huile d'avocat raffinee riche en triglycerides et huile susceptible d'etre obtenue par un tel procede |
CN1313132C (zh) * | 2006-03-02 | 2007-05-02 | 浙江新光药业有限公司 | 一种治疗冠心病的药物组合物及其制备方法 |
FR2903903B1 (fr) | 2006-07-18 | 2008-08-29 | Expanscience Laboratoires Sa | Utilisation d'un hydrolysat de proteines de riz en tant que principe actif pigmentant |
FR2910815B1 (fr) * | 2006-12-28 | 2010-10-29 | Expanscience Lab | Composition comprenant un extrait de graines de quinoa |
CN101040971B (zh) | 2007-04-20 | 2010-08-18 | 王爱红 | 一种具有祛痘、填坑、消斑作用的中药组合物 |
-
2009
- 2009-07-30 FR FR0955344A patent/FR2948566B1/fr active Active
-
2010
- 2010-07-27 JP JP2012522149A patent/JP2013500308A/ja not_active Ceased
- 2010-07-27 EP EP10740198.6A patent/EP2459166B1/fr active Active
- 2010-07-27 WO PCT/EP2010/060873 patent/WO2011012612A2/fr active Application Filing
- 2010-07-27 KR KR1020127004081A patent/KR101760959B1/ko active IP Right Grant
- 2010-07-27 CN CN201080033939.8A patent/CN102781421B/zh active Active
- 2010-07-27 US US13/387,524 patent/US8586107B2/en active Active
Patent Citations (5)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO2005044289A2 (en) * | 2003-11-07 | 2005-05-19 | Cognis France, S.A.S. | An extract of the fruit of schisandra chinensis and its pharmaceutical and cosmetic use |
CN1968708A (zh) * | 2004-04-30 | 2007-05-23 | 科学发展实验室 | 用于治疗和预防与免疫系统缺陷有关的疾病的含鳄梨肽提取物的药物 |
CN101272799A (zh) * | 2005-08-12 | 2008-09-24 | 凡诺华(英国)有限公司 | 用于治疗肝病的基于植物的药物 |
WO2008025847A2 (fr) * | 2006-08-31 | 2008-03-06 | Laboratoires Expanscience | Utilisation de sucres en c7 dans la prévention et le traitement des mycoses |
CN101200749A (zh) * | 2007-12-19 | 2008-06-18 | 大连工业大学 | 五味子活性成分多糖的制备方法 |
Non-Patent Citations (3)
Title |
---|
CONSTANCE HUYKE等: ""Composition and Biological Activity of Different Extracts from Schisandra sphenanthera and Schisandra chinensis"", 《PLANTA MED》, vol. 73, no. 10, 31 December 2007 (2007-12-31) * |
FLAVEX NATUREXTRAKTE GMBH: ""Schisandrafrüchte CO2-to Extrakt Varietat Sphenanthera, Typ Nr. 164.001》", 《HTTP://WWW.FLAVEX.COM/FILEADMIN/FLAVEX.DE/USER_UPLOAD/SPEZIFIKATION/DEUTSCH/SPEZI_SCHISANDRAFRUECHTE_CO2-TO_EXTRAKT_164_001.PDF》, 15 March 2006 (2006-03-15) * |
K.W. QUIRIN: ""Supercritical Schisandra Extracts – a New Concept for Personal Care Cosmetics"", 《COSMETIC SCIENCE TECHNOLOGY》, 31 December 2008 (2008-12-31) * |
Cited By (7)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN107427453A (zh) * | 2014-11-26 | 2017-12-01 | 科学发展实验室 | 五味子果实的肽和糖苷提取物及其对皮肤神经系统反应的改善作用 |
CN107427453B (zh) * | 2014-11-26 | 2020-11-06 | 科学发展实验室 | 五味子果实的肽和糖苷提取物及其对皮肤神经系统反应的改善作用 |
CN111132685A (zh) * | 2017-04-25 | 2020-05-08 | 瑞阳公司 | 五味子提取物的组合物和其方法 |
CN108714112A (zh) * | 2018-06-12 | 2018-10-30 | 无限极(中国)有限公司 | 组合物及含有该组合物的保湿和/或抗氧化的化妆品 |
CN108714112B (zh) * | 2018-06-12 | 2021-04-27 | 无限极(中国)有限公司 | 组合物及含有该组合物的保湿和/或抗氧化的化妆品 |
CN113855620A (zh) * | 2021-11-24 | 2021-12-31 | 安赛搏(重庆)生物技术有限公司 | 含有天山雪莲细胞培养物的组合物及其制备方法与应用 |
CN113855620B (zh) * | 2021-11-24 | 2023-08-25 | 安赛搏(重庆)生物技术有限公司 | 含有天山雪莲细胞培养物的组合物及其制备方法与应用 |
Also Published As
Publication number | Publication date |
---|---|
KR101760959B1 (ko) | 2017-07-24 |
US20120121743A1 (en) | 2012-05-17 |
FR2948566B1 (fr) | 2012-08-10 |
EP2459166B1 (fr) | 2016-10-12 |
FR2948566A1 (fr) | 2011-02-04 |
CN102781421B (zh) | 2015-07-01 |
US8586107B2 (en) | 2013-11-19 |
EP2459166A2 (fr) | 2012-06-06 |
JP2013500308A (ja) | 2013-01-07 |
WO2011012612A3 (fr) | 2012-04-19 |
WO2011012612A2 (fr) | 2011-02-03 |
KR20120063469A (ko) | 2012-06-15 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
CN102781421B (zh) | 华中五味子果实提取物和包含它的化妆品、皮肤病学和营养药组合物 | |
US10688142B2 (en) | Methods of treatment using a lipid extract of Passiflora seeds concentrated in its unsaponifiable fraction | |
CN102647920B (zh) | 大穗金合欢种子提取物和含有大穗金合欢种子提取物的组合物 | |
EP2459161B1 (fr) | Composition cosmetique pour le traitement de l'acne comprenant un extrait peptidique de schizandra sphenanthera | |
CN114929195A (zh) | 含有植物提取物的组合物 | |
US20110003760A1 (en) | Abnormal protein removing method | |
CN111053716B (zh) | 一种茯茶提取物在制备皮肤调节产品中的用途 | |
KR101274868B1 (ko) | 멍게껍질 추출물을 유효성분으로 포함하는 탈모 방지 및 발모 개선용 조성물 | |
FR2969495A1 (fr) | Extrait de parties aeriennes de maca riche en polyphenols et composition le comprenant | |
FR2999429A1 (fr) | Extrait de graines de passiflore et compositions cosmetiques, pharmaceutiques, dermatologiques ou nutraceutiques le comprenant | |
JP2002029980A (ja) | エストロゲン様作用剤及びコラーゲン産生促進剤、線維芽細胞増殖作用剤、美容用食品並びに皮膚化粧料 | |
EP2506724B1 (fr) | Extrait de graines de vigna unguiculata et compositions le comprenant | |
JP2002226323A (ja) | コラーゲン産生促進剤、コラゲナーゼ阻害剤、線維芽細胞増殖作用剤、エラスターゼ阻害剤、エストロゲン様作用剤、皮膚化粧料並びに美容用飲食品 | |
FR2969494A1 (fr) | Extrait de parties aeriennes de gynandropsis gynandra ou cleome gynandra et compositions cosmetiques, dermatologiques le comprenant | |
JP2002003393A (ja) | 線維芽細胞増殖作用剤、美容用飲食品および皮膚化粧料 | |
KR101889793B1 (ko) | 수산동물 발효물을 포함하는 탈모 방지 및 육모 촉진을 위한 조성물 | |
JP2002003390A (ja) | 線維芽細胞増殖作用剤、美容用飲食品および皮膚化粧料 | |
KR102212343B1 (ko) | 마리안 플럼 추출물을 유효성분으로 함유하는 피부 항노화 및 보습용 조성물 | |
JP2011032176A (ja) | メラニン産生促進剤 |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
C06 | Publication | ||
PB01 | Publication | ||
C10 | Entry into substantive examination | ||
SE01 | Entry into force of request for substantive examination | ||
C14 | Grant of patent or utility model | ||
GR01 | Patent grant |